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Abstract
Recurrent disease, characterized by repeated alternations between acute relapse and long re-
mission, can be a feature of both common diseases, like ear infections, and serious chronic
diseases, such as HIV infection or multiple sclerosis. Due to their poorly understood etiology
and the resultant challenge for medical treatment and patient management, recurrent diseases
attract much attention in clinical research and biomathematics. Previous studies of recurrence
by biomathematicians mainly focus on in-host models and generate recurrent patterns by in-
corporating forcing functions or stochastic elements. In this study, we investigate deterministic
in-host models through the qualitative analysis of dynamical systems, to reveal the possible
intrinsic mechanisms underlying disease recurrence.
Recurrence in HIV infection is referred to as “viral blips”, that is, transient periods of high
viral replication separated by long periods of quiescence. A 4-dimensional HIV antioxidant-
therapy model exhibiting viral blips is studied using bifurcation theory. Four conditions for the
existence of viral blips in a deterministic in-host model are proposed. Guided by the four con-
ditions, the simplest 2-dimensional infection model which shows recurrence is obtained. One
key point for recurrence is identified, that is an increasing and saturating infectivity function.
Furthermore, Hopf and generalized Hopf bifurcations, Bogdanov-Takens bifurcation, and ho-
moclinic bifurcation are proved to exist in this 2-dimensional model. Bogdanov-Takens bifur-
cation and homoclinic bifurcation provide a new mechanism for generating recurrence. From
the viewpoint of modelling, the increasing and saturating infectivity function gives rise to a
convex incidence rate, which further induces backward bifurcation and Hopf bifurcation, and
allows the infection model to exhibit rich dynamical behavior, such as bistability, recurrence,
and regular oscillation.
The relapse-remission cycle in autoimmune disease is investigated based on a regulatory T
cell model. By introducing a newly discovered class of regulatory T cells, Hopf bifurcation oc-
curs in the autoimmune model with negative backward bifurcation, and gives rise to a recurrent
pattern.
The main insight of this thesis is that recurrent disease can arise naturally from the de-
terministic dynamics of populations. It will provide a starting point for further research in
dynamical systems theory, and recurrence in other physical systems.
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effector T cells
π3 – rate (per A, per E) at which active nTReg cells are generated from the pool of ‘naive’
TReg cells, due to encounter with mature pAPCs (A) and influence of IL-2 from specific
effector T cells
β – rate (per A) at which active nTReg cells are generated from the resting pool, due to encounter
with mature pAPCs (A) and influence of IL-2 from other sources
λE – rate (per A) at which effector T cells (E) are generated from the resting pool, due to
encounter with mature pAPCs (A)
γ – rate (per E) at which self antigen (G) is released due to the actions of effector T cells (E)
σ1,3 – rate (per capita, Rn or Rd) at which mature pAPCs (A) and effective T cells are effectively
eliminated due to suppression by specific active nTReg cells (Rn) or terminal TReg cells
(Rd)
b1 – rate (per capita) at which mature pAPCs (A) are effectively eliminated due to suppression
by TReg cells of other specificities or by therapy
b3 – rate (per capita) at which effective T cells (E) are effectively eliminated due to suppression
by TReg cells of other specificities or by therapy
µA – per capita death rate of mature pAPCs
µE – per capita death rate of effector T cells (E)
µG – per capita rate at which free antigen (G) is cleared, for example due to degradation
µn – per capita death rate of active nTReg cells (Rn)
µd – per capita death rate of terminal TReg cells (Rd)
xiv
ξ – proportion of activated nTReg cells
α – rate (per E) at which immature pAPCs become mature
d – the ratio of supress effectiveness of nTReg cells to terminal TReg cells
c – the fold of matured nTReg cells expansion and proliferation to terminal TReg cells
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S , I, R – the population size of susceptible, infective, and recovered individuals
µ, δ, α – the birth/death rate, the recovery rate and the loss of immunity rate in model (4.1)
N – the total population size
Λ – the constant recruitment rate of susceptibles
d, γ, ǫ – the rates of natural death, recovery, and the disease-induced mortality
β the infection rate
k the inhibition effect
α the maximal medical resources per unit time in model (4.8)
ω the half-saturation constant
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Chapter 1
Introduction
Recurrent disease, such as several episodes of ear infections or bacterial sinusitis in one year,
can be very common and disagreeable. Recurrence can also pose serious health issues, and
even fatality [16], and it is often associated with chronic diseases for which there is no known
cure, such as human immunodeficiency virus (HIV) infection [3, 13], or lupus [10]. The pattern
of recurrent disease is an alternation between acute relapse and long remission [5, 16, 6, 8, 10].
In HIV infection for example, “viral blips” are commonly measured in patients under highly
active antiretroviral therapy (HAART), whose blood viral load is controlled for long periods
at an undetectable level, but is still punctuated periodically by short episodes of high viral
reproduction [14], as shown in Figure 1.1. Although the etiology is not well understood, HIV
infected patients chronically suffer from these episodes of acute viral relapse [7]. In addition,
important issues in recurrent disease, such as medical treatment and patient management, cry
out for new insight. In this study, we apply approaches characteristic of mathematical biology
to better understand the intrinsic mechanisms driving recurrent diseases.
1.1 Mathematical models for studying recurrence
Mathematical models using differential equations track changes in biological systems over
time, and provide new research tools to investigate and explain clinical and laboratory obser-
vations [1, 11, 12]. By translating verbal mechanisms into scientific prediction, mathematical
models play a fast-growing and well-recognized role in understanding, predicting, and con-
trolling diseases [11]. In this study, based on traditional epidemic models at the population
level, we develop and analyse in-host models at the cell-to-cell level to describe the interaction
between pathogenic agents and cells.
1.1.1 Immunological models
The body’s defence against foreign pathogen invasion is the immune system. Immunology
is the study of the immune system, including its function and possible malfunctions, such
as autoimmune disease, hypersensitivities, immune deficiency, and transplant rejection. The
immune system is built mainly at the cellular level. Mathematical models in immunology
therefore attempt to describe the dynamical world of cells and molecules inside body.
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Mathematical models in immunology, typically systems of ordinary differential equations,
are well recognized and widely used to describe immune processes, understand the underly-
ing dynamical processes, reveal intrinsic mechanisms, and predict the fate of the disease. In
addition, mathematical models can provide a persuasive way to verify verbal assumptions in
immunology. Additionally, model simplification can help to identify and emphasize the de-
termining factors in disease. Simplifications, such as quasi-steady state assumptions, are a
well-recognized way to reduce model dimension, while retaining the model’s main properties.
Although cellular processes are key to immune function, the immune response also incorpo-
rates processes of a chemical nature, such as the antigen-antibody interaction and enzyme-
catalysed reactions, for example the cytokine molecule IL-2 signaling process. Mathematical
modeling can incorporate these biochemical factors into immunological models. For example,
the influence of reactive oxygen species on HIV infection rate can be modeled according to
Michaelis-Menten kinetics, and gives rise to an increasing, saturating HIV infectivity function
in Chapter 2. This function further determines the simplest 2-dimensional HIV infection model
which shows recurrent behavior, providing a new mechanism for HIV viral blips and a fresh
insight into the elusive world of HIV infection.
1.1.2 Infection models
A basic epidemic SIR model divides the population into susceptible, infected and recovered
groups, and denotes the numbers in each group as S , I, and R, respectively. An SIR model
with no disease-related death is written as
dS
dt = bN − βIS − dS ,
dI
dt = βIS − γI − dI,
dR
dt = γI − dR, (1.1)
where the total population size is N, the birth rate is b, the common death rate for each group is
d, the infectivity is β, and the recovery rate is γ [1]. The recovery group can be reduced under
the assumption that the total population size is constant. Subsequently, the 3-dimensional
SIR model is reduced to a 2-dimensional SI model. Similarly, an in-host model tracks the
transmission of an infectious agent, for example a virus, from cell to cell within the body
of a single infected individual [12]. The basic model in this case also has three variables:
uninfected cells, X; infected cells, Y , and free virus particles, V . These variables can either
denote the total population size in an infected individual or population density in blood or
tissue [12]. Compared with the host cell, the infectious agent, such as a virus and bacterium,
is characterized by a short lifespan and extremely high reproduction rate. Due to these high
production and clearance (birth and death) rates, virus particles can be assumed to be in a
quasi-steady state with the population of infected cells, and eliminated from the system [12].
This step results in a 2-dimensional within-host model, which is proved to be equivalent to the
2-dimensional epidemic model in Chapter 4.
The spread of disease is a key point in modelling, and the rate at which new individuals are
added to the population of infectives is referred to as the incidence rate [4]. The functional form
of this term varies according to the properties of the disease and the hypothesis considered.
Based on the law of mass action, the spread of disease is usually written as the infection force,
multiplied the number of susceptibles [2]. The infection force describes the transition rate from
the susceptibles to infectives, and is usually a function of the number of infectives. The most
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common form of the infection force is linear, that is βI, where β is the per capita contact rate,
with the assumption of homogeneous mixing of both susceptible and infective populations.
By considering heterogeneous mixing and saturation effects due to fewer susceptibles being
available with the growth of the infective population, the infection force can be modified to be
an increasing and concave function in terms of the number of infectives [9]. In contrast, the
infection force may take the form of an increasing and convex function, if cooperative effects
are considered, for example if infected cells make other host cells more vulnerable to infection
[15, 17, 18].
1.2 Mathematical theories and methodologies used to study
recurrence in biological models
Biological models are characterized by changes, and differential equations are laws that rule
changes. For biological models described by differential equations, the description of the dy-
namical behavior of the differential equations is the description of the time evolution of the
biological system. The differential equations are also referred to as a dynamical system. The
solution determines how the dynamical system develops in time. For most differential equa-
tions, describing real-world problems, their solution formula or analytic solutions are difficult
or even impossible to obtain. Therefore, we apply dynamical systems theory, in particular,
qualitative methodologies including stability and bifurcation analysis to extract important in-
formation and show the fundamental, long-term qualitative behavior of the system.
In this study, we concentrate on continuous differential equation models, which is a reason-
able approximation to describe the continuous overlap of cells’ and infectious agents’ genera-
tions. Nonlinear systems theory and methodologies are applied to investigate the complexity
of the biological systems. To reveal intrinsic mechanisms underlying complex phenomena in
disease models, we use simple deterministic models to predict the long-term behavior of the
disease. In particular, asymptotic behavior is examined, such as local and global stability of
equilibrium solutions, and bifurcations from the equilibrium solutions, leading to Hopf bifur-
cation and even more complex bifurcation such as homoclinic orbits.
1.2.1 Stability analysis for equilibrium solutions
Mathematical analysis of population dynamics usually first proves well-posedness of the solu-
tions, that is, the solutions of the system should be positive and bounded due to their biological
meaning. Equilibrium solutions expose the steady-state features of the system, which can be
either stable or unstable depending upon whether the solution trajectories of the system con-
verge towards the equilibrium or diverge away from it. The stability of an equilibrium solution
can be characterized, in the sense of Lyapunov stability theory, as local or global depending
on whether the final state depends on the initial condition. In other words, global asymptotic
stability means that any solution trajectory of the system will return to the equilibrium from
any initial point in the state space; while for local asymptotic stability this only occurs for
initial points near the equilibrium solution. The path of convergence may be either direct, i.e.
without oscillating, or with oscillating behavior. Besides equilibrium solutions, many biologi-
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cal systems may exhibit complex behavior such as limit cycles, for which the trajectories may
approach or diverge from a periodic solution. We can also define the stability of limit cycles,
as stable or unstable, depending on whether they attract or repel nearby trajectories. Local
stability of the equilibrium solution can be obtained by examining the corresponding charac-
teristic equation, and usually (especially for higher-dimensional dynamical systems) applying
the Routh-Hurwitz stability criterion. This process often involves solving multivariate poly-
nomials. The Lyapunov function method (or Lyapunov direct method) is usually applied to
prove the well-posesness of the solutions and the global stability of equilibrium solutions. For
limit cycles, however, finding their stability is more involved, and requires more sophisticated
mathematical methods to be discussed next.
1.2.2 Bifurcation analysis
Bifurcation theory is fundamental for the qualitative study of dynamical systems, and can
be used to reveal complex dynamical behaviors of the biological systems under study, such
as bistability, recurrence, and regular oscillation. Characterized by a controllable parameter,
called the bifurcation parameter, bifurcation occurs at a critical value of this parameter where
the properties of equilibria change significantly. These qualitative changes can be illustrated in
a bifurcation diagram. Bifurcations can be divided into two principle classes: local bifurcations
and global bifurcations. Local bifurcations occur when the local stability of an equilibrium
changes, leading to the birth of another equilibrium solution or a limit cycle, as the bifurcation
parameter passes through a critical value. Therefore, the characteristic equation and Routh-
Hurwitz stability criterion can be applied to study local bifurcations. More precisely, the local
bifurcations can be classified as saddle-node, transcritical, and pitch-fork bifurcations, which
characterize the “jump” from one equilibrium solution to another equilibrium solution. In
this thesis, for the convenience of use in Applied Science and Engineering Society, we call
the saddle-node bifurcation point, the “turning point”. Hopf bifurcation, which characterizes
the “birth of motion” from an equilibrium solution to periodic motion. Global bifurcations,
on the other hand, occur when periodic orbits collide with each other, or with equilibria, and
cause changes in the topology of the trajectories out of a small neighborhood. The terminol-
ogy “unfolding” determines the codimension of a bifurcation, that is, how many bifurcation
parameters are required to characterize the fundamental dynamical behavior of the system. In
this study, we mainly focus on local bifurcations including saddle-node, transcritical and Hopf
bifurcations, which are all codimension-one bifurcations. We will also investigate the well-
studied codimension-two bifurcation: Bogdanov-Takens bifurcation, since it can lead to the
global bifurcation: homoclinic bifurcation. We will pay more attention to Hopf bifurcation and
homoclinic bifurcation, since they provide two mechanisms for generating recurrence.
1.2.2.1 Hopf bifurcation
Hopf bifurcation is perhaps the most typical way to generate limit cycles and recurrent phe-
nomenon. It occurs when the Jacobian matrix of a dynamical system, evaluated at an equilib-
rium, contains a simple pair of purely imaginary eigenvalues, giving rise to a nonhyperbolic
critical point: the Hopf bifurcation point. The stability of the limit cycle is determined by the
behavior of the solution trajectories of the system on the center manifold near the Hopf bifurca-
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tion point. Center manifold theory provides a means for systematically reducing the dimension
of the state space, resulting in a center manifold with reduced dimension. Further simplifying
the differential equations, describing the dynamical behavior on the reduced center manifold,
by additional coordinate transformations yields the normal form for the Hopf bifurcation. The
qualitative picture of the flows of Hopf bifurcation can be revealed by analyzing the stabil-
ity and bifurcations based on the normal form, and the stability of the bifurcating limit cycle is
determined by the coefficients of the normal form. Hopf bifurcations can be classified as super-
critial or subcritical, indicating whether the bifurcating limit cycle is stable or unstable. Center
manifold theory and normal form theory are the two most powerful and useful mathematical
tools in the study of stability and bifurcations for nonlinear dynamical systems.
1.2.2.2 Bogdanov-Takens bifurcation and homoclinic orbits
A homoclinic or saddle-connection bifurcation occurs when a limit cycle collides with a saddle
point. It is a global bifurcation and may arise from Bogdanov-Takens bifurcation. Bogdanov-
Takens bifurcation is characterized by a double-zero eigenvalue of the linearized system around
an equilibrium solution. The existence of homoclinic bifurcation, associated with Bogdanov-
Takens bifurcation, may provide a global mechanism for the existence of limit cycles and recur-
rence. By applying a rescaling or blow-up approach on the normal form obtained associated
with Bogdanov-Takens bifurcation, we may obtain a Hamiltonian system and thus properly
define a Melnikov function used to determine the homoclinic bifurcation curve, leading to
bifurcation of homoclinic orbits. Further, this approach can be employed to identify the pa-
rameter region where limit cycles exist between the Hopf bifurcation curve and the homoclinic
bifurcation curve.
1.3 Thesis contribution and structure
In this thesis, we study recurrent phenomena in infectious diseases and autoimmune diseases,
which are described by deterministic, ordinary differential equations. Local and global mech-
anisms generating recurrence are provided in explicit mathematical formulae, associated with
Hopf bifurcation, Bogdanov-Takens bifurcation and homoclinic bifurcation. Biologically, we
find that recurrent behavior can be an intrinsic property in disease dynamics. For infectious dis-
ease, an increasing and saturating infectivity function can be the determining component for
recurrence. While, for autoimmune disease, recurrence can be attributed to the newly discov-
ered terminally differentiated regulatory T cells. From the viewpoint of modeling, we believe
that the investigation of the relation between backward bifurcation and Hopf bifurcation reveals
a important finding: a convex incidence function is the key player in determining the bistable,
recurrent, and regular oscillating behaviors for a simple 2-dimensional infection model.
In Chapter 2, the dynamics of HIV viral blips are studied by investigating an established 4-
dimensional HIV antioxidant therapy model. A new blips-generating mechanism is proposed,
that is, infection makes the host more vulnerable to be infected, and is modeled by an increas-
ing, saturating infectivity function. Four conditions are proposed for proving the existence of
recurrence in deterministic in-host models.
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Chapter 3 is devoted to considering recurrent behavior in an autoimmune model. By in-
troducing a newly discovered regulatory T cell subtype, the autoimmune disease model can
exhibit Hopf bifurcation and further generate recurrent behavior.
In Chapter 4, the relation between backward bifurcation and Hopf bifurcation is examined
for exploring recurrence, by investigating the infectious disease model established in Chapter
2 as well as the autoimmune model studied in Chapter 3. We identify the parameter region
where bistability, recurrence, and regular oscillation can occur.
Chapter 5 provides a further study on the simplest 2-dimensional HIV model (established
in Chapter 2) to generate recurrence. More bifurcation parameters are involved in the study
to demonstrate complex dynamical behavior. A new mechanism for generating recurrence is
obtained from Bogdanov-Takens bifurcation and homoclinic bifurcation.
Finally, the conclusion of the thesis and discussion of future work are given in Chapter 6.
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Chapter 2
Conditions for Transient Viremia in
Deterministic In-host Models: Viral Blips
Need no Exogenous Trigger
2.1 Introduction
Viruses are infectious intracellular parasites: they can reproduce only inside the living cells of
host organisms, and must spread from host to host for continued existence. Animal viruses tend
to exhibit either an acute or persistent mode of host infection to ensure this continuity [40]. An
acute viral infection is characterised by a relatively short period of symptoms, and resolution
within days or weeks. It usually triggers the host immune response to clear the infection, and a
memory response can then prevent the same virus from infecting the same host. Pathogens such
as influenza virus and rhinovirus typically cause acute viral infections. In contrast, persistent
infections [2] establish long-lasting infections in which the virus is not fully eliminated but
remains in infected cells. Persistent infections involve both silent and productive infection
stages without rapid killing or excessive damage to infected cells. Latent infection is a type of
persistent infection.
In latent infection, no clinical signs nor detectable infectious cells can be observed during
the silent or quiescent stage of low-level viral replication. However, the virus has not been
completely cleared, and recurrent episodes of rapid viral production and release can periodi-
cally punctuate relatively long periods in the silent stage. These episodes of recurrent infection
are a clinical phenomenon observed in many latent infections [41]. Recurrent infection can
also occur in the context of drug treatment for persistent infections. Human immunodeficiency
virus (HIV), for instance, can be suppressed by highly active antiretroviral therapy (HAART)
to below the limit of detection for months or years [4, 8], nonetheless supersensitive assays can
still detect low levels of viremia during this stage [8, 31, 30]. Moreover, these long periods
of relative quiescence are typically interrupted by unexplained intermittent episodes of viremia
above the detectable limit, termed viral blips [35, 34]. Although these blips have been the focus
of much recent research [12, 17, 14, 5], their etiology is still not well-understood [17, 34].
To date, many possible explanations for viral blips during HIV infection have been explored
mathematically. An early model of the long-term pathogenesis of HIV [11] incorporates the
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activation of T cells in response to antigen, as suggested earlier by [9]. In [11], both HIV
and non-HIV antigen exposure are considered in a coupled deterministic-stochastic model.
The probability of antigenic exposure evolves continuously in time, and Poisson-distributed
exposure events are generated, by simulation, at the appropriate probabilities. This approach
captures a number of features of long-term HIV dynamics, including episodic ’bursts’ of resid-
ual viral replication. Further work [10] considers the number of distinct antigens which activate
the CD4+ T cell pool as a random variable, coupled to an ordinary differential equation (ODE)
model. Stochastic changes to this number drive fluctuation in the basic reproductive number
and viral load. This model is also able to capture the episodic burst-like nature of residual HIV
viral replication during long-term infection.
More recent models are based on the recurrent activation of latently-infected lymphocytes,
a class of T cells introduced in immunological models by Perelson et al. [32] and Rong et
al. [33], in order to explain the slower second-phase decay of plasma viremia. By introducing
antigen concentrations as an explicit variable, Jones and Perelson [23] developed a system of
ODEs which exhibits viral blips. The model describes programmed proliferation and contrac-
tion of the CD8+ T cell population, and exhibits low viral loads under HAART as expected.
Opportunistic or concurrent infection, modelled as an initial concentration of antigen, activates
the immune system and is shown by numerical simulation to elicit a transient viral blip. The
same authors further showed that occasional intercurrent infections can generate viral blips
by the activation of target cells or latently-infected cells, predicting a power law relationship
between blip amplitude and viral load [24].
In further work, by considering the asymmetric division of latently-infected cells, Rong
and Perelson [34] developed a 4-dimensional ODE model based on the basic model of latent
cell activation [32]. This new model not only generated viral blips but also maintained a sta-
ble latent reservoir in patients on HAART. In this model, latently-infected cells can divide to
produce latently-infected daughter cells, or differentiate into activated, productively-infected
cells, depending on antigen concentrations. In a further 5-dimensional ODE model [35], these
two types of daughter cells were distinguished as dependent variables, and a contraction phase
was added to the activated daughter cells. Numerical simulation showed that both cases gave
rise to viral blips and a stable latent reservoir, which were generated from the activated and the
latently-infected daughter cells, respectively. In both papers [34, 35], the antigenic stimulation
of latently infected cells was modeled as an “on-off” forcing function, and viral blips were
initiated during brief pulses in which this activation function was “on”.
Most recently, a stochastic model developed by Conway and Coombs [5] presented another
possible treatment of latent cell activation. In this model [5], the authors derive the probability
generating function for a multi-type branching process describing the populations of produc-
tively and latently infected cells, and free virus. A numerical approach is then used to estimate
the probability distribution for viral load, which is then used to predict blip amplitudes and fre-
quencies; blip durations are studied by simulation. The authors are able to conclude that with
effective drug treatment and perfect adherence to drug therapy, viral blips can not be explained
by stochastic activation of latently-infected cells, and other factors such as transient secondary
infections, or imperfect adherence, must be involved.
In order to elicit transient episodes of high viral replication, the models described above ei-
ther incorporate transient immune stimulation, for example as a forcing function, or stochastic
approaches. In contrast, recent studies have shown that simple deterministic systems can ex-
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hibit viral blips. Based on the close relation between recurrent infections and antibody (B-cell)
immunodeficiency, Yao et al. [41] investigated a 5-dimensional ODE model which included
antibody concentrations as an explicit variable, and exhibited transient periods of high viral
replication. By numerical simulation at specific, meaningful parameter values, the authors ex-
plored factors affecting the interval between recurrent episodes, and their severity. Later, an
even simpler 4-dimensional antioxidant-therapy model [39] was explored for HIV, and was
similarly used to simulate viral blips with appropriate parameter values. These examples indi-
cate that deterministic systems can produce blips as part of the natural, rich behaviour of the
non-linear system. Although to date numerical simulation has been invaluable in describing
and delineating the behaviour of these models, there is yet very little analytical work exploring
the mathematical underpinnings of recurrent infection. It should be noted that data from clin-
ical studies indicates that HIV viral blips appear to be random biological events, with varying
magnitude, frequency and duration. This suggests that stochastic tractable, and their analysis
may reveal a global picture or key underlying characteristics of the system. Moreover, non-
linear deterministic systems can indeed exhibit varying amplitudes and frequencies of motion,
particularly when the underlying parameters are functions of time. We shall return to a discus-
sion of this point in the last section of the paper.
In this paper, we take advantage of dynamical systems theory to reinvestigate deterministic
in-host infection models that exhibit viral blips. By examining the bifurcation behaviour in
parameter spaces “close” to the region where blips occur, we propose an understanding for
the features of the dynamical system which underlie this complex model behaviour. We then
propose four conditions which, when satisfied, guarantee that an in-host infection model will
exhibit long periods of quiescence, punctuated by brief periods of rapid replication: viral blips.
Based on these conditions, we develop very simple 2- and 3-dimensional models that produce
blips. Further, we apply stability criteria to determine parameter ranges which may yield blips.
Most of the models discussed in this paper share a similar infectivity function, describing
the rate at which new infected cells are created. In a final section, we examine a related 5-
dimensional immunological model and demonstrate that viral blips are possible in this system
even when infectivity is constant.
The rest of the paper is organized as follows. In Section 2, the previously proposed 4-
dimensional HIV antioxidant-therapy model is reinvestigated analytically. Based on the in-
sights of our bifurcation analysis, conditions for generating viral blips are proposed. In Section
3, we use these conditions to propose a simpler 3-dimensional in-host infection model, and
parameter ranges which will exhibit blips in the simpler model are determined. In Section 4,
we develop a 2-dimensional model, characterized by an increasing and saturating infectivity
function, which can also generate viral blips. Finally, we demonstrate that a 5-dimensional
immunological model [41] can exhibit viral blips with constant infectivity.
2.2 A 4-dimensional model which exhibits viral blips
In this section, we reconsider a 4-dimensional HIV antioxidant-supplementation therapy model
which was developed and studied numerically in [39]. This model novelly introduced reactive
oxygen species (ROS) and antioxidants to an in-host model of HIV infection. In uninfected
individuals, ROS play a positive physiological role at moderate levels [16, 25, 7, 20, 18], but
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are harmful at high levels [39].
HIV infection may lead to chronic and acute inflammatory diseases, which may cause
high levels of ROS [26] as well as lowered antioxidant levels; this phenomenon has been
observed clinically and experimentally [26, 15, 22, 36, 38]. In addition, high levels of ROS
may cause damage to CD4+ T cells, impair the immune response to HIV [37], and exacerbate
infected cell apoptosis, releasing more HIV virions. Thus, infected cells produce high levels
of ROS, which in turn increase the viral production by infected cells. To control this cycle,
antioxidant supplementation (vitamin therapy) has been suggested as a potential complement
to HIV therapy [15, 13], with the aim of counteracting and reducing ROS concentrations [16].
The equations of the 4-dimensional model are described by [39]:
x˙ = λx − dxx − (1 − ǫ)β(r)xy,
y˙ = (1 − ǫ)β(r)xy − dyy,
r˙ = λr + ky − mar − drr,
a˙ = λa + α − par − daa,
(2.1)
where x, y, r and a represent respectively the population densities of the uninfected CD4+ T
cells, infected CD4+ T cells, reactive oxygen species (ROS), and antioxidants. The constant
λx denotes the production rate of CD4+ T cells, and dxx is the death rate. Uninfected cells
become infected at rate (1− ǫ)β(r)xy, where ǫ is the effectiveness of drug therapy, and dy is the
per-capita death rate of infected CD4+ T cells. ROS are generated naturally at rate λr, and by
the infected cells at rate k y; the concentration of ROS decays at rate dr r, and is eliminated by
interaction with antioxidants at rate mar. Antioxidants are introduced into the model through
natural dietary intake at a constant rate λa, and through antioxidant supplementation at rate α,
which is treated as a bifurcation parameter. Antioxidants are eliminated from the system by
natural decay at rate daa, and by reacting with the ROS at rate par, where p is much smaller
than m.
An important novel feature of this model is that the infectivity β(r) is a positive, increasing
and saturating function of r (ROS),
β(r) = b0 + r(bmax − b0)
r + rhalf
, (2.2)
where b0 represents the infection rate in the ROS-absent case, while bmax denotes the maximum
infection rate, and rhalf is the ROS concentration at half maximum. It is obvious that β(r) > 0,
and it is also assumed that 0 < ǫ < 1. Therefore, all the parameters in equations (2.1) and (2.2)
are positive. The experimental values used for studying model (2.1) are given in Table 2.1.
Importantly, these parameters were chosen with careful reference to clinical studies, such that
the predicted equilibrium densities are clinically reasonable. Also note that the densities of
antioxidants and ROS are of order 1013 per µL, while cell densities are of the order 102 or 103
per µL.
In [39], this model was explored numerically to assess the potential of antioxidant therapy
as a complement to HIV drug therapy. In that study, regions of oscillatory behaviour, rem-
iniscent of viral blips, were observed. In the following subsections we perform a thorough
equilibrium and stability analysis of the model, in order to shed further light on the factors
underlying these rich behaviours.
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Table 2.1: Parameter values used in model (2.1) [39]
Parameter Value
λx 60.76 cells µL−1 day−1
dx 0.0570 day−1
dy 1.0 day−1
λa 2.74 × 1013 molecules µL−1 day−1
da 0.0347 day−1
ε 13
b0 2.11 × 10−4 cell−1 µL day−1
bmax 0.00621 cell−1 µL day−1
rhalf 3.57 × 1013 molecules µL−1
dr 1.66 × 107 day−1
λr 1.86 × 1021 molecules µL−1 day−1
k 1.49 × 1019 molecules cell−1 day−1
m 1.27 × 10−6 molecule−1 µL day−1
p 5.04 × 10−14 molecule−1 µL day−1
2.2.1 Well-posedness of the solutions of system (2.1)
By using the method of variation of constants, we can easily obtain the solutions of (2.1) to
show that x(t) > 0, y(t) > 0, r(t) > 0, a(t) > 0, ∀ t > 0, if x(0) > 0, y(0) > 0, r(0) > 0, a(0) >
0. To consider the boundedness of the solutions, suppose in general we have the differential
inequality: ˙T ≤ λ−dT (λ, d > 0, T (0) > 0). Then if ˙T = λ − dT , we have ˙T +dT = λ. Thus,
T (t)=T (0)e−
∫ t
0 dds+
∫ t
0 λ e
−
∫ t
s
dduds=T (0) e−d t+λd (1−e−d t), which implies that limt→+∞ sup T (t)= λd .
From the first equation of (2.1), we have x˙≤ λx−dxx, which yields limt→+∞ sup x(t)= λxdx . It is
also easy to see from the first equation of (2.1) that x(t)> 0, ∀ t > 0. Then, by adding the first
two equations of (2.1) we obtain d[x(t)+y(t)]dt =λx−dxx−dyy ≤ λx− ˜d(x+y), where ˜d=min(dx, dy).
Hence, limt→+∞ sup(x(t)+ y(t)) = λx
˜d . Therefore, for any given ε > 0, there exists t
∗ > 0,
such that x + y ≤ λx
˜d + ε, for all t ≥ t∗. For the third equation of (2.1), we similarly have
dr
dt ≤ (λr+k λx˜d )−drr, which results in limt→+∞ sup r(t)= λr
˜d+kλx
dr ˜d
. Finally, for the fourth equation
of (2.1), we get dadt ≤ (λa+α)−da a, and thus limt→+∞ sup a(t)= λa+αda . We define Clearly, Γ is a
positively invariant set and attracts all non-negative solutions of (2.1).
2.2.2 Equilibrium solutions of (2.1) and their stability
To find the equilibrium solutions of (2.1), simply setting x˙ = y˙ = r˙ = a˙ = 0 yields two
solutions: the uninfected equilibrium solution E0, and the infected equilibrium solution E1,
given respectively by
E0 : (xe0, ye0, re0, ae0) =
(
λx
dx
, 0, re0,
λr − dr re0
m re0
)
, (2.3)
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where the re0 is determined by the equation
F0(r, α) ≡ α + λa + 1
m
(
p dr r − da λr
r
)
+
da dr − p λr
m
= 0; (2.4)
and
E1 :
(
xe1, ye1, re1, ae1
)
, xe1 =
dy
(1 − ǫ) βr(re1) ,
ye1 =
λx − dx xe1
(1 − ǫ)βr(re1)xe1 , ae1 =
λa + α
da+pre1
,
(2.5)
where re1 is a function in the system parameters, particularly α (see the function F1 in equa-
tion (2.8)). Both E0 and E1 are expressed in terms of r (re0 or re1) for convenience.
We first consider the uninfected equilibrium E0. The solution of re0 is determined by (2.4),
which is a quadratic equation in r. To simplify the analysis, we use r to express the parameter α
since (2.4) is linear in α, and α is treated as a bifurcation parameter. Thus, solving F0(r, α) = 0
for α we obtain
α0(re0) = −λa − 1
m
(
p dr re0 − da λr
re0
)
− da dr − p λr
m
. (2.6)
To find the stability of the equilibrium solution E0, we first evaluate the Jacobian of system
(2.1) at E0 to get J0(re0), where (2.6) has been used, and then use det(ξ I − J0) to obtain the
4th-degree characteristic polynomial, given by P0(ξ, re0) = (ξ + dx)[ξ2 + (pre0 + da + λrre0 )ξ +
(daλr
re0
+ pdrre0)](ξ + P0r), where
P0r = dy − (1 − ǫ)λx(b0rhalf + re0bmax)dx(re0 + rhalf) . (2.7)
P0(ξ, re0) contains three factors: the first one is a linear polynomial of ξ and the second one
is a quadratic polynomial of ξ, and both are stable polynomials (i.e., their roots (eigenvalues)
have negative real part); and thus the stability of E0 only depends upon the third factor, a
linear polynomial of ξ. Therefore, when P0r > 0 (P0r < 0), the equilibrium solution E0 is
asymptotically stable (unstable).
The graph for the equation F0(r, α) = 0 given in (2.4) is shown as the red line in Fig-
ure 2.1(a), which clearly shows a hyperbola. It is seen from this red line that the relation (2.4)
also defines a single-valued function r in α, if only the positive (biologically meaningful) value
of r is considered, (i.e., the positive branch of the red line in Figure 2.1(a)). More precisely,
it can be shown that the biologically meaningful solution must be located on the first quadrant
and above, including the top branch of red line (see Figure 2.1(a)), since E0 has the component
ye0 = 0.
Next, consider the infected equilibrium solution E1. The solution for re1 can be similarly
obtained by solving the following equation,
F1(r, α) = λr + kλxdy −
kdx(r + rhalf)
(1 − ǫ)(b0rhalf + bmaxr) −
mr(λa + α)
pr + da
− drr = 0, (2.8)
which is again a linear function of α, and we can use re1 to express α as
α1(re1) = −λa + λr(pre1 + da)
mre1
+
kλx(pre1 + da)
mre1dy
− kdx(re1 + rhalf)(pre1 + da)
mre1(1 − ǫ)(b0rhalf + bmaxre1) −
(pre1 + da)dr
m
. (2.9)
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(a) (b)
Figure 2.1: (a): Complete bifurcation diagram for the 4-dimensional HIV antioxidant-therapy
model (2.1) projected on the r-α plane, with the red and blue lines denoting E0 and E1, respec-
tively; and (b): Bifurcation diagram in (a), restricted in the first quadrant, with the dotted and
solid lines indicating unstable and stable, respectively.
The graph of the equations F0(r, α) = 0 given in (2.4) and F1(r, α) = 0 given in (2.8) is shown
in Figure 2.1(a). To find the stability of E1, in a similar way, we evaluate the Jacobian of (2.1)
at E1 to obtain the 4th-degree characteristic polynomial, P1(ξ, re1)= ξ4+ a1(re1)ξ3+ a2(re1)ξ2+
a3(re1)ξ+ a4(re1), where the lengthy expressions for the coefficients a1(re1), a2(re1), a3(re1), and
a4(re1) are omitted here for brevity.
2.2.3 Bifurcation analysis
To understand the conditions underlying oscillatory behaviour and viral blips in this model, we
now consider possible bifurcations which may occur from the equilibrium solutions E0 and E1.
2.2.3.1 Transcritical bifurcation
First, for the uninfected equilibrium E0, it follows from P0(ξ, re0) and (2.7) that in general E0
is stable for P0r > 0, and the only possible singularity occurs at the critical point, determined
by P0r = 0 (see (2.7)). At this point, one eigenvalue of the characteristic polynomial becomes
zero (and the other three eigenvalues still have negative real part), leading to a static bifurcation,
and E0 becomes unstable. More precisely, when the parameter values in Table 2.1 are used,
the two equilibrium solutions E0 and E1 intersect and exchange their stability at the point(
rt, αt
) ≈ (8.89×1012, 4.58×1013), indicating that a transcritical bifurcation occurs at this
critical point (see Figure 2.1(b)). Here, the subscript ‘t’ stands for transcritical bifurcation. The
value of αt is obtained by substituting rt into either α0(rt) in (2.6) or α1(rt) in (2.9). In fact,
α0(rt) = α1(rt).
As discussed above, the biologically meaningful solutions should be above or on the unin-
fected equilibrium solution E0 (the red line shown in Figure 2.1(b)), since solutions below the
red line contain the component y < 0. It is obvious that there is no Hopf bifurcation from E0.
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Figure 2.2: The saddle-node bifurcation on the center manifold with the dotted line indicating
unstable and the solid line stable: (a) in the transformed x1-µ coordinates; and (b) in the original
coordinates.
So, the uninfected equilibrium E0 is asymptotically stable (unstable) when r < rt (r > rt) or
α > αt (α < αt)(see Figure 2.1(b)).
It should also be noted from Figure 2.1(b) that besides a transcritical bifurcation point, E1
has a saddle-node bifurcation which occurs at the so-called turning point. To determine this
turning point, using (2.9) and dα1(r)dr = 0, yields (rs, αs) ≈
(
1.72×1013, 5.06×1013
)
, where the
subscript ‘s’ denotes saddle-node bifurcation, and αs = α1(rs) by using (2.9). Note that this
bifurcation does not change the stability of E1, since the characteristic polynomial P1(ξ, re1)
still has an eigenvalue with positive real part when re1 (or α) is varied along E1 to pass through
the turning point (see Figure 2.1(b)).
The saddle-node bifurcation can be seen more clearly if we examine the local dynamics
close to the turning point; this analysis will also be useful later for analysing viral blips. At
the turning point, the system contains a 1-dimensional center manifold (whose linear part is
characterised by the eigenvalue ξ11 = 0), a 1-dimensional unstable manifold (whose linear part
is characterised by the eigenvalue ξ12 ≈ 0.142), and a 2-dimensional stable manifold (whose
linear part is characterised by the eigenvalues ξ13 ≈−0.290 and ξ14 ≈−1.26 ×108), as shown in
Figure 2.2. It is noted that the eigenvalues ξ12 and ξ11, which are both positive at the saddle-node
point, become a pair of complex conjugates with positive real part at the orange-color point
above the saddle-node point (see Figure 2.1(b)), moving towards the Hopf point. So the sub-
manifold that is the complement to the centre manifold is still expelling till meeting the Hopf
bifurcation point.
In order to find the differential equation described on the center manifold, we first apply
the transformation (x, y, r, a)T = (xe1, ye1, re1, ae1)T + Ts(x1, x2, x3, x4)T , where (xe1, ye1, re1, ae1)
is the infected equilibrium solution E1, and Ts is a constant, non-singular matrix. Under this
transformation, the Jacobian of system (2.1) becomes the Jordan canonical form: Λs ≈ Diag
{0, 0.142, −0.290, −1.26×108}. Then, by using center manifold theory [19] on the transformed
system of (2.1), we get the differential equation describing dynamics of the system, restricted
to the center manifold: x˙1≈−2.66×10−12µ−1.93×10−4x21, for which the perturbation value of µ
near the saddle-node point is roughly µ ≈ 1012, about 2% of α (see Figure 2.1(b)), as expected.
The bifurcation diagram restricted on the center manifold is depicted in Figure 2.2(a), with
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the corresponding bifurcation diagram in the original system, projected in the α-r plane as
shown in Figure 2.2(b). It should be noted that the scaling between the graphs in Figures 2.2(a)
and 2.2(b) depends upon the transformation matrix Ts. Also, note that the upper half branch
in Figure 2.2(a)(denoted by the solid line) indicates that it is stable, but is only restricted to
the 1-dimensional center manifold. For the whole system, this branch is still unstable since the
system contains an unstable manifold (as shown in Figure 2.2(b)).
2.2.3.2 Hopf bifurcation and limit cycles
To find any possible Hopf bifurcation which may occur from the infected equilibrium E1, we
first need to determine the critical points at which Hopf bifurcation occurs. The necessary and
sufficient conditions for general n-dimensional systems to have a Hopf bifurcation are obtained
in [43]. To state the theorem, consider the following general nonlinear differential system:
x˙ = f (x, α), x ∈ Rn, α ∈ Rm. (2.10)
with an equilibrium determined from f (x, α)=0, as, say, xe= xe(α). To find the stability of xe,
evaluating the Jacobian of system (2.10) at x= xe(α) yields J(α)=Dx f |x=xe(α)=
[∂ fi(xe(α),α)
∂x j
]
. The
eigenvalues of the Jacobian J(α) are determined by the following characteristic polynomial:
Pn(λ) = det[λI − J(α)]
= λn + a1(α) λn−1 + a2(α) λn−2 + · · · + an−2(α) λ2 + an−1(α) λ + an(α).
(2.11)
Then, by the Hurwitz Criterion [21], we know that the equilibrium solution xe(α) is asymp-
totically stable if and only if all the roots of the polynomial Pn(λ) have negative real part, or
equivalently, if and only if all the following Hurwitz arrangements ∆i(α), (i = 1, 2, · · · , n) are
positive:
∆1 = a1, ∆2 = det
[
a1 1
a3 a2
]
, ∆3 = det

a1 1 0
a3 a2 a1
a5 a4 a3
, · · · ∆n = an · ∆n−1.
Having defined the Hurwitz arrangements as above, we have the following theorem.
Theorem 2.2.1 [43] The necessary and sufficient condition for a Hopf bifurcation to occur
from the equilibrium solution xe(α) of system (2.10) is ∆n−1 = 0, with an > 0 and ∆i > 0, for
1 ≤ i ≤ n − 2.
In order to further consider the post-critical dynamical behaviour of the system and to de-
termine the stability of bifurcating limit cycles, we may apply normal form theory to system
(2.10). Assume that at a critical point α = αc, the Jacobian of (2.10) evaluated at the equilib-
rium xe contains a pair of purely imaginary eigenvalues ±iωc, and all other eigenvalues have
negative real part. Then, the normal form of system (2.10) associated with Hopf bifurcation
can be written in polar coordinates as (e.g., see [42])
dρ
dt = ρ
(
v0 µ + v1 ρ
2 + · · ·
)
,
dθ
dt = ωc + t0 µ + t1 ρ
2 + · · · , (2.12)
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where µ=α − αc, ρ and θ denote the amplitude and phase of motion, respectively. Then, the
first equation of (2.12) can be used to approximate the amplitude of bifurcating limit cycles
and to determine their stability. The second equation of (2.12) can determine the frequency
of periodic motion. The coefficient v1, usually called the first-order focus value, plays an
important role in determining the stability of limit cycles. When v1 < 0 (v1 > 0, respectively),
the Hopf bifurcation is called supercritical (subcritical) and the bifurcating limit cycles are
stable (unstable). The Maple program developed in [42] can be easily applied to system (2.10)
to obtain the normal form (2.12). The coefficients v0 and t0 for the linear part of system (2.10)
can be found from a linear analysis, given by [44], v0 = 12 (a11+a22), t0 = 12(a12−a21), where
ai j=
∂ fi
∂x j∂µ
, evaluated at the critical point.
We now apply the above formula to consider the infected equilibrium E1 of system (2.10).
To check if there exists Hopf bifurcation from E1, based on the fourth-degree characteristic
polynomial P1(ξ, re1), we apply the formula ∆3=a1a2a3−a23−a21a4=0 and solve this equation
for r to obtain a unique value, rH > 0, such that (by using (2.9)) αH = α1(rH) > 0. When the
parameter values in Table 2.1 are used, these critical values are given by: (rH, αH) ≈ (6.72×
1013, 2.64×1013), at which the Jacobian of system (2.1) contains a purely imaginary pair and
two negative real eigenvalues: ±0.308 i, −1.66, and −3.66×107. Thus, as α is varied across αH,
a Hopf bifurcation occurs from E1, leading to a family of limit cycles.
To find the approximate solutions of the limit cycles and to determine their stability, we
apply normal form theory to this model associated with this singularity. First, we apply a
transformation (x, y, r, a)T = (xe1, ye1, re1, ae1)T +TH (x1, x2, x3, x4)T , where (xe1, ye1, re1, ae1) is
the infected equilibrium solution E1, and TH is a constant, non-singular matrix. We obtain
a transformed system of (2.1), which is omitted here due to its lengthy expression. Then,
applying the formulas v0 = 12(a11+a22), t0 = 12 (a12−a21) to the transformed system, we obtain
v0 ≈ 3.15× 10−15 and t0 ≈ 3.33× 10−15. Further, we apply the Maple program [42] to the
transformed system to obtain v1≈−4.18×10−7, and t1≈−3.38×10−6. Thus, the normal form up
to third order is given by
dρ
dt ≈ ρ(3.15 ×10
−15µ − 4.18 ×10−7ρ2 + · · · ),
dθ
dt ≈ 0.308+3.33×10
−15 µ−3.38 ×10−6ρ2+· · · .
(2.13)
The first equation of (2.13) can be used to analyze the bifurcation and stability of bifurcating
limit cycles. Setting dρdt = 0 results in two solutions: ρ = 0, which represents the infected
equilibrium solution E1; and ρ ≈ 8.68 ×10−5 √µ (µ > 0), which is an approximation of the
amplitude of bifurcating limit cycles. Since v1 < 0, this is a supercritical Hopf bifurcation,
and bifurcating limit cycles are stable. For example, choose µ = 1012. Then, the approximate
amplitude of the limit cycle is ρ ≈ 86.8, and the frequency of the limit cycle approximately
equals ω ≈ 0.283, slightly less than ωc ≈ 0.308. The phase portrait of the simulated limit cycle,
projected on the x-y plane, is shown in Figure 2.3(d). It can be seen from Figure 2.3(a) and (d)
that the analytical prediction from the normal form, ρ ≈ 86.8, agrees well with the simulated
result.
The above analysis based on normal form theory is for local dynamical behaviour, that is,
the limit cycles must be near the Hopf critical point (rH, αH). It can be seen from Figure 2.1(b)
that values of α taken from the interval α ∈ (αH, αt) lead to unstable equilibrium solutions
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Figure 2.3: Simulated limit cycles of system (2.1) for the parameter values taken from Table
2.1, with the time course of x and y on the top row, and the corresponding phase portraits
projected on the x-y plane on the bottom row. For (a) and (d) α = 2.74 × 1013, (b) and (e)
α = 3.50 × 1013, and (c) and (f) α = 4.55 × 1013.
(since both E0 and E1 are unstable for this interval). However, due to the solutions being
non-negative and bounded, we expect that there should exist certain persistent motion such as
oscillating solutions for the values of α taken from this interval, and the amplitudes of these
oscillations can be large. For example, for α = 3.50 × 1013, the phase portrait of the simulated
solution, projected on the x-y plane is shown in Figure 2.3(e), corresponding to the oscillations
in time shown in Figure 2.3(b), which have much greater amplitude than the oscillations in
Figure 2.3(a).
Now, we take a particular value of α from the interval α ∈ (αH, αt), which is close to αt, to
simulate the system. For example, taking α=4.55×1013<αt≈4.58×1013, we obtain the phase
portrait of the simulated oscillating solution, projected on the x-y place, shown in Figure 2.3(f)
with corresponding time history of x and y shown in Figure 2.3(c). This clearly shows viral
blips.
Next, we will discuss what conditions are needed for creating the phenomenon of viral
blips.
2.2.4 Conditions for generating viral blips
In the previous subsection, we carefully analysed the occurrence of viral blips in a 4-dimensional
HIV model (2.1). System (2.1) is an example of in-host infection model, an ODE system de-
scribing the dynamics of infection within a single infected individual. In-host infection models,
based on classical Susceptible-Infected-Recovered (SIR) models in epidemiology [1], typically
include populations of uninfected target cells, infected target cells, and the infection dynamics
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between the two classes [28]. More complex models also include populations of free virus,
latently-infected cells, and various relevant components of the immune response, depending
on the infection under study. Although there are many exceptional cases, in-host models typ-
ically admit an uninfected equilibrium and at least one infected equilibrium, analogous to the
disease-free and endemic equilibria of an SIR model.
Since in-host infection models share many similar features, much of our understanding
regarding the behaviour of system (2.1) can be generalized to other models. Based on insights
obtained in analysing system (2.1), we propose in the following hypothesis four conditions for
an in-host infection model to generate viral blips.
Hypothesis 1: The following conditions are needed for an in-host infection model to gen-
erate viral blips:
(i) there exist at least two equilibrium solutions;
(ii) there exists a transcritical bifurcation at an intersection of the two equilibrium solutions;
(iii) there is a Hopf bifurcation which occurs from one of the equilibrium solutions; and
(iv) large oscillations (or more generally, global, persistent motions) can occur near the tran-
scritical critical point.
The reasons for conditions (i) and (ii) are simple, because when a parameter that reflects in-
fection severity is chosen as a bifurcation parameter, an in-host infection model typically starts
at the uninfected equilibrium and then bifurcates to the infected equilibrium as the parameter is
increased. Thus, these two equilibrium solutions must exchange their stability, yielding a tran-
scritical bifurcation. For the 4-dimensional model considered in the previous subsection, the
uninfected equilibrium E0 and the infected equilibrium E1 intersect at the critical point (αt, rt),
where they exchange their stability. In fact, E0 is stable (unstable) for α > αt (α < αt), while
the lower branch of E1 is stable (unstable) for α < αt (α > αt), as shown in Figure 2.1(b).
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Figure 2.4: Schematic diagram for explaining
the occurrence of blips.
Condition (iii), the existence of a Hopf bi-
furcation, is necessary to obtain oscillations.
It can be seen from Figure 2.1(b) that limit
cycles bifurcate from E1 at the Hopf critical
point (αH, rH), and the limit cycles become
larger if µ = α − αH > 0 increases.
The reasoning behind the last condition
(iv) is not so obvious. Large oscillations
(or global, persistent motions) are necessary,
near the transcritical point, for viral blips to
emerge. As shown in Figure 2.1(b), both E0
and E1 are unstable for α ∈ (αH, αt) (though
a part of the lower branch of E1 is stable but
it is biologically meaningless due to y < 0).
Thus, there exist large oscillations near the
transcritical critical point αt. Moreover, it is
noted from Figure 2.1(b) that at the left side
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of the transcritical point αt, the eigenvalues
evaluated at E0 are all real, containing one positive eigenvalue (ξ01 > 0) and three negative
eigenvalues (ξ0i < 0, i = 2, 3, 4). In other words, any point on the uninfected equilibrium E0 for
α < αt is a saddle point. Since ξ01 crosses zero at the critical point α = αt, ξ01 is very small near
the critical point for α < αt.
Now suppose we consider a value of α < αt, but near the critical point α = αt (e.g.,
α = 0.455 × 1014, as shown in Figure 2.3(c) and (f)). For simplicity, we may consider a sub-
manifold whose linear part is characterized by the eigenvalues ξ01 and ξ02, and the corresponding
coordinates are x01 and x02, respectively. A solution trajectory of system (2.1) for such a value of
α, projected on this submanifold, is depicted in Figure 2.4. Due to 0 < ξ01 ≪ 1, the trajectory
moves away from the critical point very slowly near the x01-axis, while it moves rapidly toward
the critical point near the x02-axis since |ξ02 | is not small. Further, due to the global boundedness
of solutions, the part of the trajectory which is not close to the saddle point moves rapidly, as
shown in Figure 2.4. This fast-slow motion yields the blips phenomenon, with slow changes
corresponding to the near-flat section in the time history, and rapid changes occurring during
the viral blips, as shown in Figure 2.3(c) and (f). In other words, the trajectory spends relatively
long periods in regions of state space which lie very close to the uninfected equilibrium, then
transiently visits regions of state space which are close to the infected equilibrium.
2.3 A simple 3-dimensional in-host infection model produc-
ing blips
Having established the conditions in Hypothesis 1 for generating viral blips, we are ready to
turn to some basic questions such as: what types of in-host infection model can generate blips?
and, what is the minimum dimension of such models?
2.3.1 Generalizing ROS to other physical variables
In model (2.1), the variable r represents ROS, which are produced naturally in the body. In HIV
infection, extra ROS are generated by infected cells, and these in turn directly accelerate HIV
progression [29, 36]. Therefore, infectivity β is an increasing and saturating function of ROS
concentrations. However, we note that the form of the infection term is not specific to HIV nor
to ROS, and models of a similar form could in fact apply to other infections. To generalize the
physical meaning of the variable r, we can for example let r denote any damage caused by the
infection, for example to the humoral immune response, to infected organs, or to the infected
individual aspecifically. The model assumes that “damage” increases with the extent of the
infection at rate ky, and is repaired or cleared at rate drr. This yields the 3-dimensional system:
x˙ = λx − dxx − β(r)xy, y˙ = β(r)xy − dyy, r˙ = ky − drr. (2.14)
To achieve an infection term similar to that in model (2.1), we further assume that accrued
damage makes target cells more vulnerable to infection, that is, accrued damage increases the
infection rate. We thus take β(r) to be an increasing, saturating function of r.
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In the original model (2.1), r represents ROS, for example H2O2, whose production and
decay rates are both extremely fast. For the more general model (2.14), we would like to
assess whether viral blips are still possible at more moderate production and repair rates, k
and dr. For ROS the decay rate dr = 1.66 ×107 day−1 implies a half life of only 4ms. We
decreased dr by several orders of magnitude; in particular, at dr = 1.0×103 day−1, a half life
of 60s, we find that viral blips are still possible. For this value of dr, we can take k = 1.49 ×
1015 molecules cell−1 day−1. Note that λr has been set to zero in (2.14) to make the model more
general.
For simplicity, let a= bmax−b0, b= b0 and c= rhalf. Then, the function β(r) is rewritten as
β(r)=b+ a r
r+c
, and a, b, and c are treated as bifurcation parameters. Parameter values λx, dx, dy,
k, dr, b0, bmax, and rhalf are given in Table 2.1. For practically meaningful solutions, the values
of the bifurcation parameters will be chosen close to the values in Table 2.1.
To analyze (2.14), we can follow the same procedure used in the previous section and treat
b as a bifurcation parameter. First of all, it is easy to prove the well-posedness of system (2.14).
Next, we get the infection-free equilibrium E0 : (xe0, ye0, re0) = (λx/dx, 0, 0) and the infected
equilibrium E1 := (xe1, ye1, re1), where xe1= dy(re1+c)(a+b)re1+bc , ye1= 1dy (λx−dxxe1), and re1 is determined
by F1(r, c) = drdy(a+b)r2+[dy(d)rbc−kdx)−kλx(a+b)] r+kc(dxdy−bλx = 0. Again, it is easy
to show that E0 and E1 intersect at the transcritical bifurcation point (bt, rt) ≈ (9.38×10−4, 0).
On the infected equilibrium E1, there are two saddle-node bifurcation points (turning points),
(bs1 , rs1) ≈ (−1.49×10−3, 4.18×1013), and (bs2 , rs2) ≈ (−5.77×10−3, 3.05×1014), and a Hopf
bifurcation point (bH, rH) ≈ (6.56×10−4, 7.24×1013).
The bifurcation diagram and simulated results are shown in Figure 2.5. All the conditions
(i)-(iv) in Hypothesis 1 are satisfied. Blips do appear since the Hopf critical point is close to
the transcritical point. However, because E0 is not globally stable, depending on the initial
conditions, the oscillation may converge to the stable equilibrium E1 (see Figure 2.5(c)), or
converge to a limit cycle with large amplitude (blips), as shown in Figure 2.5(d). Convergence
to a smaller, regular oscillation due to the Hopf bifurcation is also possible (not shown in
Figure 2.5).
2.3.2 Identifying the region of parameter space exhibiting viral blips
Having found viral blip behaviour in the simple 3-dimensional infection model (2.14), we are
now further interested in identifying the region of parameter space in which viral blips may
occur. This is particularly useful in applications since in reality, all parameters are roughly
measured. Thus, we need to study the robustness of the phenomenon to variations in the system
parameters. If blips only appear for a very small region in the parameter space, then the results
are not practically useful. The main idea of identifying the region where blips may occur is to
study the instability of the solutions of the system. Once the unstable region is identified, blips
can be found by using the other conditions in Hypothesis 1. In order to simplify the analysis,
we first introduce state variable scaling and parameter rescaling into system (2.14).
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Figure 2.5: Dynamics and bifurcation of system (2.14) for dr = 1.0×103, k = 1.49×1015: (a)
bifurcation diagram projected on the b-r plane; (b) a close-up of part (a); (c) simulated time
history y(t) converging to E1 for b = 0.001 with the initial condition (x, y, r) = (178, 46, 73)
close to E1; and (d) simulated time history y(t) converging to a stable limit cycle (blips) for
b = 0.001 with the initial condition (x, y, r)= (1005, 3, 3) close to E0.
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Figure 2.6: (a) Graph of ∆2 = 0 in the A-B-C parameter space, identifying the region yielding
oscillations; (b) cross section of panel (a) where A = 0.364; and (c) cross section of panel (a)
where C=3.94 ×10−4.
2.3.2.1 State variable scaling and parameter rescaling
Introducing the following scaling x= c1X, y= c2Y, r= c3R, t= c4τ, where c1 = λxdy , c2 =
λx
dy , c3 =
λxk
1013d2y
, c4 =
1
dy , to (2.14) and letting A =
a λx
d2y
, B = b λxd2y , C =
c d2y
1012λx k , Dx =
dx
dy , Dr =
dr
dy , yields the
following scaled system
˙X = 1 − DxX −
(
B +
AR
R +C
)
XY, ˙Y =
(
B +
AR
R +C
)
XY − Y, ˙R = Y − DrR, (2.15)
which will be used in the following analysis, with the scaled parameter values given by
A = 0.364, C = 3.94 × 10−4, Dx = 0.057, Dr = 1000, (2.16)
and B is treated as a bifurcation parameter.
2.3.2.2 Equilibrium solutions and their stability
The bifurcation patterns of the scaled system (2.15) are the same as that of system (2.14). Two
equilibrium solutions are E0 : (Xe0, Ye0, Re0) = (1/Dx, 0, 0), and E1 : (Xe1, Ye1, Re1), where
Xe1 = Re1+C(A+B)Re1+BC , Ye1 = 1 −
Dx(Re1+C)
(A+B)Re1+BC , and Re1 is determined from the equation F3(R) =
Dr(A+B)R2+[Dr(BC+1)−(A+B)]R+Dr−B)C=0.
The characteristic polynomial for E0 is P0(ξ) = (ξ + Dx) (ξ + Dr) (ξ − BDx ). It is easy to
show that E0 and E1 exchange stability at the transcritical bifurcation point B = Dx. The
characteristic polynomial for E1 is P1(ξ) = ξ3 + a1(r)ξ2 + a2(r)ξ + a3(r), and Hopf critical point
is determined by ∆2 = a1(r) a2(r) − a3(r) = 0. We fix parameters Dr and Dx, and choose A,
B and C as bifurcation parameters. Then, we want to find the parameter region where blips
may occur. First of all, a Hopf bifurcation is necessary, requiring the condition ∆2(A, B,C)=0.
The graph of ∆2(A, B,C)=0 is plotted in the 3-dimensional A-B-C parameter space, as shown
in Figure 2.6(a), where the green hypersurface defines a set of points which are Hopf critical
points; and the region bounded by the green surface is unstable for E1, leading to oscillations.
Thus blips may occur within this region and near the boundary as well, depending on the
relative position of the Hopf critical point with respect to the transcritical point.
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In the following, we fix either parameter A or C to obtain two-dimensional graphs, which
illustrate more clearly the bifurcations necessary for blips.
2.3.2.3 Parameter A fixed
Fix A = 0.364, which cuts the surface in Figure 2.6(a) to yield curves, as shown in Fig-
ure 2.6(b). The transcritical bifurcation occurs at B = 0.057, which is denoted by a red line in
Figure 2.6(b). A Hopf bifurcation occurs on the green curve, and the region bounded by the
green and red curves indicates where oscillations can happen. It should be noted that the above
results are based on local dynamical analysis, thus blips may also appear outside this bounded
region, but close to the green curve.
We take three typical values of C (as the three dotted lines shown in Figure 2.6(b)), and
obtain the Hopf critical points as follows.
C = 0.002 : (BH,RH) ≈ (1.69 ×10−1, 7.90 ×10−4),
C = 0.012 : (BH1 ,RH1) ≈ (6.27 ×10−2, 1.53 ×10−4),
C = 0.012 : (BH2 ,RH2) ≈ (1.06 ×10−1, 5.31 ×10−4),
C = 0.018 : No Hopf critical point.
(2.17)
The bifurcation diagrams corresponding to the three lines, C = 0.002, C = 0.012 and C =
0.018, are shown in the top three graphs in Figure 2.7. Six simulated results are also presented
in this figure, corresponding to the six points marked on the three dotted lines in Figure 2.6(b).
It is seen that the values taken from the points (1)−(4) generate blips; point (5) leads to a regular
oscillation, while point (6) gives a simple stable equilibrium solution, as expected. For this case
when parameter A is fixed, no blips have been found for the values outside the region bounded
by the red and green curves. It should be noted in the top middle figure of Figure 2.7 that there
are two Hopf bifurcation points on the equilibrium E1. One of them is supercritical while the
other is subcritical, but the two families of the limit cycles bifurcating from these two critical
points are both stable, since the stability change is reversed at the two points. In fact, the three
eigenvalues along the unstable part of E1 between the two Hopf bifurcation points contain one
negative eigenvalue and a pair of complex conjugates with positive real part. On the two stable
parts, the real part of the complex conjugate eigenvalues changes sign to become negative. As
the parameter C is increasing from 0.002 to 0.018, the two Hopf bifurcation points merge to a
single point on E1 (corresponding to the turning point on the green curve, see Figure 2.6(b), at
which the horizontal line is tangent to the green curve); the corresponding eigenvalues contain
a negative eigenvalue and a purely imaginary pair. This indeed characterizes a degenerate
Hopf bifurcation (e.g. see [44]), different from the Hopf bifurcation defined by (2.12). A
similar discussion applies to the other two Hopf bifurcation points shown in the top left figure
in Figure 2.8.
2.3.2.4 Parameter C fixed
Now we fix parameter C = 3.94 × 10−4, which results in curves in the A-B plane by cutting
the surface in Figure 2.6(a), as shown in Figure 2.6(c). The transcritical point is kept the same:
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Figure 2.7: Bifurcation diagrams corresponding to C = 0.002, 0.012 and 0.018, respec-
tively, and numerical simulation results for the parameter values (B,C) = (0.06, 0.002)(1),
(0.08, 0.002)(2), (0.10, 0.002)(3), (0.07, 0.012)(4), (0.09, 0.012)(5), (0.08, 0.018)(6).
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Figure 2.8: Bifurcation diagrams corresponding to A = 0.025, 0.200, 0.364, and numeri-
cal simulation results for the parameter values (A, B) = (0.025, 0.060)(1), (0.200, 0.060)(2),
(0.200, 0.070)(3), (0.200, 0.085)(4), (0.300, 0.059)(5), (0.300, 0.070)(6), (0.364, 0.060)(7),
(0.364, 0.070)(8), (0.400, 0.060)(9).
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(a) (b)
Figure 2.9: (a) Bifurcation diagram of system (2.19), showing the equilibrium solutions E0, E1,
and E2 with dashed and solid lines denoting unstable and stable, respectively; (b) Simulated
viral blips in system (2.19) for n = 0.007. Other parameter values used here are: λ = k = p =
1, d=0.01, m=b=0.05, a=0.5, c=0.1.
B = 0.057. We choose three typical values of A, and find the Hopf bifurcation points as follows.
A = 0.025 : (BH1 ,RH1) ≈ (5.82 ×10−2, 9.84 ×10−5),
A = 0.025 : (BH2 ,RH2) ≈ (6.75 ×10−2, 2.65 ×10−4),
A = 0.200 : (BH,RH) ≈ (8.32 ×10−2, 7.33 ×10−4),
A = 0.364 : (BH,RH) ≈ (3.99 ×10−2, 7.99 ×10−4).
(2.18)
The bifurcation diagrams corresponding to the three lines A = 0.025, A = 0.200 and A =
0.364 are shown in the top three graphs in Figure 2.8. Nine simulated results are also presented
in this figure, corresponding to the nine points marked on the five dotted lines in Figure 2.6(c).
It is observed from these graphs that among the nine chosen parameter values, seven cases
exhibit blips (see the points (2)−(7) and (9) in Figure 2.6(c) with the corresponding simulated
results shown in Figure 2.8). It is noted that some of these points are not even close to the
red line, nor in the region bounded by the red and green curves, suggesting that a simple 3-
dimensional HIV model can generate rich blips.
2.3.3 3-dimensional immunological model
In this subsection, we briefly consider an immunological model [28], and apply Hypothesis 1
to show that the model can have blips. For simplicity, the original 4-d model is reduced (by a
quasi-steady state assumption on the virus particles) to a 3-d model, described by
x˙ = λ − dx − β(y)xy,
y˙ = β(y)xy − ay − pyz,
z˙ = cyz − bz,
(2.19)
where x, y and z represent the densities of the infected cells, uninfected cells, and CTL, re-
spectively. The system (2.19) with constant β(y) is well-known [6, 27], which does not exhibit
blips. In order to generate viral blips, here we choose β(y)=n+myy+k , where n and m are minimum
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and maximum infectivity, and k represents the density of infected cells when the infectivity
takes its median value. Since the analysis is similar to previous models, we omit the details
and only give the results as follows. The system (2.19) has three equilibrium solutions: the
infection-free equilibrium, E0, the infected equilibrium with CTL, E1, and the infected equi-
librium without CTL, E2. There are two transcritical bifurcation points, one of them, named
“transcritical 1” in Figure 2.9(a), is at the intersection of E0 and E2: (nt1, yt1) ≈ (0.005, 0),
at which E0 and E2 exchange their stability. The second one occurs at the intersection of E1
and E2: (nt2, yt2) ≈ (−0.01, 0.5), called “transcritical 2” in Figure 2.9(a). However, note that
they only exchange their stability if restricted to a one-dimensional manifold, and both of them
are unstable in the whole space since one of the eigenvalues keep positive when crossing this
transcritical point. E1 becomes stable untill n is increased to cross a Hopf critical point (called
“Hopf 1” in Figure 2.9(a)): (n1H, y1H) ≈ (0.206, 0.5). Another Hopf bifurcation point (called
“Hopf 2” in Figure 2.9(a)) happens on E2 at (n2H, y2H) ≈ (0.0213, 1.81). The limit cycles
bifurcating from Hopf 1 are stable, while those from Hopf 2 are unstable, leading to large os-
cillating motions when the values of n are chosen from the interval (nt, n2H). The above results
show that all the four conditions in Hypothesis 1 are satisfied, and blips indeed appear. The
simulated blips for n = 0.007 are depicted in Figure 2.9(b).
2.4 A 2-dimensional in-host infection model
For the generalized 3-dimensional model discussed in Section 2.3, we assume that r is some
form of damage to the host or to the host immune system, which increases with the extent of the
infection, that is, in proportion to the infected cell density. Here, we further assume that there
is a quasi-steady state (as used in (2.14)) between the damage, r, and the infected cell density
y. Thus, the 3-dimensional HIV model can be further reduced to a 2-dimensional model, given
by
x˙ = λx − dxx − β(y)xy, y˙ = β(y)xy − dyy, (2.20)
Note that system (2.20) is now in the form of an in-host infection model, which includes only
uninfected and infected target cell populations, and the most basic “birth” and death rates.
However, we now think of the infectivity β(y) as a possible function of y; other parameters
have the same meaning as in (2.19). We will show that this simplified 2-dimensional infection
model may also be able to generate blips.
2.4.1 2-dimensional in-host model with constant and linear infection rates
First, we consider the case when the infection rate, β(y) is simply a constant function, that is
β(y) = β. Taking β itself as a bifurcation parameter, it is easy to show that there exist two
equilibrium solutions and a transcritical bifurcation point, but no Hopf bifurcation exists. This
violates Hypothesis 1, and therefore no blips can appear in this case.
Next, suppose the infection rate β(y) is a linear function of the infected cell density, y, that
is β(y) = b + ay, where the parameters a and b represent the same constants as before, and a
is treated as a bifurcation parameter. In this case, we have two equilibrium solutions E0 and
E1. But E0 is always stable for all values of a though there exists a Hopf bifurcation on E1.
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Therefore, no transcritical bifurcation point exists for this case, which violates Hypothesis 1,
implying that blips are not possible when β(y) is a linear function.
2.4.2 A 2-dimensional in-host model with saturating infection rate
Motivated by our previous results for the 3- and 4-dimensional models, we next assume that
infectivity is an increasing saturating function of the infected cell density, y, namely, β(y) =
b + ayy+c . For our numerical work, we take the same values of a and b, as used in Section 3.1,
while c is taken to be c = 50, obtained by numerical simulation based on the experimental data
given in [39]. Other parameter values are as described for model (2.14).
2.4.2.1 Scaling
For convenience in the following analysis, we first simplify system (2.20) by the following
scaling to reduce the number of parameters. Let x = e1X, y = e2Y, t = e3τ, where e1 = λxdy , e2 =
λx
dy , e3=
1
dy , and set A=
aλx
d2y
, B= λxbd2y , C=
cdy
λx
, D= dxdy . Then, the rescaled system is given by
dX
dτ = 1 − DX −
(
B +
AY
Y +C
)
XY,
dY
dτ =
(
B +
AY
Y +C
)
XY − Y,
(2.21)
with B treated as a bifurcation parameter. Taking the parameter values from [28], we have the
scaled parameter values A=0.364, C=0.823, and D=0.057 for system (2.21).
2.4.2.2 Equilibrium solutions and their stability
By setting ˙X = ˙Y = 0 in (2.21), we get two biologically meaningful equilibrium solutions:
the uninfected equilibrium solution E0 : (X0, Y0) = (1/D, 0), and the infected equilibrium
solution E1 = (X1, Y1), where X1 = Y1+C(A+B)Y1+BC , and Y1 is determined by the equation F1 =
(A+B)Y2+(D+BC−A−B)Y+(D−B)C=0. This indicates that the condition (i) in Hypothesis 1
is satisfied. Similarly, it is easy to find that E0 is stable (unstable) if B < D (B > D).
2.4.2.3 Bifurcation analysis
By using the characteristic polynomials at E0 and E1, we can show that a transcritical bifur-
cation occurs at the critical point, (Yt, Bt) = (0, 0.057), which satisfies the condition (ii) in
Hypothesis 1. E0 and E1 intersect at this critical point and exchange their stability. Further,
a Hopf bifurcation happens at the critical point (BH, YH) ≈ (0.121, 0.811). E1 is stable (un-
stable) on the right (left) side of the Hopf bifurcation point. Therefore, the condition (iii) in
Hypothesis 1 holds for this case. If we take a value of B near Bt on the side where both E0 and
E1 are unstable, then the condition (iv) in Hypothesis 1, is also satisfied and so blips occur. The
bifurcation diagram is shown in Figure 2.10(a), and the simulated viral blips for B = 0.060 are
depicted in Figure 2.10(b).
Summarizing the results of this section, we conclude that the simple 2-dimensional in-
host model is sufficiently complex to exhibit viral blips, provided the infectivity function is an
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Figure 2.10: (a) Bifurcation diagram of system (2.21) projected on the B-Y plane, with the red
and blue lines denoting the E0 and E1, respectively, dotted and solid lines indicating unstable
and stable, respectively; and (b) simulated time history of y(t) for B = 0.060.
increasing, saturating function of infected cell density. However, for this model, the range of
parameter space in which blips occur is relatively restricted, compared with the 3-dimensional
model which is established in the previous section.
An interesting question is natually raised here: does there exist a more general function
β(y) such that the existence of blips depends upon the general properties of the function like its
maximal values and/or its derivatives. In fact, it has been found that by choosing the parameter
c large enough in the function β, a threshold is reached beyond which the Hopf bifurcation, and
hence also the viral blips, disappear.
2.5 Recurrency in a 5-dimensional model
So far, we have considered 2-, 3- and 4-dimensional in-host infection models with increasing,
saturating infectivity functions, and shown that all these models exhibit blips. Moreover, it has
been shown for the 2-dimensional model (and can be shown for the 3- and 4-dimensional mod-
els, but omitted here) that replacing the infectivity function with a constant or linear function of
y will cause blips to disappear. However, in this section we will show that higher-dimensional
systems may have blips even with a constant infectivity function.
We consider a previously proposed 5-dimensional immunological model, in which recur-
rent phenomena or viral blips have been observed via numerical simulation [41]. The model
describes antibody concentrations and cytotoxic T lymphocytes (CTLs) explicitly, and is de-
scribed as follows:
x˙ = λ − dx − βxv, (2.22a)
y˙ = βxv − ay − pyz, (2.22b)
z˙ = cyz − bz + hy, (2.22c)
u˙ = ξz − ηu − kuv, (2.22d)
v˙ = ey − kuv − γxv − qv. (2.22e)
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Table 2.2: Parameter values used in model (2.22) [41].
Parameter Value
λ 104 cells µL−1 day−1
d 0.100 day−1
β 1.25 × 10−5 virion−1 µL day−1
p 10−4 cells−1 µL day−1
c 10−4 cells−1 µL day−1
b 0.200 day−1
h
[
0, 10−4
]
day−1
ξ 10.0 molecules cell−1 day−1
η 0.040 day−1
k 2.50 × 10−5 particle−1 µL day−1
e 2.50 virions cell−1 day−1
γ 5.00 × 10−5 cell−1 µL day−1
Here x, y, z, u and v are respectively the population densities of uninfected target cells, infected
target cells, CTLs, antibodies and virions. The parameters λ and dx represent uninfected cells’
constant growth rate and death rate, respectively. Target cells are infected by virus at rate,
βxv. Infected cells die at rate ay, being killed by CTLs at rate pyz. It is assumed that CTLs
proliferate at rate cyz, and decrease with the natural death rate bz. The fourth equation describes
the antibody growth rate, ξz, which is proportional to the number of CTLs, the natural death rate
of antibody, ηu, and the binding rate of one antibody with one antigen, kuv. In the last equation,
viruses are released from infected cells at rate ey, and are bound by antibody, absorbed by
uninfected cells, or cleared at rates kuv, γxv, and qv, respectively. The term, hy corresponds
to the CTL differentiated from memory T cells [41], and should be expressed as hMyzM, where
zM is the population density of virus-specific memory T cells, which produce activated CTLs
with rate hMy. In [41], zM is assumed to be a constant, and so we have h = hMzM. We will
consider two cases: h = 0 and h , 0; h = 0 is due to the absence of memory T cells (that is
zM = 0) during the primary effector stage. We will show the relation between the two cases.
For simplicity, without loss of the properties of antibodies, we assume q = 0 according to [41].
Other experimental parameter values used for studying model (2.22) are given in Table 2.2.
2.5.1 Well-posedness of model (2.22)
Due to physical meaning, negative values of the state variables of system (2.22) are not allowed.
Only non-negative initial conditions are considered and the solutions of (2.22) must not be
negative. The parameters in (2.22) are all positive due to their biological meaning. Expressing
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the solutions of the system (2.22) by variation of constants yields
x(t) = x(0) exp [−
∫ t
0 (d + βv(s)) ds] + λ
∫ t
0 exp [−
∫ t
s
(d + βv(w)) dw] ds, (2.23a)
y(t) = y(0) exp [−
∫ t
0 (a + pz(s)) ds] + β
∫ t
0 x(s)v(s) exp [−
∫ t
s
(a + pz(w)) dw] ds, (2.23b)
z(t) = z(0) exp [
∫ t
0 (cy(s) − b) ds] + h
∫ t
0 y(s) exp [
∫ t
s
(cy(w) − b) dw] ds, (2.23c)
u(t) = u(0) exp [−
∫ t
0 (η + kv(s)) ds] + ξ
∫ t
0 z(s) exp [−
∫ t
s
(η + kv(w)) dw] ds, (2.23d)
v(t) = v(0)exp [−
∫ t
0(ku(s)+γx(s)+q)ds]+e
∫ t
0 y(s) exp [−
∫ t
s
(ku(w)+γx(w)+q)dw]ds. (2.23e)
Theorem 2.5.1 When the initial conditions are taken positive, the solutions of system (2.22)
remain positive for t > 0. Moreover, they are bounded.
Proof By the initial condition x(0) > 0, it is easy to see from (2.23a) that x(t) > 0 ∀ t > 0.
Next, we show that y(t) > 0 ∀ t > 0 by an argument of contradiction. Suppose, otherwise,
y(t) < 0 for some interval t ∈ (t1, t2), t1 > 0. Since y(0) > 0, without loss of generality, we
may assume t1 is the first time for y to cross zero, i.e., y(t) > 0 ∀ t ∈ [0, t1), y(t1) = 0, and
y(t) < 0 ∀ t ∈ (t1, t2). Thus, from (2.23e) we have v(t1) > 0 due to v(0) > 0. On the other
hand, it is seen from (2.23b) that v(t) must cross zero to become negative at some t > t1 since
y(t) < 0 ∀ t ∈ (t1, t2). So let t = t3 be the first time for v(t) to cross zero, i.e., v(t3) = 0 and
v(t) > 0 ∀ t ∈ [t1, t3). Now, take t∗ = min(t2 − ǫ, t3), satisfying t∗ > t1, where 0 < ǫ ≪ 1. So
from the assumption we have y(t∗) < 0. However, on the other hand, it follows from (2.23b)
that
y(t∗) = y(t1) exp [−
∫ t∗
t1
(a + pz(s)) ds] + β
∫ t∗
t1
x(s)v(s) exp [−
∫ t∗
s
(a + pz(w)) dw] ds
= β
∫ t∗
t1
x(s)v(s) exp [−
∫ t∗
s
(a + pz(w)) dw] ds > 0, since v(s) > 0 ∀ t ∈ (t1, t∗).
leading to a contradiction. Hence y(t) > 0 ∀ t > 0, and it then follows from (2.23c) and
(2.23e) that z(t) > 0 and v(t) > 0 ∀ t > 0. Finally, by the positivity of z(t), (2.23d) gives
u(t) > 0 ∀ t > 0.
It remains to prove that positive solutions of system (2.22) are all bounded. First, consider
equation (2.22a), which yields x˙ 6 λ − dx. Given that the exponential functions have negative
exponents, we show that x(t) for t > 0 is bounded since as t → +∞,
x(t) ≤ exp (−
∫ t
0 d ds) [x(0)+λ
∫ t
0 exp (
∫ s
0 d du)ds] = x(0)e−dt + λd (1 − e−dt) ≤ λd .
Thus, denote xmax = limt→+∞ sup x(t) = λd . It is easy to see xmin > 0. Next, we add (2.22a)
and (2.22b) together, to obtain x˙ + y˙ = λ − dx − ay − pyz 6 λ − min(d, a)(x + y). Using
the same boundedness argument for x(t), we get x(t)+y(t) 6 λ
min(d, a) , as t → +∞, and thus
ymax = limt→+∞ sup y(t)6 λmin(d, a) . Now consider (2.22e), yielding v˙6 eymax−(γxmin+q) v. Sim-
ilarly using the same boundedness argument for x(t), we have limt→+∞ v(t)6 eymaxrxmin+q . To prove
boundedness of z(t) ∀ t > 0, we use proof by contradiction. Assume z(t) is unbounded, i.e.
limt→+∞ z(t)→+∞. Due to positivity of x, y, z, v and boundedness of x, y and v, it follows from
(2.22b) that y˙<0 for z>z∗, or for t> t∗>0 (z∗ and t∗ are finite), which implies limt→+∞ y(t)→0.
Then, from (2.22c) we have z˙ = (cy−b)z+hy, so for sufficiently large t, cy−b < 0, and so z˙
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becomes negative (for some z> z∗), implying that z can not increase unboundedly, which is a
contradiction. Thus, we denote zmax=max{z(t), t>0}. Finally, from equation (2.22d), we have
u˙6ξzmax−ηu, which yields u(t)6 ξzmaxη as t→+∞. Hence, we have shown that the solutions of
system (2.22) are positive and bounded.
If the initial conditions have some zero elements, it is easy to see from (2.23) that solutions
are nonnegative. Hence, system (2.22) is proved to be a well-posed biological model, with
nonnegative and bounded solutions.
2.5.2 Equilibrium solutions and their stability
The following results are obtained based on the assumption q = 0 [41]. The equilibrium
solutions of (2.22) are obtained by simply setting the vector field of (2.22) to zero. There
are two equilibrium solutions: the infection-free equilibrium: E0 : (xe0, ye0, ze0, ue0, ve0) =
(λd , 0, 0, 0, 0), and the infected equilibrium: E1 : (xe1, ye1, ze1, ue1, ve1), where ve1= λ−dxe1βxe1 , ze1=
ue1(η+kve1)
ξ
, and ye1 = ve1(kue1+γxe1)e . Further, with h = 10
−4 and other parameter values taken from
Table 2.2, ue1 can be expressed in terms of xe1, and an equation F4(xe1, a) = 0 is obtained to
determine xe1.
The stability analysis for Equilibria E0 and E1 is based on the Jacobian matrix of (2.22).
Evaluating the Jacobian at the infection-free equilibrium E0 yields the characteristic polyno-
mial PE0(Ψ)=det [ΨI−J0(E0)]= (Ψ+d)(Ψ+b)(Ψ+η)PE0a , where PE0a= Ψ2+
(γλ
d +a
)
Ψ+
(aγ−eβ)λ
d .
It is easy to see that the stability of E0 is simply determined by the sign of (aγ − eβ), i.e., E0
is stable (unstable) if (aγ − eβ) > 0 (< 0). In a similar way, we evaluate the Jacobian at E1
to obtain the 5th-degree characteristic polynomial, from which the fourth Hurwitz determinant
∆4 can be determined.
2.5.3 Bifurcation analysis for h , 0
Now we consider possible bifurcations which may occur from the equilibrium solutions E0 and
E1. First, for the infection-free equilibrium E0, as discussed in the previous subsection, E0 is
stable (unstable) if (aγ − eβ) > 0 (< 0). The only possible singularity occurs at the critical
point, determined by aγ − eβ = 0, at which one eigenvalue of the characteristic polynomial
becomes zero (and other four eigenvalues are negative), leading to a static bifurcation. The
critical point ac0 is solved from aγ − eβ = 0 as ac0 = eβγ . Thus, E0 is stable (unstable) when
a > ac0 (a < ac0), and xc0 = λd . With the parameter values in Table 2.2 (with h = 10−4), we have(xc0, ac0)= (0.625, 1.00 ×105) which actually holds for both cases h , 0 and h = 0.
As for the infected equilibrium E1, one singularity happens when a5(xe1, a) becomes zero.
Thus, the critical point is determined by the equations a5(xe1, a) = F4(xe1, a) = 0, at which,
the characteristic polynomial of E1 has a zero root. As a result, we obtain one biological
meaningful solution, (xc1, ac1) =
(
0.625, 1.00 × 105
)
. Comparing this critical point with
(xc0, ac0) shows that these two critical points are identical, implying that E0 and E1 intersect
and exchange their stability at this point. Denote this point as (xt, at) = (0.625, 1.00×105),
which is actually identical for all h , 0. The bifurcation diagram projected on the a-x plane
is shown in Figure 2.11(a). It clearly shows a stability exchange between E0 and E1 at the
transcritical point.
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Figure 2.11: Bifurcation diagram and simulated viral blips for system (2.22) with the parame-
ter values taken from Table 2.2 when a = 0.500: (a) Bifurcation diagram for h = 10−4, with the
red and blue lines denoting E0 and E1, respectively, and the dotted and solid lines indicating
unstable and stable, respectively (the lower branch of E1 is biological meaningless, due to neg-
ative values in the solution); (b) simulated time history of y(t) for h = 10−4; and (c) simulated
time history of y(t) for h = 0.
Now we turn to possible Hopf bifurcation from E1. Since the characteristic polynomial PE1
for E1 cannot be factorized into polynomials of lesser degree, we will use the Routh-Hurwitz
criterion to analyze its stability. The criterion states that the corresponding equilibrium is
asymptotically stable if and only if all the Hurwitz determinants are positive [3]. According
to [43], the necessary condition for a Hopf bifurcation to occur from the infected equilibrium
E1 is ∆4 = 0, combined with the equation F4(xe1, a) = 0, since this Hopf bifurcation point is
located on the infected equilibrium. Solving these two equations yields a biological meaningful
Hopf bifurcation point (xH, aH) ≈ (8.85×104, 0.617). Note that the Hopf bifurcation point is
above the turning point (xTurning, aTurning) ≈ (8.82×104, 0.604) in the upper branch of E1 (see
Figure 2.11).
Summarizing the above results shows that the case h , 0 satisfies all the four conditions
in Hypothesis 1 to generate recurrent infection, and indeed recurrence occurs for a ∈ (0, a∗),
where a∗ < aH. Moreover, a∗ should not be too close to aH, otherwise the period of limit cycles
bifurcating from the Hopf critical point (xH, aH) is relatively small. The bifurcation diagram,
shown in Figure 2.11(a), indicates that the Hopf critical point aH is located on the left side
of a = at, where the E0 is unstable. A simulated time course exhibiting recurrent infection is
depicted in Figure 2.11(b).
2.5.4 Bifurcation analysis for h → 0+
Now we turn to consider the special case, h = 0. It is easy to observe from equation (2.22c)
that the solutions of system (2.22) are discontinuous at h = 0. Therefore, to have continuity,
we should regard the special case h = 0, as the limiting case: h → 0+. In calculation, we
choose a small enough value of h (e.g., h = 10−8) and then do the same analysis as done for the
case h , 0. We also get two equilibrium solutions – the infection-free equilibrium E0 and the
infected equilibrium E1 – a transcritical bifurcation which occurs at the intersection of the two
equilibria, a Hopf bifurcation emerging from the infected equilibrium E1, and large oscillations
occurring near the transcritical critical point on the unstable side of the Hopf critical point,
given by (xH, aH) ≈ (8.7511×104, 0.6249). The bifurcation diagram for this case (h = 10−8)
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is similar to that shown in Figure 2.11(a), except that the two branches of E1 are much closer,
indicating that the Hopf bifurcation point moves down towards the turning point in the upper
branch of E1, which is also moving down. This implies that one branch of solution E1 becomes
almost a vertical line as h → 0+, and the Hopf critical point coincides with the turning point.
For h = 0, we treat it as the limit: h → 0+. The seemingly vertical line in the bifurcation
diagram for h = 0 disappears, clearly showing the discontinuity of E1 at h = 0. This causes
difficulty in bifurcation analysis. However, if we treat the case h = 0 as the limiting case
h → 0+, the solution E1 continuously depends on h, and the bifurcation diagram becomes
smooth. Therefore, we can still use our theory to explain the occurrence of blips for the case
h = 0, as shown in Figure 2.11(c). In fact, more precisely, when h = 0, a Bogdanov-Takens
bifurcation (double-zero singularity) occurs at the point where the Hopf and turning points
are merged. This is a codimension-2 bifurcation point, which in general needs two unfolding
(bifurcation) parameters to give a complete local dynamical analysis. In our case, the variation
of the single parameter α can be considered as a line (ray) in the two-parameter plane. It
is well known that in the vicinity of a Bogdonov-Takens bifurcation point, there exists Hopf
bifurcation and homoclinic bifurcation. Therefore, the motion generated near the codimension-
2 bifurcation point may be due to either the Hopf or homoclinic bifurcation. With respect to
the blips phenomenon, the motion is large (not the small motions bifurcating from Hopf or
homoclinic bifurcations) and is a globally persistent motion, and so it is not directly related to
the Hopf or homoclinc bifurcations. In other words, we are more interested in possible large
motions near the transcritical point.
2.6 Conclusion and discussion
In this paper, the problem of recurrent infection (viral blips) in in-host infection models is
studied via the qualitative analysis of dynamical systems. A 4-dimensional HIV antioxidant-
therapy model [39], which produces viral blips, is investigated in detail using bifurcation the-
ory. A hypothesis consisting of four conditions for the emergence of viral blips is proposed.
These conditions describe two equilibrium solutions which intersect at a transcritical bifur-
cation point, with a Hopf bifurcation which originates from the equilibrium solution. Under
these conditions, blips appear for values of the bifurcation parameter near the transcritical
point, where equilibrium solutions are unstable.
Guided by the proposed hypothesis, we propose several simpler in-host infection models
that can also generate viral blips. We develop a 3-dimensional in-host model with an increasing,
saturating infection rate similar to the HIV antioxidant-therapy model, and show that all four
conditions in the hypothesis are satisfied, leading to blips. Further, stability and bifurcation
analyses determine all possible regions in parameter space where blips may occur. We then
investigate an even simpler 2-dimensional in-host model. This very simple model can also
exhibit blips, as long as the infection rate is an increasing, saturating function of infected cell
density. We also apply the hypothesis to study a standard HIV model with CTL response [28]
and find blips by using an increasing, saturating infection rate function.
Overall, our results suggest that simple ODE models of in-host infection dynamics are
sufficient to describe transient periods of high viral replication, separated by long periods of
quiescence. Rather than needing an exogenous trigger such as stochastic stimulation of the
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Figure 2.12: Simulated viral blips of system (2.1) with varying amplitude and frequency when
using a time-varying function α(t) = αT + [ − 0.31 + 0.3e−3 cos(t/50) cos(t/100)] ×1013, where
αT = 4.58 ×1013 is the transcritical bifurcation value.
immune system, the natural dynamics of such systems may be sufficiently rich, in many cases,
to exhibit viral blips. One key to obtaining this rich behaviour is to propose an infection rate
which increases, but saturates, with the extent of the infection. This is a natural assumption
if the infection itself (high density of infected target cells) makes the host more vulnerable to
further infection. Such an assumption is certainly natural for HIV, where the primary target
cells are T lymphocytes.
All the simulated oscillating motions and blips presented in this paper show constant am-
plitudes and frequencies. This is because all parameter values are fixed in these simulations.
We note, however, that nonlinear, deterministic systems can indeed generate oscillations with
varying amplitudes and phases, called “amplitude modulation” and “frequency modulation”
due to nonlinearity. This can be seen from the equation (2.13), where both amplitude and
phase are functions of the parameter µ. Since in reality parameters are not constant, time-
varying parameters can be seen as analogous to the variation due to random perturbations in
stochastic models. Although deterministic models with fixed parameter values cannot generate
varying amplitude and phase, deterministic models can generate such variation if the system
is nonlinear and some parameters vary with time. For example, Figure 2.12 shows the result
of changing the fixed α used in Figure 2.3(c) to a time-varying deterministic function, clearly
demonstrating that a deterministic model can generate blips of varying magnitude, frequency
and duration.
We note that mathematically, a system of delay differential equations (DDEs) could also
generate oscillatory behaviours similar to viral blips. However in this case, the inherent delay
would need to be of the same order as the interval between blips, that is, on the order of several
months. Since it is difficult to suggest a physiological or immunological process that would
impose a delay of this magnitude, it seems unlikely that DDEs are the most natural approach
for modeling viral blips.
While we are able to show that linear or constant infection rates do not lead to blips in the
2-, 3- or 4-dimensional models we have studied, further study of a 5-dimensional immunolog-
ical model reveals that a system with a constant infection rate can also generate blips. This
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suggests that the use of an increasing, saturating infection rate function is not necessary, but is
effective in low-dimensional models. The results presented here provide a useful tool for the
mathematical study of viral blips or other examples of recurrent infection. The conditions in
our hypothesis may also be used or generalized to study recurrent phenomena in other physical
systems.
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Chapter 3
Modelling and Analysis of Recurrent
Autoimmune Disease
3.1 Introduction
The adaptive immune system consists of a set of highly specialized cells and processes that can
limit or eradicate the growth of foreign pathogens. Normally, the immune system must be able
to mount responses against pathogens that invade the host, but avoid attacking the organism’s
own tissues; when this discrimination fails, the result is autoimmunity. Autoimmune diseases
are often chronic and debilitating. They affect 50 million (or one in five) Americans, but are
more common in women (75 percent of cases), according to the American Autoimmune Re-
lated Diseases Association [2]. In fact, autoimmune diseases are among the main causes of
death of young and middle-aged women in developed countries [9]. Evidence is also mounting
that the prevalence of autoimmune disease is increasing: for example, a 3% global increase in
type 1 diabetes per year has been reported [26]. Although health care costs related to autoim-
mune diseases amount to over billion dollars each year in the the U.S.A. alone, patients are still
suffering from misdiagnosis and delayed diagnosis due to a lack of understanding of autoim-
mune disease. These facts illustrate the vital need to focus further research on all autoimmune
diseases.
To address autoimmune disease in a mathematical model, we first outline in brief the nor-
mal function of the immune system. The cells of the adaptive immune system are T and B
lymphocytes: B cells are involved in ‘humoral immune responses’, while T cells play a large
role in the cell-mediated immune responses. Here, we focus on the latter response. Initiation of
an adaptive immune response starts when immature dendritic cells (DCs), which are the most
important professional antigen presenting cells (pAPCs), settle at a site of infection or inflam-
mation, become activated and undergo maturation. Simultaneously, naive conventional T cells,
each bearing a specific antigen receptor, constantly circulate through the peripheral lymphoid
tissues, browsing many DCs as they carry out brief contacts, and receiving two signals: dis-
crimination of the antigen presented by DCs and interplay with co-stimulatory molecules on
the same DCs. After making a stable interaction with DCs presenting their cognate antigen,
naive T cells can be activated and proliferate into effector T cells. The proliferation phase
is significant and driven by cytokine interleukin-2 (IL-2), which can be produced by active
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conventional T cells themselves and from other sources as well.
Central tolerance is the main mechanism which allows the immune system to avoid mount-
ing a response against the organism’s own tissues. In this process, auto-reactive T cells, which
have antigen receptors specific to self antigens, are deleted during lymphocyte development in
the thymus. Nevertheless, the T cells that leave the thymus are relatively but not absolutely
safe. A large body of research has demonstrated that some auto-reactive T cells are present in
the periphery of under normal conditions [39]. In this case, peripheral tolerance is established
after T cells mature and migrate into the periphery to prevent auto-reactive T cells from direct-
ing an immune response toward self-antigens. One mechanism of peripheral tolerance is the
population of regulatory T (TReg) cells.
Regulatory T cells are a subpopulation of CD4+ T cells, that modulate the immune system,
preventing the expansion of auto-reactive T cells, and subsequent autoimmune disease [30].
Evidence [29, 4, 18] has shown that human TReg cells are phenotypically heterogeneous. Most
thymus-derived TReg cells found in the periphery are naive TReg cells [18, 22, 15], which have
not experienced T cell receptor (TCR) stimulation-mediated maturation, and are in a quiescent
stage, resistant to apoptosis. Like naive conventional T cells, in order to participate in an
immune response, naive TReg cells require activation by antigen on pAPCs and possible co-
stimulation [1, 21]. IL-2 seems to be a necessary factor [10, 33, 31] for TReg cell proliferation.
Activated conventional T cells are believed to be the main source of IL-2 [12, 41], although
there also exist other IL-2 sources, such as DCs. Following activation, naive TReg cells become
‘effector’ natural TReg (nTReg) cells, which have potent suppressive activity.
Recently, a new subset of effector nTReg cells has been discovered experimentally [5, 27].
This subset of cells have further matured to become terminally differentiated suppressors,
which show more efficient suppression, but have a shorter lifespan, than nTReg cells. Phe-
notypic analysis has demonstrated that the expression of the cell surface receptor HLA-DR
in nTReg cells is heterogeneous [28], and distinguishes this terminally differentiated subpopu-
lation; in particular HLA-DR+ TReg cells suppress proliferation of conventional T cells more
rapidly than HLA-DR− TReg cells. It is believed that activation and expansion of HLA-DR−
effector nTReg cells provoke the generation of this subset of HLA-DR+ TReg cells [5].
Despite these multi-layer barriers, self-tolerance mechanisms fail occasionally. Although
the activity of auto-reactive T cells in humans is not understood completely, research in non-
human primates has indicated that these cells in the periphery can be activated and may pro-
voke a T-cell-mediated attack against self-determinants [37], causing autoimmune disorders.
For example, when auto-reactive T cells attack the central nervous system [37], acute focal
inflammation may cause a relapse of symptoms in multiple sclerosis [38]. TReg cells are capa-
ble of limiting these attacks, and their deficiency can lead to fatal autoimmune disease which
affects multiple organs in mice [6, 14], and human beings [34, 25].
Autoimmune diseases are often chronic, requiring lifelong care and monitoring, despite the
fact that symptoms may disappear occasionally. Many autoimmune diseases are characterized
by recurrence, that is, disease relapses (return of symptoms) followed by remittance (absence of
symptoms, possibly for a long period). In several autoimmune diseases, this relapse-remission
behaviour occurs even in the absence of treatment, for example in multifocal osteomyelitis
[16, 19], eczema [13], subacute discoid lupus erythematosus [23], and psoriasis [11]. In fact,
the subtypes of some diseases are clinically classified based on the patterns of this recurrent
behaviour [38]. Therefore, an improved understanding of recurrent dynamics in autoimmune
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disease is crucial to promote correct diagnosis, patient management and treatment decisions.
Recently, the relapse-remission behavior of multiple sclerosis was studied using a stochas-
tic differential equation model developed by Mendizabal et al. [36]. The authors investigated
cross-regulation interactions, modeled as Hill functions, between regulatory and auto-reactive
effector T cells. A predator-prey system is adopted in this paper, in where auto-reactive ef-
fector T cells act as prey and TReg cells as predators. The resting auto-reactive effector T cell
and resting TReg cell populations are introduced to the deterministic predator-prey model us-
ing stochastic pulse trains [40], which model the probabilistic influx of resting cells. This
predator-prey model with stochasticity generates the characteristic relapse-remission behavior
of multiple sclerosis. The paper concludes that weakness in the negative feedback between
effector and regulatory T cells may allow the immune system to generate the typical recurrent
dynamics of autoimmune disease without the need for exogenous triggers.
Recent models introduced by Alexander and Wahl [1] capture the intrinsic feedback cycle
of autoimmunity, in which professional antigen presenting cells (pAPCs) present self-antigen,
eliciting self-reactive effector T cells, which in turn attack host tissues. The damage to host
tissue results in increased concentrations of self-antigen, activating further pAPCs. This cycle
is kept in check by the actions of TReg cells, which limit the self-reactive immune response
via several putative mechanisms. These models exhibit equilibria corresponding to tolerance
and autoimmunity, but bistability is not observed. Instead, a branching process was used to
demonstrate that from identical starting conditions, states of immune tolerance or intolerance
could be reached probabilistically. Although this set of related models offers a general approach
to autoimmunity and the role of TReg cells, they do not capture the recurrent behavior which
characterizes many autoimmune diseases.
Following the recent experimental discovery of HLA-DR+ TReg cells described above, we
chose to expand the model of Wahl and Alexander to include this new class of potently sup-
pressive cells. In some parameter regimes, we observed numerically that the expanded model
exhibits long periods of self tolerance, punctuated by brief episodes of disease recurrence, de-
terministic dynamics reminiscent of our recent investigations of viral blips in in-host infection
models [45]. In these infection models, relapse-remission behaviour may in some cases arise
simply from the nonlinear dynamics of the underlying dynamical system, in the absence of
stochasticity, therapy, or other trigger mechanisms [42, 35]. By taking advantage of dynamical
systems theory, we recently proposed four conditions which guarantee recurrent behavior in
deterministic viral infection models [45]. Given the importance of recurrence to autoimmune
disease, here we apply a similar approach to gain an analytical understanding of the dynamical
features underlying recurrence in the autoimmune model.
The rest of the paper is organized as follows. In Section 2, we introduce two established
models [1] describing autoimmune disease. We demonstrate that these two models do not have
Hopf bifurcations, and so cannot exhibit the oscillatory behavior which underlies recurrence.
Based on recent experimental findings, we introduce the new TReg subtype and establish a new
model. In Section 3, we first prove that the new model is well-posed, and then perform mathe-
matical analysis to find equilibrium solutions and determine their local and global stability. By
choosing proper bifurcation parameters, we also identify the transcritical and Hopf bifurcation
critical points, showing that the new model should display the recurrent dynamics characteristic
of many autoimmune diseases. Further, by applying center manifold theory and normal form
theory, we find approximate solutions of the limit cycles and determine their stability. Then, in
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Section 4, we use numerical simulation to verify the analytical predictions obtained in Section
4. Moreover, a comparison between the analytical and numerical results for the Hopf bifurca-
tion are given in this section. In order to identify key factors in the mechanism of recurrence, in
Section 5 we perform model reduction under a quasi-steady state assumption. This is achieved
by reducing the number of state variables and parameters, and also by a rescaling of the time
variable. Then, we prove that the original and reduced models exhibit the same dynamical be-
havior as long as the parameter values are chosen properly. Based on the reduced model, three
bifurcation parameters are used to classify the parameter ranges for which recurrence exists.
Furthermore, we show that there do not exist homoclinic orbits in either the original or the
reduced models, and so the recurrence phenomenon either comes from Hopf bifurcation or is
due to persistant oscillations. We conclude with a brief discussion of these results in Section 6.
3.2 Model development
Following recent experimental findings, we sought to introduce terminally differentiated regu-
latory T cells as an explicit variable into models established by Alexander and Wahl [1]. Their
models consider two suppressive mechanisms enacted by TReg cells. The first of these is the
direct suppression of pAPCs by TReg cells, effectively removing pAPCs from the system. The
corresponding model is given by
˙A = f v˜G − (σ1Rn + b1)A − µAA,
˙Rn = (π1E + β)A − µnRn,
˙E = λEA − µEE,
˙G = γE − v˜G − µGG,
(3.1)
where the variables A, Rn, E, G represent the populations of mature pAPCs, active nTReg cells,
active auto-reactive effector T cells, and the particular self-antigen of interest. All cell popula-
tions are specific for a given self-antigen. Parameter definitions and their numerical values are
listed in Table 3.1; meaningful numerical values were carefully chosen in [1] with extended ref-
erence to the primary literature. Model (3.1) assumes that pAPCs undergo maturation at a rate
of f v˜ G, while during this process the antigen uptaken rate is v˜ G. The activated auto-reactive
effector T cells (E) are produced at a rate of λE A by resting T cells through an interaction with
mature pAPCs (A). After activation, auto-reactive effector T cells (E) can produce IL-2, which
is required for TReg cell proliferation, while other IL-2 sources also exist. Thus nTReg cells are
activated at a rate of (π1E+β)A, where π1E represents IL-2 produced by active auto-reactive
effector T cells (E), and β represents background sources of IL-2. nTReg cells (Rn) then sup-
press pAPCs (A) at a rate of σ1RnA, while b1 represents a level of non-specific background
suppression. Auto-reactive effector T cells (E) attack the host tissues, causing the release of
self-antigen at a rate of γ E, which in turn triggers the maturation of pAPCs, and thus initiates
a new cycle of autoimmunity. Here, the death/clearance rates of the populations A, Rn, E, and
G are µA, µn, µE, and µG respectively.
Another suppressive mechanism is considered in isolation in [1], that is, nTReg cells may
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directly reduce the auto-reactive effector T cell population. This model is described by
˙A = f v˜G − µAA,
˙Rn = (π3E + β)A − µnRn,
˙E = λEA − (σ3Rn + b3)E − µEE,
˙G = γE − v˜G − µGG,
(3.2)
where the auto-reactive effector T cells are suppressed by nTReg cells and background suppres-
sion at a rate of (σ3 Rn+b3) E. Other terms have the same meaning as the counterparts in model
(3.1).
3.2.1 No recurrence in models (3.1) and (3.2)
Since the main purpose of this paper is to study recurrence in autoimmune models, we first
want to ask if the above two models (3.1) and (3.2) can exhibit this behavior. According to the
Hypothesis given in [45], a Hopf bifurcation is a necessary condition for recurrence. In this
section, we will show that the two models (3.1) and (3.2) indeed do not have a Hopf bifurcation.
For simplicity, we only briefly outline the proof for model (3.1). Similarly, one can prove this
for model (3.2).
First, as usual, we can show that the solutions of model (3.1) are non-negative if the initial
conditions are non-negative, and all solutions are bounded. Further, we show that model (3.1)
has two equilibrium solutions: one of them is the trivial equilibrium,
E0 : A0 = Rn0 = E0 = G0 = 0;
and the other is the non-trivial equilibrium,
E1 : Rn1 =
f v˜γλE − µE(b1 + µA)(v˜ + µG)
σ1µE(v˜ + µG) , E1 =
λE
µE
A1, G1 =
γλE
µE(v˜ + µG) A1,
where
A1 = − βµE2π1λE
+
√( βµE
2π1λE
)2
+
f v˜γλE − µE(b1 + µA)(v˜ + µG)
σ1π1λE
, (3.3)
for f v˜γλE − (b1 + µA)µE(v˜ + µG) > 0, and thus A1 > 0 .
Then, the stability of E0 and E1 can be determined from the linearized system of (3.1) and its
characteristic polynomials, associated with these two equilibria. The characteristic polynomial
for E0 is obtained as P0(L) = (L + µn)(L3 + a01 L2 + a02 L + a03), where
a01 = b1 + µA + µE + v˜ + µG,
a02 = µE(b1 + µA + v˜ + µG) + (b1 + µA + v˜ + µG),
a03 = µE(b1 + µA)(v˜ + µG) − f v˜γλE.
Further, it is easy to show that
∆02 = a01 a02 − a03 = (b1+µA)(µE+v˜+µG)2 + (µE+v˜+µG)[µE(v˜+µG) + (b1+µA)2] + f v˜γλE > 0.
Thus, according to the Routh-Hurwitz criterion we can conclude that the equilibrium E0 is
stable (unstable) if µE(b1 + µA)(v˜ + µG) − f v˜γλE is > 0 (< 0). The only possible bifurcation
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from E0 is a static bifurcation which occurs at the critical point, determined by f v˜γλE = µE(b1+
µA)(v˜+µG). Note that when µE(b1+µA)(v˜+µG)− f v˜γλE > 0, the equilibrium E1 does not exist.
Next, similarly we can discuss the stability of E1. The characteristic polynomial, associated
with E1 is given by P1(L) = L4 + a11 L3 + a12 L2 + a13 L + a14, where
a11 =
1
µE(v˜ + µG)
[
f v˜γλE + µE(v˜ + µG)(µu + µE + v˜ + µG)
]
,
a12 =
1
µE(v˜ + µG)
{
σ1(v˜ + µG)(π1λE A1 + βµE) A1 + f v˜γλE(µn + µE + v˜ + µG)
+µE(v˜ + µG)
[
µEµn + (µn + µE)(v˜ + µG)
]}
,
a13 =
1
µE(v˜ + µG)
{
σ1(v˜ + µG)
[
λEπ1(v˜ + µG + 2µE) A1 + βµE(µE + v˜ + µG)
]
A1
+µn
[
µ2E(v˜ + µG)2 + (µE + v˜ + µG) f v˜γλE
]}
,
a14 = σ1(v˜ + µG)(2π1λE A1 + βµE)A1,
where A1 is given in (3.3). It is easy to see that a1i > 0, i = 1, 2, 3, 4. Moreover, we can show
that
∆12 = a11 a12 − a13
=
1
µ2E(v˜ + µG)2
{
µ3E(v˜ + µG)2σ1β A1
+µ2E(v˜ + µG)2
[
µn(µE + v˜ + µG)2 + (v˜ + µG)
(
µ2E + µ
2
n + µE(v˜ + µG)
)
+µEµn(µn + b1 + µA)
]
+ f v˜γµE(v˜ + µG)λE
[
(µn + v˜ + µG)2 + µE
(
3(v˜ + µG) + µE + µn
)]
+( f v˜γλE)2(µn + µE + v˜ + µG) + µn
[
f v˜γλE + µnµE(v˜ + µG)
][
f v˜γλE − µE(b1 + µA)(v˜ + µG)
]}
> 0,
due to f v˜γλE > µE(b1 + µA)(v˜ + µG), as well as ∆13 = (a11a12 − a13)a13 − a14a211 > 0. Here the
lengthy expression of ∆13 is omitted for brevity. Therefore, E1 is stable (unstable) if f v˜γλE −
µE(b1 + µA)(v˜ + µG) > 0 (< 0). Noticing the stability condition for E0 we can see that E0 and
E1 exchange their stability at the critical point, determined by f v˜γλE = µE(b1 + µA)(v˜ + µG),
and only a transcritical bifurcation exists at this critical point. This implies that there is also no
Hopf bifurcation which can occur from the equilibrium E1.
Further, we can show that the trivial equilibrium of model (3.1) is globally asymptoti-
cally stable. This can be achieved by first considering the first, third and the last equations
of (3.1), and ignoring the nonlinear term −σ1RnA in the first equation, yielding a linear sys-
tem, which has the characteristic polynomial P0(L). Thus, by using comparison theory and
this linear system (obtained by ignoring the nonlinear term), we can easily prove that the equi-
librium E0 is globally asymptotically stable. Although we have not proved the global stabil-
ity of the non-trivial equilibrium, we have tried a number of numerical simulations, which
show that all solutions converge to E1 regardless the initial conditions as long as the condition
f v˜γλE > µE(b1 + µA)(v˜ + µG) is satisfied. Hence, we conjecture that the two models (3.1)
and (3.2) do not have any persistent solutions, except the two equilibrium solutions E0 and
E1. This motivates the development of new models for studying relapse-remission dynamics in
autoimmune disease.
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3.2.2 Developing new models
Now, based on the two models (3.1) and (3.2), we develop new models. First, instead of
considering the two immunosuppressive mechanisms in isolation, we combine them to obtain
the following 4-dimensional ODE model:
˙A = f v˜G − (σ1Rn + b1)A − µAA,
˙Rn = (π3E + β)A − µnRn,
˙E = λEA − (σ3Rn + b3)E − µEE,
˙G = γE − v˜G − µGG,
(3.4)
where the π1 is replaced by π3. Note that the numerical value of either π1 or π3 from [1] could
be used; the difference is immaterial to our analysis.
As mentioned in the introduction, phenotypic analysis indicates that the effector TReg cell
subset is heterogeneous in the expression of HLA-DR [29], which identifies a terminally dif-
ferentiated subpopulation of effector TReg cells, the HLA-DR+ TRegs. Therefore, we introduce
these short-lived but potently suppressive TReg cells into our model (3.4), denoted by Rd. Then,
we get a 5-dimensional model as follows:
˙A = f v˜G − σ1(Rn + dRd)A − b1A − µAA,
˙Rn = (π3E + β)A − µnRn − ξRn,
˙Rd = c ξRn − µdRd,
˙E = λEA − σ3(Rn + dRd)E − b3E − µEE.
˙G = γE − v˜G − µGG.
(3.5)
For the above model, the possibility remains that HLA-DR− nTReg cells may be activated to
become terminal HLA-DR+ TReg cells [29]. Therefore, we indicate the part of HLA-DR− nTReg
cells which undergo activation as an output term from Rn population, with the activation rate,
‘ξRn’. The activated HLA-DR− nTReg cells may further experience expansion and proliferation,
say three divisions, thus c = 23 = 8, which contribute an input source of HLA-DR+ TReg
cells, denoted by ‘c ξRn’. From the functional point of view, compared to HLA-DR− TReg
cells, HLA-DR+ TReg cells show more effective suppression of effector conventional T cells
and pAPCs, and secrete cytokines more rapidly [5]. Therefore, we assume the suppression
rate to pAPCs and effector T cells as ‘σ1dRdA’ and ‘σ3dRdE’, respectively, and set d = 2.
In healthy adults, HLA-DR is expressed by approximately one third of effector TReg cells in
peripheral blood [3], so here we assume in autoimmune patients the ratio is one half, implying
that the ratio RdRn is one. We can use this fact to approximate ξ in the quasi-steady state of the
Rd population, that is, cξRn − µdRd = 0, yielding ξ = 0.025. The death and clearance rates
µE and µA are based on the references given in [1], and are much the same here. Effector T
cell lifetimes are approximately 4-5 days [24], so we set µE = 0.2 day−1. The death rate of
mature pAPCs is less certain [20]; we assume the lifetime of a mature pAPC is of the same
order as that of a mature effector T cell and take µA = 0.2 day−1 as well [1]. We likewise
assume a similar death rate between the effector T cells and TReg cells, and set terminal TReg’s
death rate as µd = 0.2 day−1, and set µn = 0.1 day−1, due to the rapid death rate of terminally
differentiated effector HLA-DR+ TReg cells.
To simplify this model, for which the parameter values are shown in Table 3.1, we impose a
quasi-steady state assumption on the free antigen concentration. In particular, we know that the
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decay rate of the free antigen molecules (µG) is much faster than the dynamics of the effector
T cells (E), and we can thus assume that the free antigen is in quasi-steady state with (and
proportional to) the effector T cell population. Therefore, in the following, we shall eliminate
G from system (3.5) by setting γE − v˜G − µGG = 0 to obtain G = γµG+v˜ E, to reduce system
(3.5) by one dimension. Further, letting α = f v˜γ
µG+v˜
, we obtain a new model, given by
˙A = αE − σ1(Rn + dRd)A − b1A − µAA, (3.6a)
˙Rn = (π3E + β)A − µnRn − ξRn, (3.6b)
˙Rd = c ξRn − µdRd, (3.6c)
˙E = λEA − σ3(Rn + dRd)E − b3E − µEE. (3.6d)
The parameter definitions and their values are given in Table 3.1. The state variables in (3.6)
are defined as follows [1].
A : Mature pAPCs (professional antigen presenting cells), primarily mature dendritic cells,
which present a particular self-antigen of interest and express sufficiently high levels of
co-stimulatory molecules so as to be capable of activating T cells.
Rn : Activated natural TReg cells, HLA-DR−, specific for the antigen of interest, capable of
exerting their suppressor function.
Rd : Terminally differentiated TReg cells, HLA-DR+, with hyper-suppressive ability.
E : Active auto-reactive effector T cells that are specific for the antigen of interest. These
may be either CD4+ or CD8+ T cells, or even a combination of these two; the distinction
is not important given the other simplifications we employ.
In the following sections, we study the new model (3.6) in detail, with particular interest in
stability and bifurcation behaviors, and show that the model can exhibit cycles of relapse, inter-
vened by relatively long periods of remission, which are characteristic of several autoimmune
diseases.
3.3 Well-posedness, equilibrium solutions and stability of model
(3.6)
First, we investigate the well-posedness of the solutions of model (3.6).
3.3.1 Well-posedness
Due to physical meaning of this autoimmune disease model, only non-negative initial condi-
tions are considered and negative solutions are not allowed. Likewise the parameters in (3.6)
are all positive due to their biological meaning. More precisely, we have the following result.
Theorem 3.3.1 All solutions of system (3.6) are non-negative, if the initial conditions are non-
negative. Furthermore, they are bounded.
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Proof Write the equations (3.6a) and (3.6d) as a non-autonomous system:
˙A = −[σ1
(
Rn(t) + dRd(t)) + b1 + µA]A + αE,
˙E = −[σ3
(
Rn(t) + dRd(t)) + b3 + µE]E + λEA.
Thus, according to Theorem 2.1 (P. 81) in [32] we know that A(t) ≥ 0, and E(t) ≥ 0 for t > 0,
provided that A(0) ≥ 0 and E(0) ≥ 0. Then, Rn(t) = Rn(0) exp [−(µn + ξ)t] +
∫ t
0 [π3E(τ) +
β]A(τ) exp[−(µn + ξ)(t − τ)]dτ ≥ 0 for A(t) ≥ 0, E(t) ≥ 0 and Rn(0) ≥ 0. Further Rd(t) =
Rd(0) exp (−µd t) +
∫ t
0 c ξ Rn(τ) exp[−µd(t − τ)] dτ ≥ 0 for Rn(t) ≥ 0 and Rd(0) ≥ 0.
Next, we prove that all solutions of system (3.6) are bounded. We first consider two equa-
tions (3.6a) and (3.6d). Let
w1(t) = σ1[Rn(t) + dRd(t)] + (b1 + µA),
w2(t) = σ3[Rn(t) + dRd(t)] + (b3 + µE). (3.7)
With non-negative initial conditions, we have w1(t) > 0 and w2(t) > 0 ∀t > 0. We construct a
Lyapunov-candidate-function of the form V1(A, E) = 12(A2 + E2), ∀A, E ≥ 0. It is easy to see
that V1(A, E) > 0, ∀A, E > 0, and V1(0, 0) = 0. Taking the time derivative of V1 along the
trajectory governed by the differential equation (3.6a) and (3.6d) yields
dV1
dt
∣∣∣∣∣(3.6a), (3.6d) = A ˙A + E ˙E = A (−w1A + αE) + E (λEA − w2E)
= − (A, E) Q(t)
(
A
E
)
,
(3.8)
where
Q(t) =
[
w1(t) − 12(α + λE)
− 12(α + λE) w2(t)
]
. (3.9)
To consider the positive definiteness of Q(t), first note that w1 > 0 ∀t ≥ 0. For the sign
of det(Q), if we assume Rn(t) is unbounded, i.e., limt→+∞ Rn(t) = +∞, then it will lead to a
contradiction. Due to positivity of Rd(t), σ1, σ3, d, b1, b3, µA, and µE, it follows from (3.7) that
limt→+∞ w1(t) = limt→+∞ w2(t) = +∞, which implies that there exits finite a time t1 > 0, such
that det[Q(t)] > 0 ∀t > t1. That means Q(t) is positive definite, for t > t1. Therefore, it follows
from (3.8) that ˙V1 < 0 ∀t > t1. Thus, the equilibrium (A, E) = (0, 0) is proven to be globally
asymptotically stable, which implies limt→+∞ A(t) = limt→+∞ E(t) = 0. However, from (3.6b)
we have
lim
t→+∞
˙Rn(t) = [π3 lim
t→+∞
E(t) + β] lim
t→+∞
A(t) − (µE + ξ) lim
t→+∞
Rn(t) = −∞, (3.10)
which indicates that there exits a finite time t2 > t1 > 0, such that ˙Rn(t) < 0 ∀t > t2, leading to
limt→+∞ Rn(t) = 0, which is a contradiction with our assumption. Thus, Rn(t) is bounded and
we denote MRn = max{Rn(t), t ≥ 0}. This also means that equation (3.10) does not hold. Then,
there exits an N > 0, such that limt→+∞[π3 E(t) + β]A(t) = N. Since the positivity of E(t), π3,
and β, we have π3 E(t)+β > β ∀t > 0. Thus, there exists M∗A > 0, such that limt→+∞ A(t) = M∗A,
implying that A(t) is bounded, and we denote MA = max{A(t), t ≥ 0}.
For the remaining part of the proof, we give a general claim first. Suppose we have the
differential inequality : ˙T ≤ λ − d T (λ, d > 0, T (0) > 0). Then, for ˙T = λ − d T , we have
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solution T (t) = T (0) e−d t + λd (1 − e−d t), which implies that limt→+∞ sup T (t) = λd . Thus, from
the equation (3.6c), we have ˙Rd ≤ c ξ MRn −µd Rd, which yields limt→+∞ sup Rd(t) = c ξ MRnµd , and
so Rd is bounded. Recalling that A(t) is bounded, so for the equation (3.6d), we similarly have
˙E ≤ λE MA− (b3+µE) E, which yields limt→+∞ sup E(t) = λE MAb3+µE , implying that E(t) is bounded.
Hence, the solution of system (3.6) is bounded.
The proof is complete.
Next, we will consider the equilibrium solutions of system (3.6) and determine their stabil-
ity by using the Routh-Hurwitz criterion [17]. When we consider a Hopf bifurcation, we will
use the result given in [44] to determine the Hopf critical condition.
3.3.2 Equilibrium solutions
By setting ˙A = ˙Rn = ˙Rd = ˙E = 0 in model (3.6), we get two equilibrium solutions: the
tolerance equilibrium E0 : ( ¯A0, ¯Rn0, ¯Rd0, ¯E0) = (0, 0, 0, 0), and the autoimmune disease equi-
librium E1 : ( ¯A, ¯Rn, ¯Rd, ¯E), where
¯Rn =
[
π3(b1 + µA) ¯A + βα
]
µd ¯A
µdα(µn + ξ) − π3σ1(µd + d c ξ) ¯A2
,
¯Rd =
c ξ ¯Rn
µd
,
¯E =
[
σ1 ¯Rn(µd + d c ξ) + µd(b1 + µA)
]
¯A
µdα
.
(3.11)
and ¯A is a function in terms of the system parameters, particularly α, and determined by the
following 4th-degree equation, in which the parameter values given in Table 3.1 have been
used. Note that the rational numbers given below are obtained using symbolic computation in
which all the parameter values given in digital format (see Table 3.1) have been transformed to
rational numbers for convenience in computation.
F1(A, α) = 8138146972656250 A4 − 1521α625000000 A2 − 81α10000000 A + 58α2 − 81α640000 = 0. (3.12)
The graphs of A = 0 and F1(A, α) = 0 as given in (3.12) are shown in Figure 3.1, where
Figure 3.1(a) shows the complete bifurcation diagram, while Figure 3.1(b) only depicts the
part which is biologically meaningful. Figure 3.1(c) shows a 3-D plot, indicating why the
branch in Figure 3.1(a) is biologically meaningless.
3.3.3 Stability of the disease-free equilibrium, E0
For the stability of E0, we have the following result.
Theorem 3.3.2 When α < αt = 1λE (b1 + µA)(b3 + µE), the disease-free equilibrium E0 of the
model (3.6) is globally asymptotically stable.
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Figure 3.1: (a): Complete bifurcation diagram for model (3.6) projected on the α-A plane,
with the red and blue lines denoting E0 and E1, respectively; (b): Bifurcation diagram in (a),
restricted to the first quadrant; (c): Bifurcation diagram for model (3.6) projected on the α-A-
Rn space, with the red, green and blue lines denoting E0, the inner branch of E1, and the outer
branch of E1 which is biologically meaningless since Rn takes negative values. Here, the dotted
and solid lines indicate unstable and stable equilibria, respectively.
Proof In order to examine the stability of equilibria for system (3.6), we compute the Jacobian
matrix of system (3.6), given by
J=

−σ1(Rn+dRd)−(b1+µA) −σ1 A −σ1dA α
π3 E + β −(µn+ξ) 0 π3 A
0 c ξ −µd 0
λE −σ3 E −σ3dE −σ3(Rn+dRd)−(b3+µE)
. (3.13)
Evaluating the Jacobian (3.13) at E0 : ( ¯A0, ¯Rn0, ¯Rd0, ¯E0) = (0, 0, 0, 0), yields J|E0 , and then
setting det(L I − J|E0) zero results in a 4th-degree characteristic equation, which can be factor-
ized as
P0(L, α) = (L+µd)(L+µn+ξ)
[
L2+(b3+µE+b1+µA)L+(b1+µA)(b3+µE)−λEα
]
= 0. (3.14)
The asymptotic stability of E0 is determined by the sign of real part of the roots of Equation
(3.14): if all roots of Equation (3.14) have negative real part, then E0 is asymptotically stable;
if there is at least one root has positive real part, then E0 is unstable. In fact, P0(L, α) contains
three factors: the first two are linear polynomials in L, with positive parameter values from
Table 3.1, both of them are stable (i.e. their roots (eigenvalues) have negative real part); and
thus the stability of E0 only depends upon the third factor, which gives a quadratic equation,
L2 + (b3 + µE + b1 + µA)L + (b1 + µA)(b3 + µE) − λE α = 0. (3.15)
Using the general formula for solutions of the quadratic equation, we know that whether the
two roots of Equation (3.15) have negative real part is determined by the sign of (b3 + µE)(b1 +
µA) − λE α: the negativity (positivity) of the real part of the two roots of Equation (3.15) is
equivalent to (b3 + µE)(b1 + µA) − λE α > 0 (< 0), that is, Equation (3.15) has stable (unstable)
roots if (b3 + µE)(b1 + µA) − λE α > 0 (< 0), and a zero eigenvalue root comes out at
αt =
(b1 + µA)(b3 + µE)
λE
. (3.16)
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Here, the subscript ‘t’ stands for transcritical bifurcation. Using the parameter values from
Table 3.1, the transcritical bifurcation point is obtained as (αt, At) = (2.025 × 10−4, 0). The
equilibrium solution E0 is locally asymptotically stable (unstable), when α < αt (α > αt).
Next, we want to prove that E0 is also globally asymptotically stable for α < αt. To achieve
this, we construct a Lyapunov function of the form
V2(A, E) = 12
(
λEA2 + αE2
)
, (3.17)
which is positive-definite and continuously differentiable for all positive bounded values of A
and E, i.e., V2(0, 0) = 0 and V2(A, E) > 0 ∀A, E > 0. Moreover, the time derivative of the
Lyapunov function V2 satisfies
˙V2 = λE A ˙A + α E ˙E
= λE A [α E − σ1(Rn + dRd)A − (b1 + µA)A]
+α E [λE A − σ3(Rn + dRd)E − (b3 + µE)E]
= −λE (b1 + µA) A2 − α (b3 + µE) E2 + 2αλE A E
−(λE σ1 A2 + ασ3 E2)(Rn + dRd)
≤ −λE (b1 + µA) A2 − α (b3 + µE) E2 + 2αλE A E
= − (A E) Q (A E)T ,
which is a quadratic form, with
Q =
[
λE(b1+µA) −αλE
−αλE α(b3+µE)
]
(3.18)
being positive definite for (b1+µA)(b3+µE) > αλE. Hence, ˙V2 ≤ 0 and ˙V2 = 0 if and only if
(A, E) = (0, 0). This yields A(t), E(t) → 0 as t → +∞, for any positive initial conditions. It
follows that equation (3.6b) becomes an asymptotically autonomous equation with the limiting
equation, ˙Rn = −(µn+ξ)Rn. By the theory of asymptotically autonomous systems [7], we know
that the solution Rn(t) → 0 as t → +∞. Finally, using the same theory on equation (3.6c), we
get Rd(t) → 0 as t → +∞. Therefore, under the condition α < αt, the local stability and the
global attractivity of E0 established above give the global asymptotic stability of E0.
3.3.4 Stability of the autoimmune disease equilibrium, E1
In order to examine the stability of E1, we evaluate the Jacobian matrix (3.13) of system (3.6)
at E1, to obtain the characteristic equation det(L I − J|E1) = 0. By straightforward but tedious
computations, the characteristic polynomial of J at E1 is obtained as the following 4th-degree
polynomial:
P1(L, A, α) = L4 + a1(A, α)L3 + a2(A, α)L2 + a3(A, α)L + a4(A, α) = 0, (3.19)
where the coefficients, ai(A, α), i = 1, 2, 3, 4, are expressed in terms of A and α, with other
parameter values taken from Table 3.1, and A satisfies F1(A, α) = 0 (see equation (3.12)).
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The static bifurcation happens at equilibrium E1, when the characteristic polynomial P1(L, A, α) =
0 in (3.19) has zero root (zero eigenvalue). That means a4(A, α) = 0, and A should satisfy
F1(A, α) = 0. Thus, we obtain
As(αs) = − 21333593750000000α
3
s+26617447265625α2s−49464843750αs+8748000
3525388312500α2s−4572342000αs+979776 , (3.20)
where αs is the root of the following equation F2(αs) = αs(13530125αs−2592)× (400000αs−
81) = 0. Solving F2(αs) = 0 , and then substituting the solutions into As(αs) using Equation
(3.20), we get three points. The first one is a transcritical bifurcation point (αt, At) = (2.025 ×
10−4, 0), which is exactly the same as that we obtained from the tolerance equilibrium E0.
Moreover, at this point, all other Hurwitz arrangements are positive, that is, ∆1 = 4940 , ∆2 =
5863
16000 ,
and ∆3 = 527676400000 . The two equilibrium solutions E0 and E1 intersect and exchange their stability
at this critical point. E1 is stable when α > αt, (E1 does not exist for α < αt), as shown in Figure
3.1. Here, the subscript ‘t’ stands for transcritical bifurcation. The second point is a turning
point (αTurning, ATurning) = (1.9157 × 10−4, −1.7097), which has a negative value for A and so
is not biologically interesting (see Figure 3.1(a)). The third one is (αs, As) = (0, 0), which is
not allowed since the parameter α cannot take zero.
To check if a Hopf bifurcation exists from the infected equilibrium E1 of system (3.6), we
apply the theorem given in [44] to E1 defined by (3.11), where A satisfies equation F1(A, α) = 0
in (3.12). Based on the fourth-degree characteristic polynomial P1(L, A, α) in equation (3.19),
we apply the formula in [44], that is, ∆3(A, α) = a1 a2 a3 − a23 − a21 a4 = 0. Solving ∆3(A, α) = 0
and F1(A, α) = 0, together with the parameter values given in Table 3.1, we get two Hopf
bifurcation points: (αH1, AH1) = (7.8666 × 10−4, 11.4436), and (αH2, AH2) = (5.0387 ×
10−4, −13.1534), as shown in Figure 3.1(a). We only consider the biologically meaning-
ful point with two positive entries to obtain a unique Hopf bifurcation point: (αH, AH) =
(7.8666 × 10−4, 11.4436). Here, the subscript ‘H’ stands for Hopf bifurcation. At the critical
point (αH, AH), other conditions are satisfied: a1 = 2.0989, a2 = 0.6311, a3 = 0.1145, a4 =
0.0314, ∆2 = 1.2100, ∆3 = −0.1 × 10−18 ≈ 0. Indeed, with these given parameter values, one
can numerically calculate the Jacobian matrix of system (3.6) at E1, which contains a purely
imaginary pair and two negative real eigenvalues: ±0.2335 i, −1.7739, and −0.325. Thus, as
α is varied across the point α = αH, the equilibrium solution E1 becomes unstable and a Hopf
bifurcation occurs, leading to a family of limit cycles. Summarizing the above results gives the
following theorem.
Theorem 3.3.3 When αt < α < αH, the disease equilibrium E1 of model (3.6) is asymptotically
stable.
Now we apply normal form theory and the Maple program developed in [43] to system
(3.6) to analyze the Hopf bifurcation which occurs at the critical point (αH, AH) = (7.8666 ×
10−4, 11.4436) (with other parameters given in Table 3.1). Using a series of linear and nonlin-
ear transformations and the Maple program [43], we obtain the normal form associated with
this Hopf bifurcation up to third order, given by
r˙ = r (υ0 µ + υ1 r2), ˙θ = ωc + τ0 µ + τ1 r2, (3.21)
where υ0 = 34.2048, υ1 = −2.0161×10−12, ωc = 0.2335, τ0 = 132.8998, τ1 = −1.3186×10−11.
The steady-state solutions of equation (3.21) are determined by r˙ = ˙θ = 0, resulting in r¯1 = 0
3.4. Numerical simulation 55
and r¯22 = 0.1697 × 1014 µ. The equilibrium solution r¯1 = 0 actually represents the autoimmune
equilibrium E1 of model (3.6). A linear analysis on the first differential equation of (3.21)
shows that ddr (r˙)
∣∣∣
r¯=r¯1
= υ0 µ, and thus r¯1 = 0 (E1) is stable (unstable) for µ < 0 (> 0), as
expected. When µ is increasing from negative to cross zero, a Hopf bifurcation occurs and the
amplitude of the bifurcating limit cycles is given by the non-zero steady state solution,
r¯(µ) = 0.4119 × 107 √µ (µ > 0). (3.22)
Since ddr (r˙)
∣∣∣(3.22) = 2 υ1 r2, it indicates that the bifurcating limit cycles are stable for µ > 0.
We can get the same stability conclusion from υ1 < 0, implying that the Hopf bifurcation is
supercritical and so the bifurcating limit cycles are stable. Equation (3.22) gives the approx-
imate amplitude of the bifurcating limit cycles, while the phase of the motion is determined
by θ = ω t, where ω is given by ω = ˙θ
∣∣∣(3.22) = 0.2335 − 90.8185 µ. We summerize the above
results, yielding the following theorem.
Theorem 3.3.4 At the critical point α = αH, a supercritical Hopf bifurcation occurs, leading
to a family of stable limit cycles.
3.4 Numerical simulation
In this section, we present some simulation results to verify the analytical predictions obtained
in the previous section. In particular, we will show the comparison between the analytical
and numerical results obtained for the Hopf bifurcation. For convenience in the simulation,
we will fix all parameter values, except for α (or µ). We will vary α to demonstrate the stable
equilibrium solutions E0 and E1, and the stable limit cycles. Finally, we will also choose a large
positive value of µ, which means that this value is far away from the Hopf critical point αH, to
show the relapse-remission phenomenon. Note that the mechanism of generating recurrence in
this paper is slightly different from that defined by the conditions in Hypothesis 1 of paper [45]
in which recurrence is guaranteed to appear near a transcritical point. In this paper, recurrent
oscillations are generated far from the transcritical point αt = 2.025× 10−4. In other words, the
oscillations described in this paper are determined by more global properties of the system.
Suppose that all parameter values, except for α, are taken from Table 3.1. Then, it follows
from formula (3.16) that the equilibrium solution E0 is asymptotically stable for 0 < α < αt =
2.025 × 10−4. E0 becomes unstable when α is increased to pass through αt, and bifurcates into
the equilibrium solution E1, which is asymptotically stable for αt < α < αH = 7.8666 × 10−4.
E1 becomes unstable at α = αH, and a family of limit cycles bifurcates from this Hopf critical
point. The normal form for the Hopf bifurcation is given by (3.21). Since υ1 = −2.0161×10−12,
the Hopf bifurcation is supercritical, and the bifurcating limit cycles are stable.
Now, we first take α = 1.50 × 10−4 < αt. The simulation result is shown in Figure 3.2(a),
which clearly indicates that E0 is asymptotically stable, in agreement with the analytical pre-
diction. Next, choose αt < α = 4.0 × 10−4 < αH, for which the simulation result is depicted in
Figure 3.2(b), showing that E1 is asymptotically stable, which again agrees with the analytical
prediction. Further, we select a value of µ = 3.0 × 10−12 which implies that we take a post-
critical value of α near the Hopf critical point. This is a perfect Hopf bifurcation, as shown in
Figure 3.3.
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Figure 3.2: Simulated time history for system (3.6) with the initial condition A(0) =
17, Rn(0) = Rd(0) = 48000, E(0) = 12700 for (a) α = 1.50 × 10−4 < αt, converging to
E0; and (b) α = 4.0 × 10−4, converging to E1.
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Figure 3.3: Comparison between the simulated time history and analytical prediction for sys-
tem (3.6) with µ = 3 × 10−12, the red solid line denoting the simulation results, while the black
dash-dot line indicating the analytical predictions, showing stable limit cycles.
The simulations compared with the analytical predictions are depicted in Figure 3.3, show-
ing excellent agreement between simulation results and analytical predictions, particularly for
the smaller values of µ, as expected. Note that the analytical predictions are obtained through
a series of linear and nonlinear transformations, available from the output of the Maple pro-
grams [43]. The details are omitted here for brevity. Finally, we take α = 3.0 × 10−3 > αH,
which is not close to αH. For this case, normal form theory is not applicable since this value of
α is not near αH. In other words, if we apply the above procedure to obtain an approximation,
it would have a very large error. The simulation result is given in Figure 3.4, indeed showing
the recurrence phenomenon. It should be noted that the vertical axis in Figure 3.4 (c) and (d)
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Figure 3.4: Simulated time history for system (3.6) when α = 3 × 10−3, showing recurrence.
have a logarithmic scale so that the minimum level of effector T cells (E) can be clearly seen.
The reason for this behavior can be seen from Figure 3.4 (a) and (b) to be: the E population
grows very quickly in the absence of Rn and Rd, and then Rn responds very quickly (EA term)
and suppresses E, but Rn does not last long. This pattern is of course how the adaptive and
innate immune responses work against pathogens, as well. But why is E not eliminated like
a pathogen would be? We speculate that the system is now ‘torn between two equilibria’, as
described later in the Discussion.
3.5 Model reduction and parameter identification for autoim-
mune recurrence
In the previous sections, we have studied the 4-dimensional model (3.6) in detail and found
recurrence. Now, we are interested in finding the key factors which play the most important
roles in generating this phenomenon. To achieve this, a common approach is first to reduce
the dimension of the system under a quasi-steady state assumption, and then identify the main
system parameters (usually treated as bifurcation parameters) which may effectively influence
recurrence so that we may find the mechanism of generating relapse and remission. For model
reduction (in particular, the reduction from the 5-d model (3.5) to (3.6) and a further reduction
from the 4-d model (3.6) to a 3-d model, which will be considered below in detail), we need
to answer a fundamental question: does model reduction alter the dynamical behavior of the
system? We have carefully studied this problem and have shown that when proper parameter
values are chosen, both the original 5-d model and 4-d model, as well as the 4-d model and
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the 3-d model exhibit the same dynamical behavior: recurrence. (Details will be given in a
forthcoming paper.) Therefore, in the following, we will not consider the 5-d model (3.5), but
the 4-d model and its reduction.
3.5.1 Model reduction
For the model described by (3.6), we assume that at the site of the autoimmune reaction, the
influence of IL-2 from other sources, such as dendritic cells [1], is negligible compared to
the IL-2 generated by activated effector T cells. Therefore, we can set β = 0, and the model
becomes
˙A = αE − σ1(Rn + dRd)A − (b1 + µA)A,
˙Rn = π3EA − (µn + ξ)Rn,
˙Rd = c ξRn − µdRd,
˙E = λEA − σ3(Rn + dRd)E − (b3 + µE)E.
(3.23)
It can be shown that model (3.23) still has two equilibrium solutions. One is the tolerance
equilibrium E0 : (A, Rn, Rd, E) = (0, 0, 0, 0), and the other is the autoimmune equilib-
rium, E1 = ( ¯A, ¯Rn( ¯A), ¯Rd( ¯A), ¯E( ¯A)). We again choose α as the bifurcation parameter, and
find that the two equilibrium solutions exchange their stability at the transcritical bifurcation
point (αs, As) = (2.025 × 10−4, 0). That is, as α increases from α < αs to cross the critical
point α = αs, the stable E0 becomes unstable, while E1 emerges from this critical point and
is stable. As α continues to increase, a Hopf bifurcation occurs from E1 at the critical point
(αH, AH) = (6.4729 × 10−4, 12.4401). The simulated time history for α = 3 × 10−3 shown in
Figure 3.4 displays recurrent autoimmunity, as expected.
In order to further simplify the analysis on model (3.23), here we will adopt a quasi-steady
state assumption, which is often used in the study of biochemical and biological systems. The
basic idea of the quasi-steady state assumption can be described using the following system [8]:
x˙ = ǫ−1 f (x, y), x ∈ Rm,
y˙ = g(x, y), y ∈ Rn, (3.24)
where 0 < ǫ ≪ 1, f and g are nonlinear functions, and x and y represent ‘fast’ and ‘slow’ vari-
ables, respectively. We consider the evolution of the system from an arbitrary initial condition,
including a transient period. For the fast variable x, we may rewrite the first equation of (3.24)
as ǫ x˙ = f (x, y). Thus, for small ǫ, setting ǫ = 0 results in f (x, y) = 0, from which we obtain
an algebraic expression for x in terms of the slow variables x = x(y); x˙ , 0 (see [8] for more
details on this topic). This leads to a differential equation for the slow variable y in the form
y˙ = g(x(y), y). Intuitively, although the slow variable y is changing, the fast variable ‘catches
up’ so quickly that f (x, y) remains close to zero at all times.
Now, we return to consider system (3.23) and carefully compare the coefficients in the
system, finding that the parameter λE = 1000 is greater than all other parameters, which are on
the order of 10−6 ∼ 1. Thus, we may write the fourth equation of (3.23) as
˙E = λE
(
A − σ3
λE
(Rn + dRd)E − b3 + µE
λE
E
)
= ǫ−1
(
A − σ3
ǫ
(Rn + dRd)E − b3 + µE
ǫ
E
)
,
where ǫ = 10−3. Then, according to the general formula (3.24), we observe that E is a fast
variable, while A, Rn, and Rd are slow variables, all of the same order. This is also reflected
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Figure 3.5: Simulated time history for system (3.23) with the initial conditions A(0) = E(0) =
1, Rn(0) = Rd(0) = 0, for the bifurcation parameter α = 3×10−3: (a) for the transient period; and
(b) over a longer interval showing periodic behavior. The rates of change of cell populations,
˙A, ˙Rn, ˙Rd, and ˙E, are represented by the red solid, black dotted, blue dotted, and green solid
curves, respectively.
in the simulated time history for the transient period shown in Figure 3.5(a), which shows the
rapid rate of change in E relative to the other populations. Therefore, we can make a quasi-
steady state assumption on the fast variable E, yielding
E =
λEA
σ3(Rn + dRd) + b3 + µE , (3.25)
and so the reduced system is given by
˙A =
αλEA
σ3(Rn + dRd) + b3 + µE − σ1(Rn + dRd)A − (b1 + µA)A,
˙Rn =
π3λEA2
σ3(Rn + dRd) + b3 + µE − (µn + ξ)Rn,
˙Rd = c ξRn − µdRd.
(3.26)
3.5.2 Rescaling on system (3.26)
In order to reduce the number of parameters for convenience in analysis, we further attempt to
rescale system (3.26) by scaling the state and time variables as
Rn = e1 x, Rd = e2 y, A = e3 z, t = e4 τ. (3.27)
Then, with dτdt =
1
e4
, the left hand side of system (3.26) becomes
dRn
dt =
e1
e4
dx
dτ ,
dRd
dt =
e2
e4
dy
dτ,
dA
dt =
e3
e4
dz
dτ. (3.28)
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Next, we substitute (3.27) and (3.28) into system (3.26) to yield
dx
dτ =
e23 e4 λE π3
e21 σ3 x + e1 e2 σ3 d y + e1 (b3 + µE)
z2 − e4 (µn + ξ) x,
dy
dτ =
e1 e4 c ξ
e2
x − e4 µd y,
dz
dτ =
e4 αλE
e1 σ3 x + e2 σ3 d y + (b3 + µE) z − e1 e4 σ1 x z − e2 e4 σ1 d y z − e4 (b1 + µA) z.
(3.29)
Further, we set e1 e4 σ1 = 1, e2 e4 σ1 d = 1, e23 e4 λE π3 = 1 and e4 µd = 1 to obtain
e1 =
µd
σ1
, e2 =
µd
σ1 d
, e3 =
(
µd
λE π3
) 1
2
, e4 =
1
µd
. (3.30)
Finally, system (3.26) becomes
dx
dτ =
z2
A (x + y) + B − C x,
dy
dτ = D x − y,
dz
dτ =
E
F (x + y) + G z − x z − y z −H z,
(3.31)
where the new parameters are defined as A = σ3 µ
2
d
σ21
, B = µd
σ1
(b3 + µE), C = µn+ξµd , D =
c ξ d
µd
, E = αλE
µd
, F = σ3 µd
σ1
, G = b3 + µE, H = b1+µAµd . Here, we set E as the bifurcation
parameter, since α is used as the bifurcation parameter for the original system (3.6). We then
use the parameter values from Table 3.1 to obtain new parameter values for system (3.31) as
A = 400003 , B = 30000, C = 58 , D = 2, F = 15 , G = 920 , H = 94 . Moreover, it follows from (3.30)
that e1 = 2000003 , e2 =
100000
3 , e3 =
√
2
16 , e4 = 5.
The bifurcation patterns of the scaled system (3.31) are the same as that of the original
system (3.6), namely, there exist two equilibrium solutions: ¯E0 : (x0, y0, z0) = (0, 0, 0), and
¯E1 : (x1, y1, z1), where y1 = D x1, z1 =
√C x1 [A (1 +D) x1 + B], and x1 is determined from
the equation: (1 +D)2 F x2 + [(G +H F ) (1 +D)] x − E +H G = 0
Theorem 3.5.1 The solutions of system (3.31) are non-negative and bounded, provided that
the initial conditions are non-negative.
Proof For the non-negativeness, we write the solutions for z and y of system (3.31) by using
the method of constant variations as
z(τ) = z(0) exp
[ ∫ τ
0
( E
F [x(s) + y(s)] + G − x(s) − y(s) −H
)
ds
]
, (3.32)
and
y(τ) = y(0)e−τ +D
∫ τ
0
e−(τ−s) x(s) ds. (3.33)
There are two cases.
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Case 1. z(0) = 0. Then, it follows from (3.32) that z(τ) ≡ 0, ∀τ ≥ 0. Thus, the first equation
of system (3.31) is reduced to dxdτ = −Cx, which yields the solution x(τ) = x(0)e−Cτ.
Therefore, x(τ) ≥ 0, ∀τ ≥ 0 if x(0) ≥ 0. Then, we use (3.33) to obtain y(τ) ≥ 0, ∀τ ≥ 0
if y(0) ≥ 0.
Case 2. z(0) > 0. Then, it is easy to see from (3.32) that z(τ) > 0, ∀ τ ≥ 0. We need to discuss
four subcases.
Case 2.1. x(0) > 0 and y(0) > 0. To prove y(τ) > 0, ∀ τ > 0, we adopt the argument
of contradiction. Since y(0) > 0, we assume the first time at which y(τ) becomes
negative is τ1, i.e., y(τ) > 0, ∀τ ∈ [0, τ1), y(τ1) = 0 and y(τ) < 0, ∀τ ∈ (τ1, τ2).
Then, since y(0)e−τ > 0, (3.33) implies that there should exist an interval (τ3, τ4) ⊂
[0, τ1), such that x(τ) < 0, ∀ τ ∈ (τ3, τ4) (τ1 may equal τ4). With x(0) > 0, we
may, without loss of generality, assume τ3 is the first time x(τ) become zero, that
is, x(τ3) = 0 and x(τ), y(τ) > 0 ∀τ ∈ (0, τ3). On the other hand,
dx
dτ =
z2
A (x + y) + B − C x > −C x, for τ ∈ [0, τ3]. (3.34)
By the comparison principle, we have x(τ3) > x(0)e−Cτ3 > 0 for x(0) > 0, which
contradicts that x(τ3) = 0. Therefore, there is no time for y(τ) to be zero and then
become negative, that is, y(τ) > 0, ∀τ ≥ 0. Then, using a similar argument on
(3.34), we can prove that x(τ) > 0, ∀ τ ≥ 0.
Case 2.2 x(0) = y(0) = 0. Due to the continuity of the solutions and the conditions A >
0 and B > 0, for the term z2A (x+y)+B , there exists τ5 > 0, such that, for τ ∈ [0, τ5],
z(τ)2
A [x(τ)+y(τ)]+B > 0. Then,
dx
dτ =
z2
A (x+y)+B−C x > −C x, ∀ τ ∈ (0, τ5]. Therefore, x(τ) >
x(0)e−Cτ = 0 for τ ∈ [0, τ5]. Moreover, the solution of y(τ) = D
∫ τ
0 e
−(τ−s) x(s) ds
indicates y(τ) > 0 for τ ∈ [0, τ5]. Hence, we obtain x(τ5) > 0 and y(τ5) > 0. So we
can take τ5 as the initial point and use the conclusion obtained in Case 2.1 to show
that x(τ) > 0 and y(τ) > 0 for τ ≥ τ5. Combining the above two steps proves that
x(τ) > 0 and y(τ) > 0 for τ > 0.
Case 2.3 x(0) = 0 and y(0) > 0.
Case 2.4 x(0) > 0 and y(0) = 0.
For Cases 2.3 and 2.4, we can apply similar arguments used for proving Cases 2.1
and 2.2 to prove that the solutions of system (3.31) with these initial conditions are
non-negative.
The remainder of the proof is devoted to the boundedness of solutions. Suppose that y(τ) is
unbounded, that is, as τ→ +∞, y(τ) → +∞. Then, according to the second equation in (3.31),
we have limτ→+∞ x(τ) = +∞, and further obtain limτ→+∞ z(τ) = 0 by using the third equation
in (3.31), and then obtain limτ→+∞ x(τ) = 0 from the first equation in (3.31). This leads to a
contradiction, and so y(τ) is bounded. Now applying the boundedness of y(τ) to the second
equation in (3.31) yields the boundedness of x(τ). Finally, with bounded x(τ) and y(τ), the first
equation in (3.31) shows that z(τ) must be bounded as well. Hence, all the solutions of system
(3.31) are bounded. The proof is complete.
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The characteristic polynomial for ¯E0 is P0(L) = (L+1) (L+C) (LG−E+H G)/G, from which
it is easy to show that ¯E0 is asymptotically stable for E < Es = H G and becomes unstable at
the critical point Es = H G, from which ¯E1 appears. Further, we can use the characteristic
polynomial for ¯E1 to show that the two equilibrium solutions exchange their stability at the
transcritical bifurcation point Es = H G. Further, we have the following result for ¯E0.
Theorem 3.5.2 The trivial equilibrium E0 : (x0, y0, z0) = (0, 0, 0) is globally asymptotically
stable, for E < Es = H G.
Proof We construct the Lyapunov function, V(x, y, z) = 12 (x2 + ρ1y2 + ρ2z2) for system (3.31),
where ρ1 =
3C
D2 , and ρ2 =
1
B . V is continuously differentiable for all positive bounded values
of each variable, and positive definite with positive parameter values, i.e., V(0, 0, 0) = 0 and
V(x, y, z) > 0, ∀ x, y, z > 0. Then, the derivative of the Lyapunov function V with respect to
time, along the solution trajectory of system (3.31), yields
dV
dτ
∣∣∣∣∣(3.31) = x
dx
dτ + ρ1y
dy
dτ + ρ2z
dz
dτ
= x
[
z2
A (x + y) + B − C x
]
+ ρ1y
[D x − y] + ρ2z2
[ E
F (x + y) + G − x − y −H
]
=
[
1
A (x + y) + B − ρ2
]
xz2 − C
(
x − ρ1D
2C y
)2
− ρ1
(
1 − ρ1D
2
4C
)
y2
+
[ E
F (x + y) + G −H
]
ρ2z
2 − ρ2xz2 − ρ2yz2,
(3.35)
which implies that dVdτ < 0, ∀ x, y, z > 0 due to E < H G. The proof is complete.
The characteristic polynomial for ¯E1 is P1(L) = L3+a1(x1) L2+a2(x1) L+a3(x1). a3(x1) = 0
defines the transcritical point E = Es. The Hopf bifurcation point can be determined from the
Hurwitz arrangement ∆2 = a1(x1) a2(x1)−a3(x1) = 0. In general, we may take three parameters,
say, C, D, and E, as the bifurcation parameters. Therefore, the stability boundary, based in
particular on the Hopf critical condition, can be displayed in the 3-dimensional parameter
space as a surface. We then try to identify the region in the 3-dimensional parameter space
where recurrence may occur. For a clear view of the stability boundary, we use C = constant
or D = constant to intersect the surface to obtain planes, as shown in Figure 3.6. The curves
shown in Figure 3.6 are the stability boundary determined by the Hopf critical condition. The
graphs of ∆2(C, E) = 0 and ∆2(D, E) = 0 are plotted in the 2-dimensional C − E and D − E
parameter planes, as shown in Figure 3.6. Recurrence may occur on the right side (stable side
for bifurcating limit cycles) of the Hopf critical curves. Moreover, in these planes, we select
several fixed values for C or D to obtain the horizontal lines, as shown in Figure 3.6. Then,
we choose the points (according to the values of E) on these lines to perform simulation. Two
sets of nine simulated results are presented in Figures 3.7 and 3.8, corresponding to the nine
points marked on the five solid lines in each figure of Figure 3.6. It is seen from Figure 3.7 that
recurrence becomes more visible when the notation number of the points increases. That is, as
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D is fixed, reducing the value of C (see Figure. 3.6(a)) causes more dramatic recurrence, while
changing E in this case does not change the pattern. Figure. 3.8, on the other hand, shows
that when C is fixed at an appropriate value, the changes of D and E (see Figure. 3.6(b)) do
not play a significant role in determining recurrence. These parameter studies provide us with
information regarding which parameters play an important role in generating recurrence: while
some parameters mainly change the frequency of the motion, others only affect amplitude.
Finally, we would like to ask a question: since the recurrent pattern (or periodic solution)
occurs at the parameter values which are far away from the Hopf critical point, is there any
factor other than the Hopf bifurcation contributing to the oscillation. More specifically, do
there exist homoclinic orbits? The answer is negative, given in the following theorem.
Theorem 3.5.3 There exist no homoclinic orbits in the 3-dimensional scaled system (3.31) or
the 4-dimensional system (3.6). Thus, the stable limit cycles either come from Hopf bifurcation
or are due to persistant oscillations.
Proof First, for the 3-dimensional scaled system (3.31), note that existence of homoclinic or-
bits needs a saddle or a saddle-focus point, which requires E > H G. Evaluating the character-
istic polynomial at ¯E0 : (0, 0, 0) yields three eigenvalues: λ1 = −C, λ2 = −1, and λ3 = E−H GG .
Their corresponding eigenvectors are V1 = (1−CD , 1, 0)⊤, V2 = (0, 1, 0)⊤, and V3 = (0, 0, 1)⊤,
starting from ¯E0. Then, since for ¯E0 the eigenvalue λ3 is positive, while the other two eigen-
values λ1 and λ2 are negative, ¯E0 is a saddle point. If a homoclinic orbit exists, it must connect
the saddle point to itself, leaving in the direction tangent to V3 at ¯E0, and coming back along
a convergent trajectory to ¯E0, which is located in the stable manifold of system (3.31). It is
easy to show that the two eigenvectors V1 and V2 actually construct the stable manifold, which
is the first quadrant of the x-y plane, denoted by S 1. The solution on the stable manifold
can be expressed as v = T1v1 + T2v2, for T1, T2 ∈ R+, where v1 = (1−CD e−Cτ, e−Cτ, 0)⊤ and
v2 = (0, e−τ, 0)⊤. Then it is obvious that S 1 is invariant by verifying the solution v to satisfy
system (3.31). The complementary space of S 1 is the z-axis, which is tangent to the unstable
manifold. Thus if a homoclinic orbit exists, it must connect the unstable and stable manifolds.
However, this is impossible since there is no singular point on S 1 (expect for ¯E0), and so it
cannot intersect S 1 due to the uniqueness of solutions. Therefore, no homoclinic orbits ex-
ist in system (3.31), and thus the stable limit cycles in system (3.31) either come from Hopf
bifurcation or are due to persistent oscillations.
Next, we consider the 4-dimensional system (3.6). Note that system (3.6) also has two
equilibrium solutions E0 : ( ¯A0, ¯Rn0, ¯Rd0, ¯E0) = (0, 0, 0, 0) and E1 : ( ¯A, ¯Rn, ¯Rd, ¯E), where
¯A is determined by equation (3.12), and the other three components are given in equation
(3.11). E0 and E1 exchange their stability at a transcritical bifurcation point α = αt defined in
(3.16). When 0 < α < αt, E0 is globally asymptotically stable, and E1 does not exist; when
αt < α < αH, E0 becomes unstable, while E1 is asymptotically stable, where αH is a Hopf
bifurcation point at which limit cycles bifurcate from E1. When α > αH, E1 also becomes
unstable.
The existence of homoclinic orbits, requires the existence of a saddle or a saddle-focus
point, yielding the condition α > αt = 1λE (b1 + µA)(b3 + µE). The characteristic polynomial for
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Figure 3.6: Bifurcation diagrams for the scaled system (3.31) in 2-dimensional C−E andD−E
parameter spaces, where (a) D = 2; and (b) C = 58 ; with the red and blue lines denoting the
transcritical bifurcation and Hopf bifurcation, respectively.
E0 is given by equation (3.14), from which we obtain four eigenvalues:
L1 = −(µn + ξ),
L2 = −µd,
L3 = 12
{
−(b1 + b3 + µA + µE) −
√
(b1 + b3 + µA + µE)2 + 4λE(α − αt)
}
,
L4 = 12
{
−(b1 + b3 + µA + µE) +
√
(b1 + b3 + µA + µE)2 + 4λE(α − αt)
}
,
(3.36)
Since, α > αt and we have L3 < 0 and L4 > 0, indicating that E0 is a saddle point when
α > αt. The eigenvectors corresponding to the two negative eigenvalues L1 and L2 are V1 =(
0, µd−µn−ξ
cξ
, 1, 0
)⊤
and V2 = (0, 0, 1, 0)⊤, respectively. It is easy to verify that the solutions:
v1 = V1 e−(µn+ξ)t and v2 = V2 e−µdt satisfy system (3.6). Further, it can be shown that the
general solution, (A, Rn, Rd, E)⊤ = T1v1 + T2v2 also satisfies system (3.6), where T1, T2 ∈
R
+
. This implies that the subspace determined by A = E = 0, i.e., the first quadrant of the
Rn-Rd plane is a two-dimensional invariant stable submanifold, denoted by S 2. Hence, if a
homoclinic orbit exists in system (3.6), it cannot return to E0 via S 2, otherwise, it contradicts
the uniqueness of solutions. So, the remaining possibility for a homoclinic orbit to appear
is in the complementary space of S 2, which is the first quadrant of the A-E plane, denoted
by C : {(A, Rn, Rd, E) |A, E ≥ 0, Rn = Rd = 0} on which the dynamics are described by
˙A = αE − (b1 + µA)A, ˙E = λEA− (b3 + µE)E. However, this system is linear. So no homoclinic
orbits can exist in system (3.6), and thus the stable limit cycles in system (3.6) either come
from Hopf bifurcation, or are due to persistent oscillations. The proof is complete.
In this section, we have made two reductions, one based on a quasi-steady state assumption
and the other based on rescaling. It should be noted that these two reductions have a funda-
mental difference. The latter one actually generates an equivalent system, i.e., system (3.31)
is equivalent to system (3.26), while the former yields system (3.26) which is different from
system (3.23). However, system (3.26) still keeps the basic interesting dynamic behaviour
(recurrency) as that of the original system (3.23) under the quasi-steady state assumption.
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Figure 3.7: Numerical simulations for equation (3.31) with the parameter values (E, C) taken
as: (1) (13, 1.0), (2) (8.5, 0.8), (3) (10, 0.8), (4) (5, 0.625), (5) (6, 0.625), (6) (3, 0.4), (7)
(4, 0.4), (8) (2, 0.2), (9) (3, 0.2).
3.6 Conclusion and discussion
Adaptive immunity in vertebrates comprises an extremely complex dynamical system, and
much remains to be elucidated, particularly with respect to the role and action of regulatory T
cells. In this contribution, we demonstrate that the addition of a newly discovered subclass of
TReg cells, the terminally differentiated HLA-DR+ class [5, 27], alters the dynamical behavior
of a general model of autoimmune disease [1]. In particular, rather than being restricted to
stable equilibria corresponding to self-tolerance and autoimmunity, the system now displays
long periods of quiescence, punctuated by brief bursts of autoimmune activity. These cycles
of relapse and remission, characteristic of many autoimmune diseases, arise naturally from the
dynamical behavior of the system, without the need for stochastic input or exogenous environ-
mental triggers.
As an intuitive explanation for this phenomenon, we argue that the dynamical system is
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Figure 3.8: Numerical simulation for equation (3.31) with the parameter values (E, D) taken
as: (1) (8, 1.5), (2) (10, 1.5), (3) (5, 2), (4) (7, 2), (5) (4, 3), (6) (6, 3), (7) (3, 4), (8) (5, 4), (9)
(2.5, 5).
‘torn between two equilibria’, one of which is the trivial equilibrium corresponding to immune
tolerance (self-reactive populations at zero), the other corresponding to a full-blown autoim-
mune reaction. As a result, after the Hopf bifurcation the model populations remain close to the
tolerance equilibrium for long intervals, during which immune regulation (the TReg population)
gradually wanes. When regulatory populations are sufficiently small, the autoreactive effector
population escapes immune regulation and a brief episode of autoimmune disease, a relapse,
occurs.
Although the cycles of relapse and remission observed in this system occur at regular in-
tervals, we note that even slight fluctuations in the parameter values, or deterministic changes
in parameters over time, can result in highly variable intervals between relapse episodes, as
demonstrated in [45]. We also note that in any organism, self-antigen is likely to be continually
present at low levels. Thus, even if the relevant populations reach extremely low frequencies
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during the cycles of remission predicted here, pAPCs specific for self-antigen are likely to
be periodically generated, renewing the relapse-remission cyle if they are activated when the
TReg populations have waned. This could be a further factor contributing to variable intervals
between relapse episodes.
Clearly, the models we analyse are extreme simplifications of the mechanisms of immune
regulation. As the precise mechanisms of action of regulatory T cells are further elucidated,
more accurate and predictive models should be possible. Nonetheless we hope that the main
insight of this paper, that recurrence in autoimmune diseases can arise naturally from the com-
plex interplay of dynamic populations, will serve as a starting point for further research both
in dynamical systems theory, and in theoretical immunology.
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Table 3.1: Parameter definitions and values used in Chapter 3.
Para. Definition Values
v˜ per capita rate at which free antigen (G) is taken up
by immature pAPCs
0.0025 day−1 per
molecule of G
f proportion of antigen molecules that, upon uptake,
lead to maturation of the pAPC to enter population
A
1 × 10−4
π1 rate (per A, per E) at which active nTReg cells are gen-
erated from the pool of ‘naive’ TReg cells, due to en-
counter with mature pAPCs (A) and influence of IL-2
from specific effector T cells
0.0160 day−1/E
per A (π1)
π3 rate (per A, per E) at which active nTReg cells are gen-
erated from the pool of ‘naive’ TReg cells, due to en-
counter with mature pAPCs (A) and influence of IL-2
from specific effector T cells
0.0256 day−1/E
per A (π3)
β rate (per A) at which active nTReg cells are generated
from the resting pool, due to encounter with mature
pAPCs (A) and influence of IL-2 from other sources
200 day−1/A
λE rate (per A) at which effector T cells (E) are generated
from the resting pool, due to encounter with mature
pAPCs (A)
1000 day−1/A
γ rate (per E) at which self antigen (G) is released due
to the actions of effector T cells (E)
2000 day−1/E
σ1,3 rate (per capita, Rn or Rd) at which mature pAPCs (A)
and effective T cells are effectively eliminated due to
suppression by specific active nTReg cells (Rn) or ter-
minal TReg cells (Rd)
3×10−6 day−1 per
Rn or Rd per A
b1 rate (per capita) at which mature pAPCs (A) are effec-
tively eliminated due to suppression by TReg cells of
other specificities or by therapy
0.25 day−1/E
b3 rate (per capita) at which effective T cells (E) are ef-
fectively eliminated due to suppression by TReg cells
of other specificities or by therapy
0.25 day−1/E
µA per capita death rate of mature pAPCs 0.2 day−1/A
µE per capita death rate of effector T cells (E) 0.2 day−1/E
µG per capita rate at which free antigen (G) is cleared, for
example due to degradation
5 day−1/G
µn per capita death rate of active nTReg cells (Rn) 0.1 day−1/Rn
µd per capita death rate of terminal TReg cells (Rd) 0.2 day−1/Rd
ξ proportion of activated nTReg cells 0.025Rn
α rate (per E) at which immature pAPCs become ma-
ture
Bifurcation param-
eter
d the ratio of supress effectiveness of nTReg cells to ter-
minal TReg cells
2
c the fold of matured nTReg cells expansion and prolif-
eration to terminal TReg cells
23 = 8
Chapter 4
Backward Bifurcation Underlies Rich
Dynamics in Simple Disease Models
4.1 Introduction
In the mathematical modelling of epidemic diseases, the fate of the disease can be predicted
through the uninfected and infected equilibria and their stability. The basic reproduction num-
ber, R0, represents the average number of new infectives introduced into an otherwise disease-
free system by a single infective, and is usually chosen as the bifurcation parameter. If the
model involves a forward bifurcation, the uninfected equilibrium is in general globally asymp-
totically stable [28], characterized by R0 < 1, and infection fails to invade in this parameter
regime. The threshold R0 = 1 defines a bifurcation (or critical) point, and when R0 > 1, a
stable infected equilibrium emerges. This simple exchange of stability implies that complex
dynamics will not typically occur in forward bifurcation.
In contrast, backward bifurcation describes a scenario in which a turning point of the in-
fected equilibrium exists in a region where all state variables are positive, and R0 < 1. This
induces multiple infected equilibria, disrupting the global stability of the uninfected equilib-
rium. Multiple stable states (e.g., bistability) may likewise appear [15, 47, 4, 2]. Instead of
converging globally to the uninfected equilibrium when R0 < 1, the solution may approach an
infected equilibrium, depending on initial conditions.
In practice, the phenomenon of backward bifurcation gives rise to new challenges in disease
control, since reducing R0 such that R0 < 1 is not sufficient to eliminate the disease [22, 5].
Instead, R0 needs to be reduced past the critical value given by the turning point [22], since
the result in [47] shows that the uninfected equilibrium in backward bifurcation is globally
stable if R0 is smaller than the turning point. Furthermore, an infective outbreak or catastrophe
may occur if R0 increases and crosses unity, while the upper branch of the infected equilibrium
remains stable [15, 21, 48, 49]. In addition, oscillation or even recurrent phenomena may occur
if uninfected and infected equilibria coexist in a parameter range, and both are unstable [48,
49]. Hadeler [22] predicted oscillations arising from backward bifurcation, and Brauer [5]
pointed out that the unstable infected equilibrium “commonly arises from Hopf bifurcation”,
but did not demonstrate oscillations.
Several mechanisms leading to backward bifurcation have been proposed, such as partially
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effective vaccination programs [5, 2], educational influence on infectives’ behavior [22], the
interaction among multi-group models [10, 9, 25] and multiple stages of infection [40]. In
this study, we will investigate the emergence of backward bifurcation in three simple disease
models which have arisen in the study of epidemiology, in-host disease and autoimmunity. In
each case, we find that backward bifurcation facilitates the emergence of Hopf bifurcation(s),
and Hopf bifurcation in turn underlies a range of complex and clinically relevant dynamical
behaviors.
A central theme in our investigation is the role of the incidence rate in the epidemiologi-
cal and in-host disease models. The incidence rate describes the speed at which an infection
spreads; it denotes the rate at which susceptibles become infectives. Under the assumptions
of mass action, incidence is written as the product of the infection force and the number of
susceptibles. For example, if S and I denote the susceptible and infective population size re-
spectively, a bilinear incidence rate, f (S , I) = βS I (where β is a positive constant), is linear in
each of the state variables: S and I.
The possibility of saturation effects [8, 7] has motivated the modification of the incidence
rate from bilinear to nonlinear. Saturation occurs when the number of susceptible contacts
per infective drops off as the proportion of infectives increases. A nonlinear incidence rate,
therefore, typically increases sublinearly with respect to the growth of the infective population,
and may finally reach an upper bound. The development of nonlinear incidence was first
investigated in the form βI pS q (where β, p, and q are positive constants), see [32, 31, 23, 24, 13,
29]. Other forms of nonlinear incidence have also been analysed, such as kI pS/(1 + αIl) [32],
and kS ln(1 + vP/k) [6].
Since the nonlinear incidence functions described above were often developed to incor-
porate saturation effects, these functions are typically concave at realistic parameter values.
Korobeinikov and Maini [28] used this feature to derive general results for disease models with
concave incidence. They proved that standard epidemiological models with concave incidence
functions will have globally asymptotically stable uninfected and infected equilibria for R0 < 1
and R0 > 1, respectively.
More specifically, denoting the incidence rate function as f (S , I, N), where N is the popu-
lation size, the classical SIRS model considered in [28] takes the form
dS
dt = µN − f (S , I, N)− µS + αR,
dI
dt = f (S , I, N)− (δ+ µ)I,
dR
dt = δI − αR− µR, (4.1)
where µ, δ, and α represent the birth/death rate, the recovery rate and the loss of immunity
rate, respectively. When α = 0, system (4.1) becomes an SIR model. Assuming that the total
population size is constant, that is, N = S + I + R, the above system can be reduced to a
2-dimensional model:
dS
dt = µN − f (S , I, N) − µS ,
dI
dt = f (S , I, N) − (δ + µ)I. (4.2)
Moreover, it is assumed in [28] that the function f (S , I, N), denoting the incidence rate, satis-
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fies the following three conditions [28]:
f (S , 0, N) = f (0, I, N) = 0, (4.3a)
∂ f (S , I, N)
∂I
> 0, ∂ f (S , I, N)
∂S
> 0, ∀ S , I > 0 (4.3b)
∂2 f (S , I, N)
∂I2
≤ 0, ∀ S , I > 0. (4.3c)
The first two conditions (4.3a) and (4.3b) are necessary to ensure that the model is bio-
logically meaningful. The third condition (4.3c) implies that the incidence rate f (S , I, N),
is concave with respect to the number of infectives. It is also assumed that ∂ f (S , I, N)
∂I evalu-
ated at the uninfected equilibrium is proportional to the basic reproduction number R0 [42],
and thus should be a positive finite number [28]. Korobeinikov and Maini first considered
˙I = 0, or f (S , I, N) − (δ + µ)I = 0, and showed that forward bifurcation occurs in model (4.2)
with a concave incidence function. They further proved that the uninfected equilibrium Q0 =
(S 0, I0) = (N, 0) and the infected equilibrium ¯Q = ( ¯S , ¯I) are globally asymptotically stable,
when R0 = 1δ+µ
∂ f (S 0, I0, N)
∂I < 1 and R0 > 1, respectively.
In the sections to follow, for an incidence rate function f (S , I), satisfying (4.3a) and (4.3b),
we define f (S , I) as concave, if it satisfies (4.3c); as convex, if ∂2 f (S , I)
∂I2 > 0, ∀ I > 0; and as
convex-concave, if there exist 0 < I1 < I2 ≤ +∞, such that ∂ f (S , I)∂I > 0, ∀ I ∈ (0, I2), and
∂2 f (S , I)
∂I2 > 0, ∀ I ∈ (0, I1), ∂
2 f (S , I)
∂I2 = 0, for I = I1,
∂2 f (S , I)
∂I2 < 0, ∀ I ∈ (I1, I2).
Several models closely related to (4.2) have been previously studied. For example, by
adding a saturating treatment term to model (4.2) with a concave incidence rate, Zhou and
Fan [51] showed that this model may yield backward bifurcation and Hopf bifurcation. With an
even more sophisticated nonlinear incidence rate function: kI pS/(1+αIl) [38], where p = l = 2,
Ruan and Wang [38] proved that a reduced 2-dimensional SIRS model could exhibit backward
bifurcation, Hopf bifurcation, and even Bogdanov-Takens bifurcation and homoclinic bifurca-
tion. Although the choice of p = l = 2 was not motivated by a specific physical process, this
important result demonstrates that a nonlinear incidence rate can induce backward bifurcation,
and further generate complex dynamics in a simple disease model.
One of the focal points of our study will be a convex incidence function which arose in a
4-dimensional HIV antioxidant therapy model [43]. In this model, the infectivity of infected
cells was proposed to be an increasing function of the density of reactive oxygen species,
which themselves increase as the infection progresses. In [43], meaningful parameter values
were carefully chosen by data fitting to both experimental and clinical results. In this parameter
regime, the model was observed to capture the phenomenon of viral blips, that is, long periods
of undetectable viral load punctuated by brief episodes of high viral load. Viral blips have been
observed clinically in HIV patients under highly active antiretroviral therapy [11, 14, 35, 34],
and have received much attention in the research literature, both by experimentalists [17, 18,
20] and mathematicians [16, 27, 12, 37, 36]. Nonetheless, the mechanisms underlying this
phenomenon are still not thoroughly understood [20, 36].
We recently re-examined the model developed in [43], with the aim of providing new in-
sight into the mechanism of HIV viral blips [48, 49]. Focusing on the dynamics of the slow
manifold of this model, we reduced the dimension of the 4-dimensional model by using quasi-
steady state assumptions. After a further generalization and parameter rescaling process, a
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2-dimensional in-host HIV model [48, 49] was obtained, given by
dX
dτ = 1 − DX − (B +
AY
Y +C
)XY, dYdτ = (B +
AY
Y +C
)XY − Y, (4.4)
where X and Y denote the concentrations of the uninfected and infected cells respectively. The
constant influx rate and the death rate of Y have been scaled to 1. The death rate of X is D. The
2-dimensional infection model above (4.4), reduced from the 4-dimensional HIV model [43],
preserves the viral blips observed in the HIV model.
Importantly, system (4.4) is equivalent to the SIR model (4.2), except that the incidence
function is convex, as we will show in section 4.2.2. This equivalence can be demonstrated if
we set S = e1x, I = e2y, and t = e3τ with e1 = e2 = µNδ+µ and e3 =
1
δ+µ
. In this case, system (4.2)
is rescaled to
dx
dτ = 1 −
µ
δ + µ
x − 1
µN
f (x, y), dydτ =
1
µN
f (x, y) − y, (4.5)
which takes the same form as system (4.4). Therefore, although system (4.2) arises in epidemi-
ology and system (4.4) was derived as an in-host model, they are mathematically equivalent in
this sense. We will refer to both systems (4.2) and (4.4) as infection models.
In previous work [48, 49], we analyze the recurrent behavior which emerges in system (4.4)
in some detail. Recurrence is a particular form of oscillatory behavior characterized by long
periods of time close to the uninfected equilibrium, punctuated by brief episodes of high in-
fection [45]. Thus HIV viral blips are an example of recurrent behavior, but recurrence is a
more general feature of many diseases [45, 49]. We have demonstrated that the increasing
and saturating infectivity function of system (4.4) is critical to the emergence of recurrent be-
haviour. This form of an infectivity function corresponds to a convex incidence rate function
in the associated 2-dimensional infection model (4.4), and can likewise induce recurrence in
this model. Convex incidence has been previously suggested to model ‘cooperation effects’ in
epidemiology [28], or cooperative phenomena in reactions between enzyme and substrate, as
proposed by Murray [33].
The rest of this paper is organized as follows. In Section 2, we study two 2-dimensional
infection models, both closely related to system (4.2). We show that system (4.2) with either
(a) a concave incidence rate and saturating treatment term or (b) a convex incidence rate as
shown in system (4.4), can exhibit backward bifurcation; we then identify the necessary terms
in the system equations which cause this phenomenon. In Section 3, we demonstrate that
in both models, backward bifurcation increases the likelihood of a Hopf bifurcation on the
upper branch of the infected equilibrium. Studying system (4.4) in greater detail, we illustrate
how the location of the Hopf bifurcations and their directions (supercritical or subcritical),
determine the possible dynamical behaviors, concluding that backward bifurcation facilitates
Hopf bifurcation(s), which then underly the rich behaviours observed in these models. In
Section 4, we explore backward bifurcation further, presenting an autoimmune disease model
which exhibits negative backward bifurcation, that is, a bifurcation for which the turning point
when R0 < 1 is located in a region where one or more state variables is negative. Although
this bifurcation introduces two branches of the infected equilibrium, we demonstrate that, in
the biologically feasible area, only forward bifurcation exists in this model. We then present a
modification to this autoimmune model, motivated by the recent discovery of a new cell type,
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which generates a negative backward bifurcation and Hopf bifurcation, and allows recurrent
behavior to emerge. A conclusion is drawn in Section 5.
4.2 Backward bifurcation
In this section, we study backward bifurcation in two 2-dimensional infection models. In par-
ticular, we explore the essential terms and parameter relations which are needed to generate
backward bifurcation. Furthermore, we examine the convex incidence rate, and reveal its un-
derlying role in determining the emergence of backward bifurcation.
4.2.1 Backward bifurcation in the infection model with concave incidence
First, we consider the SIR model with concave incidence, described by the following equa-
tions [51]:
dS
dt = Λ −
βS I
1 + kI − dS ,
dI
dt =
βS I
1 + kI − (d + γ + ǫ)I,
dR
dt = γI − dR, (4.6)
where S , I and R denote the number of susceptible, infective, and recovered individuals, re-
spectively; Λ is the constant recruitment rate of susceptibles; d, γ, and ǫ represent the rates of
natural death, recovery, and the disease-induced mortality, respectively. Note that the function
βS I
1+kI is an incidence rate of the form
kIlS
1+αIh [32], when l = h = 1. Here, β is the infection rate, and
k measures the inhibition effect. Since the variable R is not involved in the first two equations,
system (4.6) can be reduced to a 2-dimensional model as
dS
dt = Λ −
βS I
1 + kI − dS ,
dI
dt =
βS I
1 + kI − (d + γ + ǫ)I. (4.7)
In [51] an additional assumption regarding limited medical treatment resources is introduced
to the above model, leading to a model with a saturating treatment term, given by
dS
dt = f1(S , I) = Λ −
βS I
1 + kI − dS ,
dI
dt = f2(S , I) =
βS I
1 + kI − (d + γ + ǫ)I −
αI
ω + I
, (4.8)
where the real, positive parameter α represents the maximal medical resources per unit time,
and the real, positive parameter ω is the half-saturation constant. For simplicity, let the func-
tions on the right-hand side of the equations in (4.8) be f1 and f2, respectively. Then, the
equilibrium solutions of system (4.8) are obtained by solving the following algebraic equa-
tions: f1(S , I) = 0 and f2(S , I) = 0. from which the disease-free equilibrium can be easily
obtained as ¯E0 = (Λ/d, 0). For the infected equilibrium ¯E = ( ¯S , ¯I), ¯S is solved from f1 = 0 as
¯S (I) = Λ(1 + kI)(dk + β)I + d . Then, substituting S =
¯S (I) into f2 = 0 yields a quadratic equation of
the form
F (I) = AI2 + BI + C = 0, (4.9)
which in turn gives two roots: ¯I1, 2 = −B±
√
B2−4AC
2A , where, A = (d + γ + ǫ)(dk + β), B =
[(dk + β)ω + d](d + γ + ǫ) + (dk + β)α − βΛ, C = [(d + γ + ǫ)ω + α]d − βΛω for system (4.8).
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Since all parameters take positive values, we haveA > 0. To get the two positive roots essential
for backward bifurcation, it is required that B < 0 and C > 0. Noticing that β, Λ, ω > 0, we
can see that the infection force, β, the constant influx of the susceptibles, Λ, and the effect
of medical treatment αI
ω+I are indispensible terms for backward bifurcation. The number of
positive infected equilibrium solutions changes from two to one when the value of C passes
from negative to positive, which gives a critical point at C = 0, that is, [(d+γ+ǫ)ω+α]d = βΛω,
which is equivalent to R0 = βΛ(d+γ+ǫ+α/ω)d = 1.
On the other hand, we may infer the emergence of backward bifurcation without solving
the equilibrium conditions. If we do not consider the medical treatment term αI
ω+I and remove
it from system (4.8), that leads to system (4.7), which is a typical example of an SIR model
studied by (4.2). By setting the incidence function as f3(S , I) = βS I1+kI , we have f3(0, I) =
f3(S , 0) = 0; ∂ f3(S , I)∂S = βI1+kI > 0 and ∂ f3(S , I)∂I = βS(1+kI)2 > 0 for all S , I > 0; and ∂
2 f3(S , I)
∂I2 =
−2βkS (1 + kI)−3 < 0 for all S , I > 0. Therefore, the incidence function f3(S , I), satisfies
the conditions given in (4.3). In particular, the function is concave, and can only have one
intersection point with the line (d+γ+ǫ)I in the I-S plane, as shown in Figure 4.1(a). Thus, the
uniqueness of the positive infected equilibrium implies that backward bifurcation cannot occur
in this case. Moreover, according to the result in [28], the uninfected and infected equilibria
are globally asymptotically stable for R0 = βΛd(d+γ+ǫ) < 1 and R0 > 1, respectively. No complex
dynamical behavior happens in system (4.7).
In contrast, when we introduce the loss of the infectives due to medical treatment, the
dynamics of system (4.8) differ greatly from system (4.7). In particular, backward bifurcation
emerges and complex dynamical behaviors may occur. To clarify this effect, we denote the
function induced by ˙I = 0 from (4.8) as f4(S , I) = βS I1+kI − αIω+I . Note that f4(S , I) is not
an incidence rate. But, if we fix S = ˜S > 0, there exist 0 < I1 < I2 < +∞, such that
∂ f4( ˜S , I)
∂I =
1
(1+kI)2(ω+I)2 [β ˜S (ω + I)2 − αω(1 + kI)2] > 0, ∀ I ∈ (0, I2); and ∂
2 f4( ˜S , I)
∂I2 = −2kβ ˜S (1 +
kI)−3 + 2αω(ω + I)−3 > 0, ∀ I ∈ (0, I1), ∂
2 f4( ˜S , I)
∂I2 = 0, for I = I1,
∂2 f4( ˜S , I)
∂I2 < 0, ∀ I ∈ (I1, I2).
Thus, f4( ˜S , I) actually has a convex-concave ‘S ’ shape, and may have two positive intersection
points with the ray line, g1(I) = (d + γ + ǫ)I, in the first quadrant; see Figure 4.1(b). These
intersections contribute the two positive equilibrium solutions that are a necessary feature of
backward bifurcation.
In summary we may conclude that the necessary terms which should be contained in system
(4.8) in order to have backward bifurcation are the constant influx Λ, the infection force β, and
the saturating medical treatment αI
ω+I .
4.2.2 Backward bifurcation in the infection model with convex incidence
Now we consider the 2-dimensional infection model (4.4) which exhibits viral blips, stud-
ied in [48, 49]. The motivation for this model was a series of clinical discoveries indicating
that viral infection can increase the density of a harmful chemical substance [19, 30, 39, 26],
thereby amplifying an associated biochemical reaction [41], and thus accelerating the infec-
tion rate [19]. This cooperative phenomenon in viral infection is expressed by an increasing,
saturating infectivity function: (B + AYY+C ). According to the principle of mass action, the inci-
dence function is then denoted as (B + AYY+C )XY , which is a convex function with respect to the
infectives’ density Y .
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(a)
I
f3( ˜S , I) = β
˜S I
1 + kI
g1(I) = (d + γ + ǫ)I
(b)
I
f4( ˜S , I) = β
˜S I
1 + kI −
αI
ω + I
g1(I) = (d + γ + ǫ)I
Figure 4.1: Graphs of the incidence function f3 in system (4.6, 4.7) and function f4 in sys-
tem (4.8) with respect to I, for which ˜S = 50 has been used. The parameter values are chosen
as β = 0.01, k = 0.01, α = 6, ω = 7, d = 0.1, γ = 0.01, ǫ = 0.02, according to [51]. The
solid lines denote f3 in (a) and f4 in (b), while the dashed ray lines in both graphs represent
g1(I) = (d + γ + ε)I. (a) the incidence function f3(S , I) = βS I1+kI , showing one intersection point
with g1; and (b) the function f4(S , I) = βS I1+kI − αIω+I , showing two intersection points with g1.
To analyze the occurrence of possible backward bifurcation, we first examine the two equi-
librium solutions from the following equations:
f5(X, Y) = 1 − DX − (B + AYY +C )XY = 0, f6(X, Y) = (B +
AY
Y +C
)XY − Y = 0, (4.10)
where all parameters A, B, C and D are positive constants. It is easy to find the uninfected
equilibrium ¯E0 = ( ¯X0, ¯Y0) = ( 1D , 0), whose characteristic polynomial has two roots: λ1 = −D <
0, and λ2 = BD − 1, which gives R0 = BD . Consequently, ¯E0 is stable (unstable) for R0 < 1 (> 1).
To find the infected equilibrium solution, setting f6(X, Y) = 0 yields ¯X1(Y) = Y+C(A+B)Y+BC , which
is then substituted into f5(X, Y) = 0 to give the following quadratic equation:
F5(Y) = (A + B)Y2 + (BC + D − A − B)Y +C(D − B) = 0. (4.11)
In order to have two real, positive roots, two conditions must be satisfied, that is, BC + D −
A − B < 0 and D − B > 0, or in compact form, 0 < D − B < A − BC. The condition
D − B > 0 is equivalent to 0 < R0 = BD < 1, which is a necessary condition for backward
bifurcation. Moreover, the positive influx constant, having been scaled to 1, is a necessary term
for the positive equilibrium of Y . Therefore, the positive influx rate term and the increasing
and saturating infectivity function are necessary for backward bifurcation.
In the rest of the subsection, we further examine the incidence function,
f7(X, Y) = (B + AYY +C )XY, (4.12)
without solving the equilibrium solutions. The incidence function f7 obviously satisfies the
condition (4.3a), as well as the condition (4.3b) since ∂
∂X f7(X, Y) = [B + AY(Y + C)−1]Y > 0
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Figure 4.2: Graphs of the incidence functions f7( ˜X,Y) and f7(Y) for the parameter values
A = 0.364, B = 0.03, C = 0.823, and D = 0.057. The incidence functions are denoted by the
solid lines, while the ray lines, determined by g2(Y) = Y , are denoted by dotted lines: (a) the
incidence function f7( ˜X,Y), showing one intersection point with g2 with an inset, with a fixed
value ˜X = 12.54; and (b) the incidence function f7(Y), showing two intersection points with an
inset.
and ∂
∂Y f7(X, Y) = ACXY(Y + C)−2 + [B + AY(Y + C)−1]X > 0 for all X, Y > 0. However, the
second partial derivative of f7(X, Y) with respect to Y , ∂2∂Y2 f7(X, Y) = 2AC2X(X + C)−3 > 0
for all X, Y > 0, showing that f7(X, Y) is a convex function with respect to the variable Y .
Consequently, f7(X, Y) can only have one intersection with g2(Y) = Y , implying that only one
equilibrium solution would exist if we only consider the second equation in (4.10), as shown
Figure 4.2 (a). However, when considering both conditions given in (4.10) for equilibrium
solutions, we will have two intersection points between f7 and g2. According to the first equa-
tion in (4.10), that is f5(X, Y) = 0, we can use Y to express X in the equilibrium state as
¯X(Y) = (Y +C)[(A+ B)Y2 + (BC +D)Y +DC]−1. Substituting ¯X(Y) into f7(X, Y) in (4.12), we
obtain
f7(Y) = Y[(A + B)Y + BC][(A + B)Y2 + (BC + D)Y +CD]−1, (4.13)
and ∂
∂Y f7(Y) = D[(A + B)Y2 + 2(A + B)CY + BC2][(A + B)Y2 + (BC + D)Y +CD]−2 > 0 for all
X, Y > 0. However, the sign of ∂2
∂Y2 f7(Y) = −2D[(A+ B)2Y3 + 3C(A+ B)2Y2 + 3(A+ B)BC2Y +
(B2C−AD)C2][(A+B)Y2+ (BC+D)Y +CD]−3, could alter at the inflection point from positive
to negative as Y increases. Therefore, with appropriate parameter values, f7(Y) can have a
convex-concave ‘S ’ shape, yielding two intersection points with the ray line, g2(y), in the first
quadrant of the X-Y plane, as shown in Figure 4.2 (b). The above discussion, as illustrated in
Figure 4.2, implies that system (4.4) can have two positive equilibrium solutions when R0 < 1,
and thus backward bifurcation may occur.
Remark 1. Summarizing the discussions and results given in this section indicates that a dis-
ease model with a convex-concave incidence function may lead to backward bifurcation, which
in turn implies: (a) the system has at least two equilibrium solutions, and the two equilibrium
solutions intersect at a transcritical bifurcation point; and (b) at least one of the equilibrium
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solutions is determined by a nonlinear equation.
4.3 Hopf bifurcation
In the previous section, we studied backward bifurcation and established the necessary con-
ditions for the occurrence of backward bifurcation in two models. In this section, we turn to
Hopf bifurcation, since it typically underlies the change of stability in the upper branch of the
infected equilibrium, the key condition in determining whether a model can exhibit oscillation
or even recurrence. Again, we will present detailed studies for the two models.
4.3.1 Hopf bifurcation in the infection model with concave incidence
In this subsection, we study two cases of an infection model with concave incidence: sys-
tem (4.7) and (4.8). First, we discuss the equilibrium solutions and their stability by using the
Jacobian matrix, denoted by J, and examining the corresponding characteristic polynomial,
P|J(L) = L2 + Tr(J)L + Det(J). (4.14)
Bifurcation analysis is conducted by choosing Λ as the bifurcation parameter.
First, we consider the case without saturating medical treatment, system (4.7). This system
satisfies the three conditions in (4.3), and consequently, its uninfected equilibrium ¯E0 = (Λd , 0)
is globally asymptotically stable if R0 = βΛ(d+γ+ǫ)d ≤ 1, while the infected equilibrium ¯E1 =
( kΛ+d+γ+ǫdk+β , βΛ−(d+γ+ǫ)d(dk+β)(d+γ+ǫ) ) emerges and is globally asymptotically stable if R0 > 1. Therefore, for
this case the system has only one transcritical bifurcation point at R0 = 1 and no complex
dynamics can occur.
Next, with the saturating treatment term, system (4.8) violates the conditions established for
model (4.3), but leads to the possibility of complex dynamical behaviors. In fact, evaluating the
Jacobian matrix J1 = J|(4.8)( ¯E0) at the uninfected equilibrium, ¯E0 = (Λd , 0), yields the character-
istic polynomial in the form of (4.14), denoted by P|J1(L), with Tr(J1) =
(
−βΛd + ǫ + αω + 2d
)
,
and Det(J1) =
(
−βΛ + d2 + dǫ + αd
ω
)
= Tr(J1) d − d2. This indicates that Det(J1) < 0 when
Tr(J1) = 0, and thus Hopf bifurcation cannot occur from ¯E0. On the other hand, a static bifur-
cation can occur when Det(J1) = 0, that is, ΛS = 1β (d2+dǫ + αdω ), where the subscript ‘S ’ refers
to static bifurcation. Therefore, ¯E0 is stable (unstable) for Λ < ΛS (> ΛS ), or R0 < 1(> 1),
with R0 = βΛd−1(d + γ + ǫ + αω)−1 [51].
We will show that complex dynamical behaviors can emerge in system (4.8) from the in-
fected equilibrium ¯E1 = ( ¯S , ¯I), where ¯I is determined from the equation F (I) = 0 in (4.9).
In the Λ-I plane, the bifurcation diagram as shown in Figure 4.3 (1)-(4), indicates a turning
point on the curve with appropriate parameter values, determined by both the quadratic equa-
tion (4.9) and the relation dΛdI = −∂F∂I /∂F∂Λ = 0, which is equivalent to ∂F∂I = 0. Solving ∂F∂I = 0
yields the turning point of I, denoted by IT (‘T ’ means turning), taking the form
IT =
1
2
[
βΛT
(dk + β)(d + ǫ) − ω −
d
dk + β −
α
d + ǫ
]
, (4.15)
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where ΛT is obtained from F (IT ) = 0, see (4.9). Thus, when IT > 0 (< 0), the turning point of
the quadratic curve appears above (below) the I-axis, meaning that backward bifurcation occurs
for I > 0 (< 0). Evaluating the Jacobian matrix at the infected equilibrium ¯E1, and further
denoting it as J2 = J|(4.8)( ¯E1), we obtain the characteristic polynomial in the form of (4.14),
with Tr(J2) = a11/[(ω+I)2(kI+1)(dkI+βI+d)] and Det(J2) = a21/[(ω+I)2(kI+1)(dkI+βI+d)],
where a11 = a1a−a1b and a21 = a2a−a2b, with a1b = βΛ(ω+ I)2 and a2b = da1b, and a1a and a2a
only contain positive terms (their expressions are omitted here for brevity). Therefore, we can
rewrite Det(J2) = a21d d/[(ω+ I)2(kI+1)(dkI+βI+d)]. Determining whether a Hopf bifurcation
can occur from ¯E is equivalent to finding whether Det(J2) remains positive when Tr(J2) = 0.
Ignoring the positive factors in the following subtraction yields
h1(I) = Tr(J2) − Det(J2)/d(ω + I)2(kI + 1)(dkI + βI + d) = a11 −
1
d a21 = a1a −
1
d a2a, (4.16)
where h1(I) = 1d (dkI + βI + d)[(kI + 1)d2(ω + I)2 − βǫI(ω + I)2 − αβωI]. Thus, when a1a = 0,
1
d a2a and h1(I) have opposite signs, implying that when Tr(J2) = 0, Det(J2) could be positive
only if h1(I) is negative. Therefore, the necessary condition for system (4.8) to have a Hopf
bifurcation from the infected equilibrium ¯E1 is that h1(I) is negative.
In the remaining part of this subsection, we demonstrate various dynamics which may hap-
pen in system (4.8) with different parameter values of k, as shown in Table 4.1. Taking other
parameter values as α = 6, ω = 7, ǫ = 0.02, γ = 0.01, β = 0.01, and d = 0.1, and solving the
two equations Tr(J2) = 0 and F (I) = 0 in (4.9) gives the Hopf bifurcation point candidates,
(ΛH, IH), for which h1(IH) < 0. Since the formula for the transcritical bifurcation point ΛS has
no relation with k, (ΛS , IS ) = (9.87, 0) is a fixed value pair in Table 4.1. Bifurcation diagrams
and associated numerical simulations are shown in Figure 4.3 corresponding to the five cases
given in Table 4.1. The blue lines and red curves represent the uninfected equilibrium ¯E0 and
infected equilibrium ¯E1, respectively. The stable and unstable equilibrium solutions are shown
by solid and dashed lines/curves, respectively. Backward bifurcation occurs in Cases 1, 2,
and 3 (see Table 4.1), which are illustrated by the corresponding bifurcation diagrams in Fig-
ures 4.3(1), (2), and (3), respectively. For Cases 1 and 2, only one Hopf bifurcation occurs on
the upper branch of the infected equilibrium ¯E1, and this bifurcation point exists at the critical
point ΛH < ΛS for Case 1 and ΛH > ΛS , for Case 2. For Case 1 with Λ = 9.78, the simulated
time history converges to ¯E0 with initial condition IC= [93.6, 0.44], shown in Figure 4.3(1a),
but converges to ¯E1 with initial condition IC= [46.8, 10], shown in Figure 4.3(1b). This clearly
indicates the bistable behavior when ΛH < ΛS , and an overlapping stable region for both ¯E0
and ¯E1 exists (see Figure 4.3(1)). The recurrent behavior for Case 2 is simulated at Λ = 9.87
with IC= [50, 5], shown in Figure 4.3(2a). For Case 2, ΛH > ΛS , and an overlapping unstable
parameter region for both ¯E0 and ¯E1 occurs between ΛS and ΛH (see Figure 4.3(2)). For Case
3, two Hopf bifurcations occur on the left side of ΛS , and a stable part in the upper branch of
¯E1 exists when Λ passes through the critical value Λ = ΛS . In this case, although backward bi-
furcation still exists and the turning point is also located above the Λ-axis, giving two branches
of biologically feasible ¯E1, only regular oscillating behavior is observed. The simulated time
history is conducted at Λ = 10, with initial condition IC= [50, 2], shown in Figure 4.3(3a).
For Case 4, only forward bifurcation occurs in the biologically feasible region, and the turning
point for backward bifurcation moves down to the fourth quadrant, that is, negative backward
bifurcation occurs in this case. The whole upper branch of ¯E1 in the first quadrant is stable,
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Table 4.1: Dynamics of system (4.8) for different values of k,
with α = 6, ω = 7, ǫ = 0.02, γ = 0.01, β = 0.01, d = 0.1,
and a fixed transcritical bifurcation point (ΛS , IS ) = (9.87, 0).
Case k (ΛT , IT ) h1(I) < 0 (ΛH, IH) Dynamics Notes
1 0.001 (9.48, 4.57) I ∈ [1.72, ∞] (9.73, 10.28) Bistability ΛH < ΛS
2 0.01 (9.71, 2.82) I ∈ [1.76, ∞] (9.96, 8.00) Recurrence ΛH > ΛS
3 0.02 (9.85, 0.84) I ∈ [1.82, ∞] (9.88, 2.09),
(10.14, 5.62)
Oscillation Two Hopf
critical points
4 0.027 (9.86, −0.65) I ∈ [1.85, 30.65] No Hopf No
oscillation
Negative
backward
bifurcation
5 0.05 No Turning I ∈ [2.01, 15.03] (6.18, −22.15) No
oscillation
No backward
bifurcation
therefore, no oscillations (or recurrence) can happen. Finally, further increases to the value
of k change the shape of the red curves, as shown in Figure 4.3(5), which again indicates
that no biologically meaningful backward bifurcation or oscillations can occur. Note that in
Figure 4.3(5) a Hopf bifurcation point exists on the lower branch of the equilibrium solution,
which is biologically unfeasible since it is entirely below the horizontal axis. In conclusion,
interesting dynamical behaviors can emerge in system (4.8) if backward bifurcation occurs.
4.3.2 Hopf bifurcation in the infection model with convex incidence
In this subsection, we return to system (4.4), that is, the 2-dimensional HIV model with con-
vex incidence derived in [48, 49], and analyze the various dynamical phenomena which sys-
tem (4.4) could possibly exhibit. To achieve this, we set B as the bifurcation parameter, and
A as a control parameter; the bifurcation analysis will be carried out for various values of A.
Also, simulated time histories are provided to illustrate the dynamical behavior predicted in the
analysis.
We first consider the uninfected equilibrium ¯E0 = ( 1D , 0), which has two eigenvalues. One
of them, given by λ1| ¯E0 = −D, is always negative. The other one is λ2| ¯E0 = BD − 1. Thus,
depending upon the relation between B and D, λ2| ¯E0 = 0 gives a static bifurcation at BS = D
(or R0 = BD = 1), which is further proved to be a transcritical bifurcation. Here the ‘S’ in
subscript stands for static bifurcation. Therefore, ¯E0 is stable when B < D (or R0 < 1), loses
its stability and becomes unstable when B increases to pass through BS = D, that is B > D (or
R0 > 1), and no other bifurcations can happen.
Next, we examine the infected equilibrium ¯E1 = ( ¯X, ¯Y). Since ¯X(Y) = Y+C(A+B)Y+BC , ¯Y is
determined by the quadratic equation (4.11), which gives the turning point (BT , YT ) as
BT =
−A + D + 2√ACD
C + 1
, YT =
A + B − BC − D
A + B
, (4.17)
where ‘T ’ in the subscript stands for turning bifurcation. We perform a further bifurcation
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Figure 4.3: Bifurcation diagrams and simulations associated with the five cases given in Ta-
ble 4.1, demonstrating various dynamical behaviors.
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analysis on its corresponding characteristic polynomial (4.14), which takes the form
P|
¯E1(λ,Y) = λ2 +
a1a
[(A + B)Y + BC](Y +C)λ +
a2a
[(A + B)Y + BC](Y +C) , where
a1a = (A + B)2Y3 + (2BC + D)(A + B)Y2 + (B2C2 + ACD + 2BCD − AC)Y + BC2D,
a2a = (A + B)2Y3 + 2(A + B)BCY2 + (B2C − AD)CY.
(4.18)
Therefore, the sign of the subtraction between the trace and determinant is determined by
h2(Y) = a1a − a2a = D(A+ B)Y2 + [2CD(A+ B)− AC]Y + BC2D. Here the equilibrium solution
of Y and other parameters satisfy the quadratic equation (4.11), which leads to an explicit
expression, given by ¯B = −AY2+(D−A)Y+CDY2+(C−1)Y−C . Substituting B = ¯B into h2(Y), we obtain
h2(Y)|B= ¯B = a1a − a2a =
[AC(D − 1) − D2]Y2 − [AC(D − 1) + 2CD2]Y −C2D2
Y − 1 . (4.19)
Hopf bifurcation may occur when the trace is zero, while the determinant is still positive. This
implies h2(Y) < 0, which is possible with appropriately chosen parameter values. Hence, by
solving a1a = 0 in (4.18) together with the quadratic equation (4.11), we get two pairs of points
denoted by (Bh1, Yh1) and (Bh2, Yh2), which are candidates for Hopf bifurcation. Then validat-
ing the above two points by substituting them back into the characteristic polynomial (4.18),
respectively, we denote the Hopf bifurcation point as (BH, YH) if this validation confirms their
existence. According to [47], Hopf bifurcation can happen only from the upper branch of the
infected equilibrium ¯E1.
The various dynamical behaviors which may appear in system (4.4) have been classified in
Table 4.2 for different values of the parameter A, with fixed values of C = 0.823 and D = 0.057.
Thus, the transcritical bifurcation point is fixed for all cases: BS = D = 0.057 and YS = 0. The
two solutions Bh1 and Bh2 are solved from the two equations (4.18) P| ¯E1(λ,Y) = 0 and (4.11)
F5(Y) = 0, respectively. They become a Hopf bifurcation point only if their corresponding Y
values (Yh1 and Yh2, respectively) are in the range such that h2(Y) < 0. Otherwise, system (4.4)
has a pair of real eigenvalues with opposite signs at (Bh1, Yh1) or (Bh2, Yh2), which is denoted
by the superscript ‘∗’ (which is actually a saddle point) in Table 4.2, while the Hopf bifurcation
point is denoted by the superscript ‘H’ in Table 4.2.
Next, we further examine the direction of the Hopf bifurcation, that is, check whether it is a
supercritical or subcritical Hopf bifurcation. Since the Jacobian matrix of the system evaluated
at the Hopf bifurcation point has a pair of purely imaginary eigenvalues, the linearized system
(4.4) does not determine the nonlinear behavior of the system. Therefore, we take advantage
of normal form theory to study the existence of the limit cycles bifurcating from the Hopf
bifurcation point as well as their stability. As mentioned earlier, Hopf bifurcation can only
occur from the upper branch of the infected equilibrium ¯E1, therefore we first transform the
fixed point ¯E1 to the origin by a shifting transformation, and, in addition, make the parameter
transformation B = BH + µ; the Hopf bifurcation point is thus defined as µ = µH = 0. Then the
normal form of system (4.4) near the critical point, µ = µH = 0, takes the form up to third-order
approximation:
r˙ = d µ r + a r3 + O(r5), ˙θ = ωc + c µ + b r2 + O(r4), (4.20)
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Table 4.2: Parameter values taken to illustrate various dynamics of system (4.4).
The fixed transcritical bifurcation point: (BS , YS ) = (0.057, 0)
Case A (BT , YT ) h2(Y) < 0, Y ∈ (Bh1, Yh1) (Bh2, Yh2) Dynamics Notes
1 0.80 (−0.1950, 0.5850) (0.0036, 0.9830) (0.0355, 0.8725)H (0.054, 0.0034)∗ Unstable
limit cycle,
Bistable
Bh1 < BS
2 0.71 (−0.1580, 0.5660) (0.0040, 0.9800) (0.0539, 0.0038)∗ (0.0574, 0.8650)H Recurrence Bh2 > BS
3 0.60 (−0.1140, 0.5380) (0.0048, 0.9769) (0.0540, 0.0045)∗ (0.0819, 0.8530)H Recurrence Bh2 > BS
4 0.07 (0.0557, 0.0909) (0.0476, 0.8030) (0.0560, 0.0470)∗ (0.1015, 0.5612)H Recurrence Bh2 > BS
5 0.06 (0.056558, 0.05581) (0.0574, 0.7700) (0.056559, 0.0574)H (0.0961, 0.5225)H Recurrence Bh1 < BS
< Bh2
6 0.05 (0.05697, 0.01442) (0.0724, 0.7232) (0.0574, 0.0741)H (0.0894, 0.4701)H Recurrence Bh1 < BS
< Bh2
7 0.04 (0.0569, −0.0358) (0.0986, 0.6507) (0.0592, 0.1071)H (0.0806, 0.3897)H Oscillation Bh1 < BS
< Bh2
YT < 0
8 0.03 (0.0559, −0.0994) (0.1611, 0.5149) — — ¯E1 stable YT < 0
Table 4.3: Classification of Hopf bifurcations based on the normal form (4.20).
Class Stability of r¯ = 0 Stability of r¯2=− dµ
a
Hopf bifurcation
µ < 0 µ > 0 µ < 0 µ > 0
(a): d > 0, a > 0 stable unstable unstable – subcritical
(b): d > 0, a < 0 stable unstable – stable supercritical
(c): d < 0, a > 0 unstable stable – unstable subcritical
(d): d < 0, a < 0 unstable stable stable – supercritical
where r and θ represent the amplitude and phase of the motion, respectively. The first equation
of (4.20) can be used for bifurcation and stability analysis, while the second equation of (4.20)
can be used to determine the frequency of the bifurcating periodic motions. The positive ωc in
the second equation of (4.20) is the imaginary part of the eigenvalues at the Hopf bifurcation
point. The parameters d and c can be easily obtained from a linear analysis, while a and b must
be derived using a nonlinear analysis, with the Maple program available in, say, [46].
Note that the infected equilibrium ¯E1 is represented by the fixed point r¯ = 0 of system
(4.20), while the nonzero fixed point r¯ > 0 (satisfying r¯2 = −dµ
a
) is an approximate solution for
a limit cycle or periodic orbit. The periodic orbit is asymptotically stable (unstable) if a < 0
(a > 0), and the corresponding Hopf bifurcation is called supercritical (subcritical). According
to the Poincare-Andronov Hopf Bifurcation theorem [44], for µ sufficiently small, there are
four possibilities for the existence of periodic orbits and their stability, which are classified in
Table 4.3, based on the four sets of the parameter values in the normal form (4.20). Then we
use the results presented in Table 4.3 with a nonlinear analysis based on normal form theory to
classify the Hopf bifurcations appearing in Table 4.2, and the results are shown in Table 4.4.
To illustrate the analytical results given in Tables 4.2 and 4.4, we provide the bifurcation
diagrams in Figures 4.4 (1)-(8). These figures depict the uninfected equilibrium ¯E0 and the
infected equilibrium ¯E1 in blue and red, respectively. The solid and dashed lines differen-
tiate stable and unstable states of the equilibrium solutions. The bifurcation points on the
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Table 4.4: Classification of Hopf bifurcations appearing in Table 4.2.
Case A Hopf bifurcation
point (BH, YH)
d a Stability of
limit cycles
Table 4.3
class
1 0.8 (0.0355, 0.8725) −1.0722 0.2114 × 10−2 Unstable (c)
2 0.71 (0.0574, 0.8650) −1.0726 0.1424 × 10−2 Unstable (c)
3 0.6 (0.0819, 0.8530) −1.0733 0.6755 × 10−3 Unstable (c)
4 0.07 (0.1015, 0.5612) −1.0307 −0.8791 × 10−3 stable (d)
5 0.06 (0.056559, 0.0574) 884.27 −0.1019 Stable (b)
(0.0961, 0.5225) −1.0079 −0.8613 × 10−3 Stable (d)
6 0.05 (0.0574, 0.0741) 18.232 −0.3145 × 10−2 Stable (b)
(0.0894, 0.4701) −0.9629 −0.8457 × 10−3 Stable (d)
7 0.04 (0.0592, 0.1071) 4.7242 −0.1577 × 10−2 Stable (b)
(0.0805, 0.3897) −0.8437 −0.8438 × 10−3 Stable (d)
equilibrium solutions are highlighted by solid black dots. Moreover, ‘Transcritical’, ‘Turn-
ing’, ‘Hopfsub’, and ‘Hopfsuper’, are used to denote Transcritical bifurcation, Turning point,
subcritical Hopf bifurcation, and supercritical Hopf bifurcation, respectively. Simulated time
histories are used to validate the analytical results, and to show different dynamical behav-
iors in each case listed in Tables 4.2 and 4.4. Subcritical Hopf bifurcation occurs in Cases
1-3, shown in Figures 4.4 (1)-(3). A = 0.8 is used in Figure 4.4 (1) for Case 1. Choosing
B = 0.036, we have E0 = [17.1282566, 0.023689] and E1 = [2.233533, 0.8726886]. The
simulated solution converges to E0 or E1, with initial condition taken as ICd = [17.13, 0.024]
or ICc = [2.233, 0.873], shown in Figures 4.4 (1d) and (1c), respectively. Figures 4.4 (1a) and
(1b), on the other hand, show the unstable limit cycle bifurcating from the subcritical Hopf
bifurcation with ICc = [2.233, 0.873].
Figure 4.4 (2) corresponds to Case 2 with A = 0.71. Choosing B = 0.0572 ∈ [BS , BH]
yields recurrence, independent of the initial conditions, see, for example, the result given in
Figure 4.4 (2b) with ICb = [2.4, 0.5]. However, for B = 0.06 > BH, the simulated time
history converges to E1, with an initial condition close to E1, such as ICa = [2.4, 0.6] as shown
in Figure 4.4 (2a); or shows recurrence with an initial condition far away from E1, such as
ICc = [2.4, 0.4], as shown in Figure 4.4 (2c).
Figure 4.4 (3) plots the result for Case 3 with A = 0.6, and shows a broader region be-
tween the transcritical and Hopf bifurcation points, associated with a larger recurrent region.
Recurrence occurs independent of the initial conditions for B = 0.083 ∈ [BS , BH], giving
E0 = [12.048, 0] and E1 = [2.576, 0.852], as shown in Figures 4.4 (3a) and (3b), with
ICa = [2.7, 0.84] and ICb = [14, 0.1], respectively. But if we choose B = 0.07 > BH,
we have E0 = [14.286, 0] and E1 = [2.67, 0.8478]. The time history converges to E1 with
ICc = [2.6, 0.8], or shows recurrence with ICd = [2.6, 0.1], as shown in Figure 4.4 (3c) and
(3d), respectively.
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Supercritical Hopf bifurcations occur in Cases 4-7, as shown in Figures 4.4 (4)-(7). Fig-
ure 4.4 (4) depicts the result for Case 4 with A = 0.07. Only one supercritical Hopf bifurcation
happens in this case, and gives a large recurrent parameter region between the transcritical and
Hopf bifurcation points. Although the simulated recurrent behavior does not depend on ini-
tial conditions, the recurrent pattern will fade out with the growth of the value of B from the
transcritical point to the Hopf bifurcation point, see Figures 4.4 (4a) and (4b) with the same
ICa, b = [8, 0.1], but different values of B: B = 0.06 and B = 0.09, respectively.
Figure 4.4 (5) shows the result for Case 5 with A = 0.06. A transcritical bifurcation hap-
pens between two supercritical Hopf bifurcations. The recurrent region still starts from the
transcritical point and independent of the initial conditions, but is narrower than that shown in
Figure 4.4 (4). The simulated recurrent behavior for this case is conducted at IC= [12, 0.1]
and B = 0.06. Figure 4.4 (6) corresponds to Case 6 with A = 0.05, and two supercritical Hopf
bifurcations occur on the right side of the transcritical bifurcation point, which makes the re-
current region even narrower and the recurrent pattern less obvious, as shown in the simulated
time history with IC= [10, 0.1] and B = 0.06. Negative backward bifurcations occur in Cases
7 and 8, as shown in Figure 4.4 (7) and (8). Although two Hopf bifurcations are still present
in Case 7, see Figure 4.4 (7), only a regular oscillating pattern exists. For Case 8, no Hopf
bifurcation happens in the biologically feasible part of E1, and therefore no more interesting
dynamics occur.
In general, backward bifurcation, which occurs above the horizontal axis, is much more
likely to induce Hopf bifurcation. A Hopf bifurcation can only occur along the upper branch
of ¯E1, since ¯E0 only changes its stability at a transcritical bifurcation point, and any point on
the lower branch of ¯E1 is a saddle node [47]. Moreover, Hopf bifurcation can lead to a change
in the stability of the upper branch of the infected equilibrium ¯E1. Thus the system further
develops bistable, recurrent, or regular oscillating behavior, corresponding to Cases 1 − 7 in
Tables 4.2 and 4.4, and in Figures 4.4 (1)-(7). In particular, bistability happens when both
equilibria ¯E0 and ¯E1 share a stable parameter region, see Case 1 in Table 4.2 and Figure 4.4
(1).
As for recurrent behavior, we observe that recurrence is more likely to happen if the fol-
lowing two conditions are satisfied for the upper branch of ¯E1: (1) the equilibrium remains
unstable as the bifurcation parameter increases and crosses the trancritical point, where ¯E0 and
¯E1 intersect, such that the two equilibria share an unstable parameter range; and (2) at least one
Hopf bifurcation occurs from ¯E1. As shown in Cases 2-6 in Table 4.2, and the corresponding
Figures 4.4 (2)-(5), the common recurrent parameter region for both subcritical and supercriti-
cal Hopf bifurcations starts beside the transcritical point, and is located entirely in the unstable
parameter region of ¯E0 and ¯E1. The simulated recurrent pattern becomes more pronounced
if the value of the bifurcation parameter is close to the transcritical point, but approaches an
oscillatory pattern as the parameter diverges from the transcritical point, as shown in Figure 4.4
(4a) and (4b). In this common recurrent parameter region, recurrence occurs independent of
initial conditions; see Figures 4.4 (3a) and (3b). In addition to the common recurrent region,
for subcritical bifurcation, seen in Table 4.2 for Cases (2) and (3) and Figures 4.4 (2) and (3),
recurrence may also appear on the stable side of the subcritical Hopf bifurcation point with an
initial condition close to ¯E1. Moreover, the subcritical Hopf bifurcation and the transcritical
point should be close to each other for a clear recurrent pattern. When this is not the case, the
periodic solutions show a more regular oscillating pattern, as compared in Figures 4.4 (2c) and
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(3d). Although two Hopf bifurcation points occur in Table 4.2 for Case 5, see Figure 4.4 (5),
the transcritical point is located inside the unstable range of the upper branch of ¯E1, between
the two Hopf bifurcation points. A recurrent pattern still characterizes the dynamical behavior
in this case. However, if the unstable range of ¯E1, between the two Hopf bifurcation points,
is located entirely in the unstable range of ¯E0, and moves further away from the transcritical
point, the recurrent motion gradually becomes a regular oscillation, as shown in Figures 4.4 (6)
and (7).
Summarizing the results and discussions presented in the previous two sections, we have
the following observations.
1. Due to the fact that ¯E0 only changes its stability at the transcritical bifurcation point, and
the fact that any point on the lower branch of ¯E1 is a saddle node, Hopf bifurcation can
only occur from the upper branch of ¯E1. A Hopf bifurcation may result in convergent,
recurrent, bistable, or regular oscillating behaviors.
2. Backward bifurcation gives rise to two branches in the infected equilibrium ¯E1. Hopf
bifurcation is more likely to happen when the turning point of the backward bifurcation
is located on the positive part of the equilibrium solution in the bifurcation diagram, as
shown in Figures 4.4 (2)-(6). This means that we have two biologically feasible infected
equilibria, which is essential to observe bistability, as shown in Figure 4.4 (1).
3. However, if the turning point on the infected equilibrium ¯E1, or the backward bifurcation
moves down to the negative part of a state variable in the bifurcation diagram, that is,
negative backward bifurcation occurs, then Hopf bifurcation is very unlikely to happen.
Although Figure 4.4 (7) shows an exceptional case, the parameter range for such a Hopf
bifurcation is very narrow.
4. The bifurcation diagram for system (4.4) with A = 0.03, shown in Figure 4.4 (8), is a
typical model with negative backward bifurcation. Such negative backward bifurcation
may occur in higher-dimensional systems. However, by considering more state variables,
which make the system more complicated, Hopf bifurcation can happen in the upper
branch of the negative backward bifurcation. We will discuss this possibility in more
detail in the next section by examining an autoimmune disease model.
The results obtained in this section suggest the following summary.
Remark 2. If a disease model contains a backward bifurcation on an equilibrium solution, then
as the system parameters are varied, there may exist none, one or two Hopf bifurcations from
the equilibrium solution, which may be supercritical or subcritical. If further this equilibrium
has a transcritical bifurcation point at which it exchanges its stability with another equilibrium,
then recurrence can occur between the transcritical and Hopf bifurcation points and near
the transcritical point, where both equilibrium solutions are unstable, and bistability happens
when Hopf bifurcation makes a shared stable parameter region for both equilibria.
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4.4 Negative backward bifurcation in an autoimmune dis-
ease model
In the previous section, we examined three cases of negative backward bifurcation: Table 4.1
Case 4 for system (4.8) and Table 4.2 Case (7) and (8) for system 4.4. The analytical and
numerical results showed that solutions typically converge to the infected equilibrium in these
cases, and the parameter range for Hopf bifurcation is very limited. As a result, negative
backward bifurcation tends to give no interesting behavior. In this section, however, we shall
explore an established autoimmune model [1] in which negative backward bifurcation occurs.
We demonstrate that after modification, the autoimmune model can also exhibit recurrence.
The autoimmune model [1] takes the form
dA
dt = f v˜G − (σ1Rn + b1)A − µAA
dRn
dt = (π1E + β)A − µnRn
dE
dt = λEA − µEE
dG
dt = γE − v˜G − µGG,
(4.21)
where mature pAPCs (A) undergo maturation by intaking self-antigen (G), at rate f v˜, and are
suppressed by specific regulatory T cells, TReg cells (Rn), at rate σ1; b1 represents additional
non-specific background suppression. The TReg cells are activated by mature pAPCs at a rate
proportional to the number of auto-reactive effector T cells (E) at rate π1, and by other sources
at rate β. Active auto-reactive effector T cells (E) come from the activation process initiated
by mature pAPCs, at rate λE, then attack healthy body tissue and release free self-antigen (G)
at rate γ, which is ready for mature pAPCs to engulf; the antigen engulfing rate is v˜. The death
rates of the populations A, Rn, E, and G are denoted by µA, µn, µE, and µG, respectively.
Following the steps described in detail in [50], system (4.21), can be reduced via quasi-
steady state analysis to a 2-dimensional system:
dA
dt = [
f v˜γλE
µE(v˜+µG) − b1 − µA]A − σ1RnA,
dRn
dt = (π1λEµE A + β)A − µnRn.
(4.22)
For simplicity, we set a = f v˜γλE
µE(v˜+µG) − b1 − µA and b =
π1λE
µE
. For the stability and bifurcation
analysis, we choose λE as the bifurcation parameter. System (4.22) has a disease-free equi-
librium ¯E0 = (0, 0), which is stable if a > 0 or λE > (b1+µA)(v˜+µG)µEf v˜γ ; and unstable if a < 0 or
λE <
(b1+µA)(v˜+µG)µE
f v˜γ . Thus a static bifurcation occurs on ¯E0 when a = 0 or λE =
(b1+µA)(v˜+µG)µE
f v˜γ .
The disease equilibrium is given by ¯E1 = ( ¯A, ¯Rn), in which ¯Rn = (b ¯A+β) ¯Aµn , and ¯A is given by the
roots of the following equation,
f8(A) = bσ1A2 + βσ1A − µna. (4.23)
Equation (4.23) has two roots with negative signs if a < 0, with opposite signs if a > 0, and
only one zero root if a = 0. This means that a negative backward bifurcation is possible in
system (4.22) with proper parameter values. We further examine the characteristic equation
at ¯E1, which shares the same form as equation (4.14), with Tr(J| ¯E1) = 1µn (bσ1A2 + βσ1A +
µ2n − aµn) := a11 and Det(J| ¯E1) = 3bσ1A2 + 2βσ1A − aµn := a12. Solving f8(A) = 0 and
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a12 = Det(J| ¯E1) = 0, gives the static bifurcation point of ¯E1 at ( ¯A, a) = (0, 0) or ( ¯A, λE) =
(0, (b1+µA)(v˜+µG)µEf v˜γ ), which is a transcritical bifurcation point between ¯E0 and ¯E1. Moreover,
Hopf bifurcation can happen if and only if f8(A) = 0 and a11 = Tr(J| ¯E) = 0, which can be
satisfied only if µn = 0. This implies that the positive branch of ¯E1 is stable for any positive
values of µn. Thus, this model cannot exhibit recurrence, bistability, or even regular oscillation.
The same conclusion was obtained in [50] for the original 4-dimensional model (4.21).
However, a recent experimental discovery [3] has revealed a new class of terminally differ-
entiated TReg cells. As described in detail in [50], introducing this cell population, denoted Rd,
into the model yields the full system
dA
dt = f v˜G − σ1(Rn + dRd)A − (b1 + µA)A
dRn
dt = (π1E + β)A − µnRn − ξRn
dRd
dt = cξRn − µdRd
dE
dt = λEA − µEE
dG
dt = γE − v˜G − µGG
(4.24)
and quasi-steady state analysis then yields a reduced 3-dimensional model in the form
dA
dt = [
f v˜γλE
(v˜+µG)µE − (b1 + µA)]A − σ1(Rn + dRd)A,
dRn
dt = (π1λEµE A + β)A − µnRn − ξRn,
dRd
dt = cξRn − µdRd.
(4.25)
Again, here λE is chosen as the bifurcation parameter for stability and bifurcation analysis. It is
easy to show that system (4.25) still has a disease-free equilibrium ¯E0 as (A, Rn, Rd) = (0, 0, 0),
and a disease equilibrium ¯E1 as ( ¯A, ¯Rn, ¯Rd), where ¯Rd = cξ ¯Rnµd , ¯Rn =
βµE+π1λE ¯A
µE(µn+ξ)
¯A, and ¯A is
determined from the following quadratic equation:
f9(A) = π1λEA2 + βµEA + µd(µn + ξ)(v˜ + µG)(cdξ + µd)σ1 [− fγv˜λE + (b1 + µA)(µG + v˜)µE], (4.26)
which gives two negative roots if λE < λES = (b1+µA)(µG+v˜)µEfγv˜ , and two roots with opposite signs
when λE > λES . The critical point is determined by λE = λES , which is actually the intersection
point of ¯E0 and ¯E1. The two equilibrium solutions exchange their stability at λES , leading to
a transcritical bifurcation at ( ¯A, λE) = (0, λES ). Note that the negative backward bifurcation
still happens in system 4.25. Moreover, a Hopf bifurcation occurs from the upper branch of
¯E1, giving rise to oscillation and recurrence.
Realistic parameter values have been obtained in [50], and are given as follows:
f = 1 × 10−4, v˜ = 0.25 × 10−2, σ1 = 3 × 10−6, b1 = 0.25, µA = 0.2, π1 = 0.016,
β = 200, µn = 0.1, µE = 0.2, γ = 2000, µG = 5, µd = 0.2, c = 8, d = 2, ξ = 0.025.
For the above parameter values, the Hopf critical point is obtained at (AH, λEH)= (5.6739, 1691.6414),
while the turning point is at (AT , λET )= (−1.4205, 879.9848), and the transcritical bifurcation
point is at (AS , λES )= (0, 900.45). These three bifurcation points and the stability of equilib-
rium solutions are shown in the bifurcation diagram given in Figure 4.5(a), and the simulated
recurrent time history is plotted in Figure 4.5(b) for λE = λEH + 1000.
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Figure 4.5: Dynamics of system (4.22): (a) bifurcation diagram; and (b) simulated time history
for λE = λEH + 1000.
In summary, when negative backward bifurcation occurs, that is, the turning point is lo-
cated in the negative state variable space, less complex dynamical behavior will be present.
Hopf bifurcation in a biologically feasible area does not happen in the reduced 2-dimensional
system (4.22), nor in the original system (4.21) [50]. However, if we increase the dimension of
the system, Hopf bifurcation and complex dynamical phenomena can emerge, as shown in our
results for system (4.25).
4.5 Conclusion
In this paper, we first review the previous work on a reduced 2-dimensional infection model
with a concave incidence rate [28]. The authors proved that the disease equilibrium will emerge
and be globally stable when the basic reproduction number R0 is greater than 1. This means
that no complex dynamical phenomenon can occur in such models. However, by adding an
extra saturating treatment term to this simple 2-dimensional infection model, the resulting sys-
tem (4.7) considered in [51] can exhibit backward bifurcation, which increases the parameter
range for Hopf bifurcation, which in turn leads to recurrent, bistable and regular oscillating
behaviors.
Instead of adding an extra term, a 2-dimensional infection model with a convex incidence
function can likewise show rich dynamics due to the occurrence of backward bifurcation, giv-
ing rise to two types of Hopf bifurcation. Biologically, a convex incidence rate implies that
existing infection makes the host more vulnerable to further infection, showing a cooperative
effect in disease progression. From the view point of mathematics, the convex incidence func-
tion enables backward bifurcation to occur on the positive branch of the disease equilibrium
solution, which further generates Hopf bifurcation. The location and direction of Hopf bifurca-
tion(s), determined by parameter values, can further give rise to bistable, recurrent, and regular
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oscillating behaviors.
Cooperative effects also occur during the progression of autoimmune disease. However, for
an autoimmune model with negative backward bifurcation, in which the turning point is located
on the negative state variable space, the biologically feasible parameter range in which Hopf
bifurcation may occur is limited. By introducing an additional state variable to the autoimmune
model, recurrent phenomenon are once again observed.
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Chapter 5
Dynamical Analysis of a 2-dimensional
Disease Model with Convex Incidence
5.1 Introduction
Mathematical models in epidemiology and in-host disease share common features, dividing a
population of individuals (epidemiology) or cells (in-host) into discrete classes relevant to the
disease dynamics, and typically describing their dynamics with a system of ordinary differential
equations (ODEs). A key feature of such systems is the incidence function, which defines the
spread of the infection to susceptibles.
For example, in classical epidemiological models, the incidence rate is often assumed to
take the form βS IN , where S (t) is the number of susceptible individuals, I(t) is the number
of infectives and β is a constant, the transmission rate [3]. When N, the population size, is
constant, this incidence function is also simply written as βS I. Similarly, for in-host models,
the rate at which uninfected cells become infected is often described as βxy, where x(t) reflects
the uninfected cell density and y(t) denotes the density of infected cells [23].
Bilinear incidence functions of this form have been used extensively and are well-studied
in the mathematical literature. As described in greater detail elsewhere [17], a number of
possibilities for non-linear incidence functions have also been studied in some detail, including
the general form βI pS q, where p and q are positive constants [21, 20, 14, 15, 8, 19], and several
more complex forms [21, 6].
Because of physical limitations on the number of new infections possible as disease preva-
lence increases, a common feature of many incidence functions is their concavity with respect
to the number of infectives. In particular, the incidence rate f (S , I, N) typically satisfies the
condition
∂2 f (S , I, N)
∂I2
≤ 0.
Taking advantage of this common feature, Korobeinikov and Maini [17] derived elegant results
for all concave incidence functions, showing the global asymptotic stability of the disease-free
equilibrium when the basic reproduction number R0 ≤ 1, and global asymptotic stability of the
endemic equilibrium when R0 > 1, for the standard SIRS model [3] with a constant population
size. In other words, the concavity of the incidence rate guarantees the uniqueness and stability
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of the endemic equilibrium in these models, and these powerful results apply to any concave
incidence function.
In contrast, we have recently analyzed a number of ODE models with convex incidence
functions. If incidence is convex, or “synergistic”, the rate at which new infections occur can
increase supralinearly with disease prevalence. This situation can arise in a number of real-
istic scenarios. For example, in in-host models of the human immunodeficiency virus (HIV),
increasing the extent of the infection involves greater damage to the immune system, and can
thus increase the incidence rate [25]. Similarly, in autoimmune disease, increases to the au-
toimmune response against self tissue can cause a positive feedback loop which will further in-
crease the incidence rate [1]. While these two examples both arise in in-host disease modelling,
catastrophic outbreak or pandemic conditions could also result in convex epidemiological inci-
dence. In particular, an outbreak that is severe enough to compromise health care infrastructure
(increasing hospital crowding and front-line worker exposure rates, for example) could involve
a supralinear increase in incidence rates with disease prevalence.
In this contribution, we analyze in detail the possible dynamical behaviors of a simple 2-
dimensional disease model with a convex, or synergistic, incidence function. The system we
analyze is a standard non-dimensionalized SI model which arises in both epidemiology and
in-host modelling: it assumes a birth rate into the susceptible population, death rates for both
populations, and an incidence rate between the two. The incidence function we study has an
analytical form which has arisen in a number of models previously analyzed [25, 1, 27, 28, 29].
Its behavior is such that when the infective population I is small, incidence increases linearly
with I; when I is large, incidence also increases linearly, but with a steeper slope. A convex
region of the function connects these limiting behaviors.
In marked contrast to the powerful general conclusions obtained for concave incidence
functions [17], we find that a wide range of dynamical behaviors are possible when inci-
dence is synergistic. In particular, as previously analyzed in related higher-dimensional mod-
els [27, 28, 29], we note the appearance of recurrent infection, that is, cycles consisting of long
periods close to the disease free equilibrium, punctuated by brief bursts of disease. This pattern
of recurrence occurs in many diseases, including the intriguing pattern of “viral blips” in HIV,
as well as the recurrent episodes characteristic of autoimmune diseases, such as multiple scle-
rosis [7], multifocal osteomyelitis [12, 16], lupus [22], eczema [11], and psoriasis [10]. In this
contribution, we explore several mechanisms which can underly these physiologically relevant
patterns of infection, finding that when the incidence function is convex, bistable equilibrium
solutions, Hopf and generalized Hopf bifurcations and, in particular, homoclinic bifurcations
may all contribute to disease recurrence.
In related work, Ruan and Wang [24] analyzed a reduced SI model, which has a zero
disease-free equilibrium and a positive endemic equilibrium. In this model, R0 = 0, although it
can be shown that the disease can still persist. In [24], the authors also considered Hopf bifur-
cation, Bogdanov-Takens bifurcation and homoclinic orbits. The structure of the model in [24]
is mathematically appealing, such that the authors could transform the model to a Lie´nard sys-
tem and then prove the uniqueness of the limit cycle from Hopf bifurcation. Moreover, their
analysis of the homoclinic orbit takes the standard form (e.g., see [13]). In contrast, the model
we study in this contribution has been derived from physical considerations and has known
realistic parameter ranges, however this model cannot be transformed to a Lie´nard system, and
the analysis of homoclinic orbits does not follow the standard form.
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The rest of the paper is organized as follows. In next section, we give a detailed dynam-
ical analysis of the simple 2-dimensional disease model. In Section 3, Hopf and generalized
Hopf bifurcations are studied in detail, which may be the main features underlying complex
dynamical behaviors. Then, in Section 4, Bogdanov-Takens bifurcation and homclinic bifurca-
tion are investigated, giving rise to another scenario/mechanism for generating blips. Finally,
conclusions and discussion are given in Section 5.
5.2 Dynamics of the 2-D disease model
Consider the 2-dimensional system:
dX
dτ = 1 − D X − (B +
A Y
Y +C
) X Y,
dY
dτ = (B +
A Y
Y +C
) X Y − Y,
(5.1)
where all parameters, A, B, C and D take positive real values. This system was originally
derived as an in-host model of HIV dynamics [25], but has been reduced in dimension and
non-dimensionalized using quasi-steady state assumptions as described in [27, 28]. Although
arising from in-host disease modeling, the reduced 2-D system is also equivalent to the SIRS
model studied in [17], taking the recovery rate, α of [17], to be zero. At appropriate parameter
values, system (1) thus represents either an in-host infection (susceptible and infected cells),
or an SIR epidemiological model (susceptible and infected individuals). The key difference
between system (1) and the class of models studied in [17] is that the incidence function in
system (1), XY(B+ AY/(Y +C)), is convex. Our goal is to understand the dynamical behaviors
made possible by this convexity.
In [27, 28], this 2-dimensional model is not analyzed in detail. For example, well-posedness
of solutions of this system and the global stability of the disease-free equilibrium were not
considered; and a trapping region was proved only for fixed parameter values when B > D. In
the following subsections, we will provide general proofs for the above mentioned problems
with no additional restriction on the positive parameter values.
5.2.1 Well-posedness of solutions
We first prove the positiveness and boundedness of solutions of system (5.1). We have the
following result.
Theorem 5.2.1 Solutions of system (5.1) are non-negative provided the initial conditions are
non-negative, and further these solutions are eventually attracted to a bounded region.
Proof Using the first equation of system (5.1), with the formulae of variation of parameters,
we obtain
X(τ) = X(0)e−
∫ τ
0
[
D+(B+ AY(s)Y(s)+C )Y(s)
]
ds
+
∫ τ
0
e−
∫ τ
s
[
D+(B+ AY(u)Y(u)+C )Y(u)
]
duds, (5.2)
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which clearly indicates that X(τ) > 0 for τ > 0 if X(0) ≥ 0. Next, we rewrite the second
equation of (5.1) as
dY
dτ = (BX − 1)Y +
A XY2
Y +C
.
We have shown X = X(τ) > 0 for τ > 0. Suppose Y(0) ≥ 0. Then, by continuity of solutions,
there exists τ1 > 0 such that
A X(τ)Y2(τ)
Y(τ) +C ≥ 0 for τ ∈ [0, τ1].
Hence, the solution of Y must be non-negative for τ ∈ (0, τ1], and so Y(τ1) ≥ 0. Now, starting
from τ = τ1, we apply the above argument to ensure that there exists τ2 > τ1 such that
A X(τ)Y2(τ)
Y(τ) +C ≥ 0 for τ ∈ [τ1, τ2].
Repeating the process, we have shown that Y(τ) ≥ 0 for τ > 0 as long as X(τ) > 0 (τ > 0) and
Y(0) ≥ 0.
To prove the boundedness of the solutions, we choose (Lyapunov) function
L(X,Y) = X + Y, (5.3)
which is positive definite for positive solutions. Differentiating L with respect to time τ, along
the trajectory of system (5.1) yields
dL
dτ
∣∣∣∣∣(5.1) =
dX
dτ +
dY
dτ = 1 − DX − Y
{
< 0 if DX + Y > 1,
> 0 if DX + Y < 1,
which indicates that X and Y are bounded.
5.2.2 Construction of generic trapping region
More precisely, we can construct a trapping region for all possible positive parameter values, to
which all solutions are attracted. Before stating the theorem, we first note that system (5.1) has
two equilibrium solutions obtained by setting dXdτ =
dY
dτ = 0: one is the disease-free equilibrium,
E0 = ( 1D , 0), which is a boundary equilibrium, and other is the endemic equilibrium, E1 =
(X1,Y1), which is an interior equilibrium, where
Y1 = 1 − DX1, (5.4)
and X1 is determined from the quadratic polynomial equation:
Q(X) = D(A + B)X2 − (A + B + D + BC)X +C + 1
= 1D
[(A + B)(1 − DX)2
−(A + B − D − BC)(1 − DX) −C(B − D)]
= 0.
(5.5)
The existence of E1 depends on the values of the parameters.
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Theorem 5.2.2 There exists a trapping region G, in the shape of a right triangle, bounded by
the X-axis, the Y-axis and the line X + Y = max{1, 1D } + ε (0 < ε ≪ 1).
Proof First, consider the X-axis. Note that E0 = ( 1D , 0) is located on the X-axis, with two
eigenvalues, ξ1 = −D and ξ2 = BD − 1, and their corresponding eigenvectors are v1 = (1, 0) and
v2 = (1, DB (1 − D) − 1), respectively. Moreover, v1 is in the direction of the X-axis, which can
be shown to be a solution trajectory of the system. With a negative eigenvalue, the trajectory
along the X-axis converges to the point E0. Thus, the X-axis is a separator (invariant manifold)
of the dynamical system, and so no trajectory can cross it due to the uniqueness of solutions.
Hence, every trajectory entering the region G cannot escape from this boundary – the X-axis.
On the Y-axis, it is easy to obtain dXdτ = 1 and
dY
dτ = −Y , showing that all trajectories cross
the Y-axis from left to right.
Next, we want to prove that all trajectories which cross the line L actually move into the
region G. To achieve this, note that the direction of the line L is (1,−1), and so the normal
direction of the line in its gradient direction is (1, 1). Define
S (Y) = (1, 1) • (dXdτ ,
dY
dτ ) =
dX
dτ +
dY
dτ ,
where the dot denotes inner product (or dot product). We need to show S (Y) < 0 for 0 < Y <
max{1, 1D } + ε. Simplifying S (Y) yields
S (Y) = dXdτ +
dY
dτ =
[
1−DX−
(
B+
A Y
Y +C
)
X Y
]
+
(
B+
A Y
Y +C
)
XY−Y
= 1 − D X − Y = 1 − D X −
[
max
{
1,
1
D
}
+ ε − X
]
= −ε + 1 −max
{
1,
1
D
}
+ (1 − D)X
=

−ε + (1 − 1D) + (1 − D)X, D < 1
−ε, D = 1
−ε − (D − 1)X, D > 1
 for 0<X<max
{
1,
1
D
}
+ε
≤ −εmin{1, D} < 0.
Note that one may set ε = 0 for D , 1. Hence, for all positive parameter values, there always
exists a trapping region G, bounded by the X-axis, the Y-axis, and the line L, and all trajectories
move into G when crossing the Y-axis and the line L, and once they enter G, they cannot escape
from the X-axis.
In the following, we consider the dynamical behaviour of system (5.1) according to the
conditions: B < D, B > D and B = D. Note that system (5.1) is actually equivalent to the
model studied in [17] when Y is small so that Y2 ≈ 0. In this case, system (5.1) has bilinear
incidence, which is concave, and the local R0 = BD . Thus, we expect that the disease-free
equilibrium, E0, when Y is in fact small, is locally stable when B < D, and becomes a saddle
point when B > D.
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5.2.3 Dynamical behavior of (5.1) when B < D
First, we study the dynamical behavior of system (5.1) when B < D. In particular, we want to
investigate the global stability of the disease-free equilibrium E0. For convenience, define
H1
△
= A + B − D − BC − 2
√
C(A + B)(D − B), (B < D). (5.6)
We have the following result.
Theorem 5.2.3 When B < D, the disease-free equilibrium E0 of system (5.1) is globally
asymptotically stable if H1 < 0, under which the endemic equilibrium E1 does not exist. Oth-
erwise, there exist two disease equilibria – one of them is a saddle point while the other may
be a stable (or an unstable) node or focus – and no definite conclusion can be made regarding
the global stability of E0.
Proof First, it is easy to see that when B < D, the disease-free equilibrium E0 is a stable
node since both eigenvalues are negative. In order to prove this theorem, we also need the
information about the disease equilibrium E1. Solving equation (5.5) yields two roots:
X± =
(A + B + D + BC) ± √∆
2D(A + B) , (5.7)
where
∆ = (A + B + D + BC)2 − 4(C + 1)D(A + B)
= (A + B − D − BC)2 − 4C(A + B)(D − B), (5.8)
which implies that the existence condition for X± when B < D is given by
∆ = (A + B − D − BC)2 − 4C(A + B)(D − B)
=
[
A + B − D − BC + 2√C(A + B)(D − B) ]H1 > 0. (5.9)
Now, based on H1, we discuss the existence condition of biologically meaningful solutions X±.
(i) When H1 ≥ 0, it yields ∆ ≥ 0, for which 0 < X− ≤ X+ < 1D , implying that the disease
equilibrium E1 has two solutions E1+: (X+,Y+) and E1−: (X−,Y−). In particular, when
H1 = 0, 0 < X− = X+ < 1D , indicating a saddle-node bifurcation to occur from the
equilibrium E1.
(ii) When H1 < 0, there are two cases.
(iia) If −2√C(A+B)(D−B) < A+B−D−BC < 2√C(A+B)(D−B), then ∆ < 0, and so
there is no real solution for X±. Thus, equilibrium E1 does not exist.
(iib) If A + B − D − BC ≤ −2√C(A + B)(D − B) under which ∆ ≥ 0, we then have
X+ ≥ X− ≥ 1D , showing that there do not exist biologically meaningful equilibria
E1.
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The above discussions show that a biologically meaningful equilibrium E1 does not exist if
H1 < 0 (with B < D), and in this case, there exists only one stable equilibrium E0 on the
boundary of the trapping region G. By index theory, this means that all trajectories of system
(5.1) must converge to the stable node E0, and so the disease-free equilibrium E0 is globally
asymptotically stable if H1 < 0 when B < D.
Remark The condition B ≥ D guarantees the existence of unique disease equilibrium E1, for
which the disease-free equilibrium E0 is a saddle point. (When B = D, E0 is a degenerate saddle
point, which will be proved later in Section 5.2.5.) When B < D, the disease equilibrium E1
may or may not exist. The additional condition H1 ≥ 0 (with B < D) guarantees the existence
of two disease equilibria E1± (E1− = E1+ when B = D). It can be easily seen from (5.6) that
when B < D, H1 ≥ 0 implies A + B − D − BC > 0, i.e., A > (D − B) + BC, indicating that
A must pass through a threshold value to generate the disease equilibrium solution E1. This is
clear from the second equation of (5.1), which can be rewritten as dYdτ = [(BX − 1) + AXYY+C ]Y ,
that the first term BX − 1 < 0 for X < 1D and B < D. Thus, dYdτ < 0 with small values of A
for all values of X, implying that Y will die out. When the value of A exceeds its threshold, dYdτ
becomes positive at least for some values of X, which makes Y gain a steady state and thus the
disease equilibrium E1 exists. Biologically, the threshold value of the contact rate, A, means
that the interaction between X and Y produces sufficient infection such that Y persists.
In the remainder of the proof, we assume that B < D and H1 ≥ 0. If H1 > 0, then
0 < X− < X+ < 1D , which implies that two biologically meaningful equilibrium solutions exist
for E1. When H1 = 0, we have 0 < X− = X+ < 1D = X0, which means that there is only one
solution for equilibrium E1. To find the stability of the equilibrium E1, evaluating the Jacobian
matrix of system (5.1) at E1 results in
J(E1) =
 −D − (B +
A Y
Y+C ) Y −(B + A YY+C ) X − ACXY(Y+C)2
(B + A YY+C ) Y (B + A YY+C ) X + ACXY(Y+C)2 − 1

(X,Y)=(X1,Y1)
=
 −
1
X1
−1 − ACX1Y1(Y1+C)2
1
X1
− D ACX1Y1(Y1+C)2
 .
(5.10)
Then, the characteristic equation of E1 is given by
ξ2 − Tr(J) ξ + det(J) = 0, (5.11)
where
det(J) = − ACY1(Y1+C)2 +
(
1
X1
− D
)(
1 + ACX1Y1(Y1+C)2
)
= 1X1 − D −
CD
Y1+C
AY1
Y1+C X1
= 1X1 − D −
CD
Y1+C
(
1
X1
− B
)
X1
= 1(1−DX1+C)X1
1
D
[(D + BC)(1 − DX1)2
+2C(D − B)(1 − DX1) +C(B − D)]
=
− (1−DX1)
(1−DX1+C)X1
[(A+B+D+BC)X1−2(1+C)] (by using (5.5))
=
− (1−DX1)
2D(A+B)(1−DX1+C)X1
[√
∆
(√
∆ ± (A + B + D + BC)],
(5.12)
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in which Y1 = 1 − DX1 and (5.7) have been used. Since it is assumed that H1 > 0, i.e.
∆ = (A + B + D + BC)2 − 4(C + 1)D(A + B) > 0, we have
det(J) < 0 for X1 = X+, and det(J) > 0 for X1 = X−. (5.13)
When det(J) < 0, the two eigenvalues of the characteristic polynomial (5.11) are real with
opposite signs, and thus the equilibrium point E1+= (X+,Y+) is a saddle point.
To consider the property of another equilibrium point E1−= (X−,Y−), we need to calculate
Tr(J) as follows:
Tr(J) = − 1X1 +
ACX1Y1
(Y1+C)2
= − 1X1 +
CX1
Y1+C
(
1
X1
− B
)
=
−(1−DX1)−C+CX1(1−BX1)
X1(Y1+C)
= − 1X1(Y1+C)
[
BCX21 − (C + D)X1 +C + 1
]
= − 1(Y−+C)
[(BC − DA − DB)X− + (A + B + BC −C)]
= − 12D(A+B)(Y−+C)
[
AD(A + B −C) + BC(DA + DB + BC)
−(D − B)(A + B)(C + D) + (DA + DB − BC)√∆],
(5.14)
which can be positive or negative, depending upon the values of parameters. Therefore, the
equilibrium point E1− may be a stable (or an unstable) node or focus.
Summarizing the above results, we have shown that when B < D, the boundary equilibrium
E0 is a stable node. Moreover, when H1 < 0, a biologically meaningful disease equilibrium E1
does not exist and E0 is the unique equilibrium solution, so it is globally asymptotically stable
by applying Theorem 5.2.2. When H1 ≥ 0, there exist two disease equilibria, E1+ and E1− (E1−
coincides E1+ if H1 = 0, giving rise to a saddle-node bifurcation), and E1+ is a saddle point,
while E1− may be a stable (or an unstable) node or focus. In this case, no conclusion can be
made regarding for the global stability of the disease-free equilibrium E0.
When det(J) > 0, we may use Tr(J) and det(J) to further classify the equilibrium point E1−.
For convenience, let
H2
△
= (D−B)(A+B)(C+D) − AD(A+B−C) − BC(DA+DB+BC)
−(DA + DB − BC)√∆, (A + B + D +C − √∆ > 0),
(5.15)
and
H3
△
= Tr2(J) − 4 det(J), (A + B + D +C −
√
∆ > 0). (5.16)
Thus, Tr(J) has the same sign of H2, and det(J) has the same sign of A + B + D +C −
√
∆, but
H2 and A + B + D +C −
√
∆ only depends upon the parameters A, B, C and D.
Then, E1− can be classified according to the signs of H2 and H3, as shown in Table 5.1,
where SF, UF, SN, UN, DSN and DUN stand for Stable Focus, Unstable Focus, Stable Node,
Unstable Node, Degenerate Stable Node and Degenerate Unstable Node, respectively.
Now, we consider the numerical values of the parameters used in [27, 28] to demonstrate
different dynamical behaviors of system (5.1) for B < D. The typical values used [27, 28] are
A = 0.364, C = 0.823, D = 0.057, B = 0.060, (5.17)
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Table 5.1: Classification of E1− (H1 ≥ 0).
H2 < 0 H2 > 0 H2 = 0
H3 < 0 SF UF Center
H3 > 0 SN UN −−−
H3 = 0 DSN DUN Double-zero
for which viral blips occur. Note that B = D = 0.057 is the transcritical point between the
equilibrium solutions E0 and E1, and the oscillating behavior (blips) shown in [27, 28] is for
B > D. Here, we want to change the parameter values near the above set of values for B < D
to demonstrate more interesting dynamical behaviors, in particular, the bistable equilibrium
solutions, Hopf and generalized Hopf bifurcations, and Bogdanov-Takens (BT) bifurcation. It
is not easy to see the relation between H1, H2 and H3 in a 4-dimensional parameter space. Thus,
we fix B = 0.054, and choose two values for D = 0.057, 0.087, and then plot the three curves
H1 = H2 = H3 = 0 on the A-C plane, as shown in Figures 5.1 and 5.2, where the red curve, blue
curve and green curve correspond to H1 = 0, H2 = 0 and H3 = 0, respectively. We should point
out that in [27, 28] the parameter B (B > D) is treated as a bifurcation parameter to explore
the blips phenomenon. In this paper, we want to take the parameters A and C as bifurcation
parameters and investigate their effects on dynamical behavior, since these two parameters
involved in the β(X,Y) function play a very important role in the modelling. Figures 5.1 and 5.2
clearly indicate the regions corresponding to the classification shown in Table 5.1. If we vary
the parameters B and D, we will obtain more such figures, showing rich patterns of dynamical
behaviors. It should be noted from Figure 5.1(a) that the very narrow region bounded by the red
curve and green curve corresponds to H1 > 0, H2 > 0 and H3 > 0, and thus taking parameter
values from this region generate an unstable node E1−. Each point on the curve Tr(J) = 0 yields
a Hopf critical point, leading to bifurcation of limit cycles. At the intersection point of the blue
curve (H2 = 0) and the green curve (H3 = 0), as shown in Figures 5.1(b) and Figure 5.2(b),
Tr(J) = det(J) = 0, giving rise to a BT bifurcation, characterized by a double-zero eigenvalue.
Thus, by using Figures 5.1 and 5.2, we can easily find different values of A and C to get different
types of the equilibrium E1−. Also note from these two figures that the BT bifurcation point,
marked by a circle, is actually the intersection point of all three curves H1 = H2 = H3 = 0. A
number of sets of these parameter values and their corresponding classification of E1− are given
in Table 5.2. In this section, we present the results for the non-degenerate cases (H2 H3 , 0),
and leave the degenerate cases, leading to Hopf and generalized Hopf bifurcations, and BT
bifurcation, to be considered later in Sections 5.3 and 5.4.
Hence, when B < D and H1 ≥ 0, for positive parameter values, there may exist bistable
equilibrium solutions E0 and E1, and bifurcation of limit cycles or even homoclinic orbits from
the BT bifurcation.
In the following, we will further investigate the bistable equilibrium solutions in more de-
tails using simulation, and then try to provide some biological explanation. For complete-
ness, we also show the results for the cases H1 < 0 and H1 = 0, see Table 5.2, where
A(1) = 0.09559649, A(2) = 0.26302225. Note that the results for the two sets of values in
rows three and eight (see Table 5.2) are obtained by taking a point from the narrow region
of Figure 5.1(a) and a point from the narrow region of Figure 5.1(b), respectively. We shall
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(a) (b)H1 <0
H3 >0
H1 >0 H3 <0
H2 >0
H2 <0
❳❳③H1 =0
SD
❳❳③H3 =0
✁
✁✕
H2 =0 HF
No
E1
❳❳② UN
UF
SF
No
E1
UF
SF
•
•
◦
BT
subH
subH
Figure 5.1: (a) Plot of the three curves H1 = 0 (in red), H2 = 0 (in blue) and H3 = 0 (in green),
on the A-C plane for B = 0.054, D = 0.057, with signs of H1, H2 and H3 indicated; and (b) a
zoomed in region near the origin.
Table 5.2: Classification of E1− for given parameter values (D > B = 0.054).
A C D E1− Eigenvalues H1 Class
0.100 1.050 0.057 No E1, E0 exist −0.0570, −0.0526 < 0 SN
A(1) 0.950 0.057 (15.122, 0.1380) 0.0940, 0 = 0 DUN
0.100 0.950 0.057 (13.901, 0.2076) 0.0999, 0.0327 > 0 UN
0.364 0.823 0.057 (4.3959, 0.7494) 0.0858±0.3747i > 0 UF
0.464 0.523 0.057 (2.9509, 0.8318) −0.0072±0.5132i > 0 SF
0.260 0.823 0.087 No E1, E0 exist −0.0870, −0.3793 < 0 SN
A(2) 0.823 0.087 (8.1300, 0.2927) 0.2908, 0 = 0 DUN
0.264 0.823 0.087 (7.8326, 0.3186) 0.2719, 0.0165 > 0 UN
0.364 0.823 0.087 (4.9202, 0.5719) 0.1150 ± 0.2556i > 0 UF
0.364 0.250 0.087 (3.0732, 0.7326) −0.0566 ± 0.4655i > 0 SF
5.200 0.223 0.087 (0.2331, 0.9797) −1.8817,−2.2251 > 0 SN
present the simulations for the sets of values in Table 5.2 in the rows 4, 5, 6, 7, 8 and 11,
and the corresponding points in the (A,C) parameter space are marked by the black points in
Figures 5.1 and 5.2. Also, in Figures 5.1(b) and 5.2(b), the saddle-node (SD) bifurcation, de-
termined by H1 = 0, and the Hopf (HF) bifurcation, determined by H2 = 0, are indicated, and
the BT bifurcation is marked by a circle.
5.2.3.1 A = 0.364, C = 0.823, D = 0.057, B = 0.054
For this set of parameter values, system (5.1) has three equilibrium solutions: E0 = (X0,Y0) =
(17.5439, 0), E1+ = (X1+,Y1+) = (17.4056, 0.0079) and E1− = (X1−,Y1−) = (4.3959, 0.7494).
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Figure 5.2: (a) Plot of the three curves H1 = 0 (in red), H2 = 0 (in blue) and H3 = 0 (in green),
on the A-C plane for B = 0.054, D = 0.087, with signs of H1, H2 and H3 indicated; and (b) a
zoomed in region near the origin.
It can be shown that E0 is a stable node, E1+ is a saddle point, while E1− is an unstable focus.
The phase portrait is shown in Figure 5.3, indicating that there do not exist limit cycles, and
the disease-free equilibrium E0 is actually globally asymptotically stable.
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Figure 5.3: Simulated phase portrait of system (5.1) for A = 0.364, C = 0.823, D = 0.057, B =
0.054, showing the global stability of E0: (a) depicting three equilibrium points E0, E1+, E1−;
and (b) showing E0, E1+ in a zoomed in region.
5.2.3.2 A = 0.464, C = 0.523, D = 0.057, B = 0.054
For this set of parameter values, system (5.1) still has three equilibrium solutions: E0 =
(X0,Y0) = (17.5439, 0), remains unchanged from the previous case since D is not changed,
and is a stable node; E1+ = (X1+,Y1+) = (17.4800, 0.0036) is still a saddle point, but now
E1− = (X1−,Y1−) = (2.9509, 0.8318) becomes a stable focus. The phase portrait for this case
is depicted in Figure 5.4, which shows an unstable limit cycle enclosing the stable focus E1−.
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Figure 5.4: Simulated phase portrait of system (5.1) for A = 0.464, C = 0.523, D = 0.057, B =
0.054, showing the bistable equilibria E0 and E1− and an unstable limit cycle: (a) depicting
three equilibrium points E0, E1+, E1−; and (b) showing E0, E1+ in a zoomed in region.
Thus, for this set of parameter values, there exist bistable equilibrium solutions E0 and E1−.
The attracting region for E1− is the region inside the limit cycle, while the area outside the limit
cycle is the attracting region for E0.
To view the bistable equilibrium solutions, we plot the bifurcation diagram in the A-X plane
for fixed values: C = 0.523, D = 0.057, B = 0.054, as shown in Figure 5.5, where the solid red
line and blue curve denote the stable equilibria E0 and E1−, respectively, while the dashed blue
line represents the unstable equilibrium E1+. A saddle-node bifurcation point is seen between
E1− and E1+, which is actually the underlying cause for the existence of bistable equilibrium
solutions. In fact, the saddle-node bifurcation point is the turning point on the solution curve
E1.
E0
E1−
E1+
E0
E1−
◦ SD
(a) (b)
Figure 5.5: (a) Bifurcation diagram for the bistable equilibrium solutions for B = 0.054, C =
0.823, D = 0.057; and (b) a zoomed in region near the equilibrium E0.
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5.2.3.3 A = 0.264, C = 0.823, D = 0.087, B = 0.054
For this set of parameter values, system (5.1) has three equilibrium solutions: E0 = (X0,Y0) =
(11.4943, 0), a stable node; E1+ = (X1+,Y1+) = (8.4127, 0.2681), a saddle point; and E1− =
(X1−,Y1−) = (7.8326, 0.3186), an unstable node. The phase portrait for this case is given in
Figure 5.6, showing that there do not exist limit cycles, and the disease-free equilibrium E0 is
actually globally asymptotically stable.
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Figure 5.6: Simulated phase portrait of system (5.1) for A = 0.264, C = 0.823, D = 0.087, B =
0.054, showing the global stability of E0: (a) depicting three equilibrium points E0, E1+, E1−;
and (b) showing E0, E1+ in a zoomed in region.
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Figure 5.7: Simulated phase portrait of system (5.1) for A = 5.2, C = 0.223, D = 0.097, B =
0.064, showing the bistable equilibria E0 and E1−: (a) depicting three equilibrium points
E0, E1+, E1−; and (b) showing E0, E1+ in a zoomed in region.
5.2.3.4 A = 5.200, C = 0.223, D = 0.087, B = 0.054
For this set of parameter values, system (5.1) still has three equilibrium solutions: E0 =
(X0,Y0) = (11.4943, 0), a stable node; E1+ = (X1+,Y1+) = (11.4778, 0.0014), a saddle point;
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and E1− = (X1−,Y1−) = (0.2331, 0.9797), a stable node. The phase portrait for this case is
depicted in Figure 5.7, which shows no limit cycles to exist, but there still exist bistable equi-
librium solutions E0 and E1−. The attracting regions for E0 and E1− are separated by the two
trajectories passing through the saddle point E1+. A similar bifurcation diagram like that given
in Figure 5.5 can be obtained.
5.2.3.5 A = 0.26302225, C = 0.823, D = 0.087, B = 0.054 (H1 = 0)
For this set of parameter values, H1 = 0 under which E1+ = E1− = E1 = (8.1300, 0.2927),
which is an unstable node, and thus the disease-free equilibrium E0 = (11.4943, 0) is globally
asymptotically stable, as shown in Figure 5.8.
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Figure 5.8: Simulated phase portrait of system (5.1) for A = 0.26302225, C = 0.823, D =
0.087, B = 0.054, showing the global stability of E0: (a) depicting two equilibrium points
E0, E1; and (b) showing E0, E1 in a zoomed in region.
5.2.3.6 A = 0.260, C = 0.823, D = 0.087, B = 0.054 (H1 < 0)
For this set of parameter values, H1 = −0.002136 < 0 under which E1 does not exist, and so
the disease-free equilibrium E0 = (11.4943, 0) is globally asymptotically stable. The simulated
phase portrait is similar to Figure 5.8(a) but without the existence of E1.
The most interesting phenomenon found in this section for B < D is the bistable equilibrium
solutions E0 and E1. E0 is always a stable node, while E1− may be a stable focus (see Figure 5.4)
or a stable node (see Figure 5.7). The separator between the two attracting regions of the two
stable equilibria is either an unstable limit cycle (see Figure 5.4) or the saddle trajectories.
Dynamically, this bistable phenomenon is due to the existence of a saddle-node bifurcation on
the equilibrium solution E1, which has two branches, one of them is stable and the other is
unstable. Biologically, this phenomenon is not fully understood. System (5.1) was developed
from an in-host model of HIV infection, and there has been evidence of possible bistability in
this disease. In particular, the equilibrium viral load, or “viral set point” can differ by orders
of magnitude among patients. Several authors have previously suggested bistable equilibrium
solutions as an explanation for the phenomenon [2, 18].
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It is also noted from Figures 5.3, 5.6 and 5.8 that when E1− is unstable (either focus or node),
the equilibrium E0 seems globally asymptotically stable. This may be explained as follows:
first, it can be seen from Figure 5.1 that when the parameters A and C are varied to cross
the blue curve, defined by H2 = 0, from the botton-right to the top-left (e.g., in the negative
direction of the A-axis), the equilibrium E1− changes from a stable focus (SF) to an unstable
focus (UF). Hopf bifurcation occurs when the parameters are varied to cross the blue curve.
The simulations shown in Figures 5.4 and 5.3 correspond to the two points chosen from the SF
region and UF region, respectively, implying that the Hopf bifurcation is subcritical. This is
why an unstable limit cycle is shown in Figure 5.4, while there is no limit cycle in Figure 5.3
and so all trajectories converge to the stable node E0. Similarly, the simulations shown in
Figures 5.6 and 5.8 imply that when the parameters A and C are varied to cross the blue curve
(H2 = 0 in Figure 5.2) from the bottom-right to the top-left, a subcritical Hopf bifurcation
occurs. The proof for the two subcritical Hopf bifurcations will be given in Section 5.3.
5.2.4 Dynamical behavior of (5.1) when B > D
Now, we discuss the dynamical behavior of system (5.1) for B > D. In this case, E0 becomes a
saddle point, while E1 always exists, since equation (5.5) always has two roots for
∆ = (A + B + D + BC)2 − 4(C + 1)D(A + B)
= (A + B − D − BC)2 + 4C(A + B)(B − D)
> (A + B − D − BC)2 (due to B > D)
≥ 0,
and thus 0 < X− < X+. Further, noticing from (5.5) that Q(0) = C + 1 > 0 and Q( 1D) =
−C( BD − 1) < 0 (B > D), we have
0 < X− <
1
D
< X+.
Thus,
X1 = X− =
(A + B + D + BC) − √∆
2D(A + B) , since X1 ∈
[
0, 1
D
]
,
which guarantees that 0 ≤ Y1 = 1 − DX1 ≤ 1.
Since E0 is a saddle point (unstable), and X1+ > 1D (which yields Y1+ < 0) is not biologically
meaningful, bistable equilibria cannot exist bistable equilibria for this case B > D. To find the
stability of E1 (i.e., E1−) when B > D, we first show that det(J) > 0. This can be obtained using
(5.12) as follows:
det(J) = 1X1 − D + CDY1+C (BX1 − 1)
> 1X1 − D +
CD
Y1+C (DX1 − 1) (B > D)
=
(
1
X1
− D
)(
1 − CDX1Y1+C
)
(0 < DX1 < 1, 0 < Y1 < 1)
>
(
1
X1
− D
)(
1 − DX1
)
= 1X1 (1 − DX1)2 > 0.
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Therefore, all the formulae derived in the previous section for E1− (when B < D) and the
results shown in Table 5.1 can be applied here to classify the type of the equilibrium E1− (when
B > D). Similarly, we may fix B and D and then plot the two curves H2 = H3 = 0 on the
A-C plane to identify the possible parameter values which yield different qualitative behavior
of system (5.1). Note that now for B > D we do not need the condition H1 > 0 since ∆ > 0
is guaranteed when B > D. Two sets of values for (B, D) = (0.057, 0.060), (0.087, 0.090) are
chosen to plot the figures. However, it is found that these two figures are quite similar, implying
that, unlike the case B < D, here slightly varying B and D does not change the behavior of the
system. Hence, we only present the result for (B, D) = (0.057, 0.060), as shown in Figure 5.9.
It can be seen that for this case, there is no saddle-node bifurcation, nor BT bifurcation, since
H1 > 0 for all parameter values.
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Figure 5.9: (a) Plot of two curves H2 = 0 (in blue) and H3 = 0 (in green), on the A-C plane for
B = 0.060, D = 0.057, with signs of H2 and H3 indicated; and (b) a zoomed in region near the
origin.
It is also seen from Figure 5.9 that for most of the parameter values, H3 < 0, in particular for
not very large values of A. This means that for most of parameter values, E1 is a focus. Further,
it can be shown that for the points bounded by the blue curve (H2 = 0, i.e. Tr(J) = 0) the
equilibrium E1 is an unstable focus. Therefore, for these parameter values, by Theorem 5.2.2,
we can conclude that there exists at least one stable limit cycle inside the trapping region G.
When the parameter values are taken from the region outside the region bounded by the blue
curve, the equilibrium E1 is the unique equilibrium inside the trapping region G, and thus the
equilibrium E1 is globally asymptotically stable.
Now, we are ready to prove the following theorem.
Theorem 5.2.4 When B > D and H2 > 0, system (5.1) has at least one stable limit cycle, and
the limit cycle must not bifurcate from a homoclinic orbit.
Proof First, we show that the positive equilibrium E1 = E1− = (X1,Y1) is inside the trapping
region G, defined in Theorem 5.2.2. That is, the point E1 should be below the line L: X + Y =
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max(1, 1D ) + ε. Note that Y1 = 1 − DX1 for 0 < X1 < 1D , implying that the point (X1,Y1) is on
the line, defined by DX + Y = 1, which is obviously below the line L.
To prove that limit cycles do not bifurcate from a homoclinic orbit, first note that the only
possible homoclinic orbit comes from the saddle point E0 when B > D. Thus, it suffices to
show that there do not exist homoclinic orbits passing through this singular point. Otherwise,
suppose there exists a homoclinic orbit passing through this point, then the homoclinic orbit
must leave this point along the direction of the eigenvector v2 = (1, DB (1−D)− 1) and return to
this point along the direction of the eigenvector v1 = (1, 0), that is, the direction of the X-axis.
In other words, the homoclinic orbit must return to the saddle point along the X-axis. But we
have already shown that the X-axis itself is a solution trajectory, and thus other trajectories, in
particular, the one leaving the saddle point along the v2 direction, cannot connect to the X-axis
due to the uniqueness of solutions.
The proof of Theorem 5.2.4 is complete.
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Figure 5.10: Simulated blips of system (5.1) for A = 0.364, C = 0.823, D = 0.057, B = 0.060:
(a) time history showing blips; and (b) phase portrait showing a limit cycle.
To end this section, we present three simulations for the common parameter values: D =
0.057, B = 0.060; but for (A,C) = (0.364, 0.823), (0.364, 0.350) and (5.2, 0.2), respectively.
The first simulation is shown in Figure 5.10, which yields a blip-like oscillation, as has been
discussed in [27, 28]. The simulations for the second and third cases are depicted in Fig-
ures 5.11(a) and (b), respectively. Figure 5.11(a) shows that E1 is asymptotically stable and
all trajectories starting from the initial points inside an unstable limit cycle converge to this
equilibrium E1; while trajectories outside the unstable limit cycle converge to a separator of
the saddle point E0. Figure 5.11(b) indicates that E1 is globally asymptotically stable without
the existence of limit cycles.
The results shown in Figures 5.10 and 5.11 clearly indicate that the Hopf bifurcation which
occurs on the left branch of the blue curve in Figure 5.9 is supercritical (when, say, A is increas-
ing to cross the blue curve), generating the stable limit cycle (blips) shown in Figure 5.10, and
the bifurcation which occurs on the right branch of the blue curve (see Figure 5.9) is subcritical
(when, say, A is decreasing to cross the blue curve), leading to the unstable limit cycle shown
in figure 5.11(a). The proof for the supercritical and subcritical Hopf bifurcations will be given
in Section 5.3.
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Figure 5.11: Simulated phase portrait of system (5.1) when (B, D) = (0.060, 0.057): (a) for
(A,C) = (0.364, 0.352) showing the trajectories inside an unstable limit cycle convergent to
the stable equilibrium E1; and (b) for (A,C) = (5.2, 0.2) showing the global stability of E1
without existence of limit cycles.
5.2.5 Dynamical behavior of (5.1) when B = D
We now turn to the case B = D. First note that when B = D, the equilibrium E1+ = (X+,Y+)
coincides with the disease-free equilibrium E0, while the other equilibrium E1− = (X−,Y−) =
( 1+CA+D , A−DCA+D ). In order to have X− < 1D , we require A + D > D + DC, or A > DC. Note that
when A < DC, the equilibrium E1− does not exist; and when A = DC, the equilibrium E1− also
coincides with E0. So for the generic case, we assume A > DC in this subsection.
To find the stability of E0 for this case, we note that the two eigenvalues associated with
this equilibrium now become −D and 0, which is a critical case and the application of center
manifold theory is required to determine its stability. To achieve this, we introduce an affine
transformation, given by
(
X
Y
)
=
( 1
D
0
)
+
[
1 1
0 −D
] (
u1
u2
)
, (5.18)
into (5.1) to obtain a system, expanded around (u1, u2) = (0, 0), as
du1
dτ = −Du1 + D(D − 1)u1u2 +
1
C (A − DC)(1 − D)u22
+ADC (1 − D)u1u22 + · · · ,du2
dτ = Du1u2 −
1
C (A − DC) u22 − ADC u1u22 + · · · ,
(5.19)
whose linear part is now in the Jordan canonical form with eigenvalues −D and 0. To find the
center manifold, let u1 = h(u2) = a2u22 + O(u32) and then use (5.19) to find a2 = (1−D)(A−DC)DC .
Therefore, the center manifold up to second order is given by
WC =
{(
u1, u2
) ∣∣∣∣ u1 = (1 − D)(A − DC)DC u22 + O(u32)
}
,
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and the differential equation describing the dynamics on the center manifold is
du2
dτ = −
1
C
(A − DC) u22 +
(1 − D)(A − DC)
C
u32 + O(u42). (5.20)
Since Y = −Du2 > 0, we only consider u2 < 0. Note that the leading term in (5.20) is
− 1C (A − DC) u22 with a negative coefficient, implying that u2 is decreasing from a negative
initial value (and so Y is increasing from a positive initial value). Hence, the equilibrium E0 is
a degenerate saddle point, similar to the case when B > D.
Next, we consider the stability of E1−. Evaluating the Jacobian (5.10) at this equilibrium
yields
J(E1−) =
 −
A+D
1+C − A+2AC−DC
2
A(1+C)
A−DC
1+C
C(A−DC)
A(1+C)
 ,
which in turn results in two eigenvalues, given by
ξ± =
−[C(A−DC)−A(A+D)]±
√
[C(A−DC)−A(A+D)]2−4A(1+C)(A−DC)2
2A(1+C) . (5.21)
Hence, under the condition A > DC, the equilibrium E1− is asymptotically stable (unstable) if
C(A − DC) − A(A + D) < 0 (> 0), which is a node (focus) when [C(A − DC) − A(A + D)]2 −
4A(1 +C)(A − DC)2 > 0 (< 0). In order to find parameter values for these four categories, let
H∗1
△
= HB=D1 = A − DC,
H∗2
△
= HB=D2 = C(A − DC) − A(A + D),
H∗3
△
= HB=D3 = [C(A − DC) − A(A + D)]2 − 4A(1 +C)(A − DC)2.
Then choosing B = 0.057, we plot the three curves H∗1 = H∗2 = H∗3 = 0 on the A-C plane, as
shown in Figure 5.12, from which it is easy to find the parameter values which correspond to
different classifications of the equilibrium E1−. Since the equilibrium E0 is a degenerate saddle
node and only one solution exists for E1, this case B = D is similar to the case B > D. Thus,
in general, if E1 is unstable (either a focus or a node), then there must exist stable limit cycles;
if E1 is stable, then it is globally asymptotically stable. When the parameter values of A and C
are chosen from the blue curve (see Figure 5.12) defined by H∗2 = 0, Hopf bifurcation occurs,
leading to limit cycles. This will be further discussed in the next section.
5.3 Hopf and generalized Hopf bifurcations
In this section, we consider bifurcation of limit cycles due to Hopf and generalized Hopf bi-
furcations. There are three types of Hopf bifurcations, which occur from the critical blue line
H2 = 0 for B < D (see Figures 5.1 and 5.2) and B > D (see Figures 5.9), and from the critical
blue line H∗2 = 0 for B = D (see Figure 5.12). First we give a detailed analysis for the case
B = D, and then summarize the results for other cases with representative simulations.
118 Chapter 5. Dynamical analysis of a 2-d disease model with convex incidence
(a) (b)❳③H∗2>0
H
∗
3
>0
SN
H
∗
1
<0
H
∗
2
<0
H
∗
3
>0
UN
H
∗
2
<0
H
∗
3
<0
UF
H
∗
2
>0 H
∗
3
<0 SF
H
∗
1
<0
SN
SF UF
∗
∗
supH
subH supH
supH
subH
•
•
•
∗
Figure 5.12: (a) Plot of the three curves H∗1 = 0 (in red), H∗2 = 0 (in blue) and H∗3 = 0 (in green),
on the A-C plane for B = D = 0.057, with the regions indicated for the classifications SF, UF,
SN and UN; and (b) a zoomed in region near the turning point.
5.3.1 Hopf bifurcation
We first consider Hopf bifurcation, starting from the case: B = D = 0.057, for which the Hopf
critical points are located on the blue curve defined by H∗2 = 0 (see Figure 5.12) is determined
from the equation A(A + D) −C(A − DC) = 0, from which we solve for C to obtain
C± =
500 ± √A(19300A − 3249)
57 A ,
(
A >
3249
193000
)
, (5.22)
where we use B = D = 571000 to facilitate symbolic computation. Note that the leftmost point
on the blue curve is given by (A,C) = ( 3249193000 , 57386). The solutions C− and C+ correspond to
the points (see Figure 5.12(b)) on the upper and lower branches of the H∗2 = 0 curve, respec-
tively. In order to apply normal form theory to calculate the first-order focus value (or the first
Lyapunov constant), we introduce an affine transformation, given by
(
X
Y
)
=

1000(1+C)
1000A+57
1000A−57C
1000A+57
+
[
1 0
−A(1000A+57)
1000+2000AC−57C2
−1000A(1+C)ωc
1000+2000AC−57C2
](
u1
u2
)
,
where ωc = 1000A−57C1000√A(1+C) > 0 (since 1000A−57C > 0 due to Y > 0), into (5.1) to yield a system to
be expanded around (u1, u2) = (0, 0) up to third-order terms, and then apply the Maple program
for computing the normal forms associated with Hopf and generalized Hop bifurcations [26] to
this system to obtain the normal form in polar coordinates up to third-order terms as follows:
dr
dτ = r
[
v0 µ + v1 r
2 + o(r4)], dθdτ = ωc + t0 µ + t1 r2 + o(r4), (5.23)
where µ is a perturbation parameter to measure the distance from a critical point on the blue
curve H∗2 = 0 along the positive direction of the A-axis. v0 and v1 are the zero-order and the
first-order focus values. The first equation of (5.23) can be used to perform bifurcation analysis
and the sign of v1 determines whether the Hopf bifurcation is supercritical or subcritical. The
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values v0 and t0 can be found from a linear analysis, while v1 and t1 are obtained by applying
the Maple program. The calculation shows that
v0 =
57C2−1000A2
2000A2(1+C) , t0 =
1000A+57C
4000A
√
A(1+C) , (5.24)
and the output of the Maple program gives v1− and v1+, corresponding to C− and C+, respec-
tively, as
v1±=
− 3249(1000A+57)3
8000000000A(500A+Am)(500A+57−Am)3(557000A+60249−1000Am)3
×[(386499928503500000000000A5 + 86140825778098500000000A4
+7051942944965614500000A3 + 223356947766097675500A2
−3214238968494000000A+38317671392498001)
±(879676636999000000000A4 + 203371596920829000000A3
+17848597867145253000A2 + 759905488695261807A
+24859340130996000) Am].
where Am =
√
A(193000A − 3249). It can be shown that v1+ < 0 for A > 3249193000 ≈ 0.0168. For
v1−, it has two real roots: A = 0.0184 and A = 0.9210 such that v1− > 0 ∀A ∈ (0.0184, 0.9210)
and v1− < 0 ∀A ∈ (0.0168, 0.0184)⋃(0.9210,∞). Moreover, it can be shown that v0 > 0
when C = C+ for any values of A > 0.0168, and there is a critical point on C−, defined
by A = 0.0260, such that when C = C−, v0 > 0 for A ∈ (0.0168, 0.0260) but v0 < 0 for
A > 0.0260. Therefore, we can combine the information on the signs of v0 and v1 to precisely
determine whether a Hopf bifurcation is supercritical or subcritical. In fact, on the upper branch
C+ of the blue curve H∗2 = 0, all Hopf bifurcations are supercritical, while on the lower branch
C−, the Hopf bifurcation is supercritical for A ∈ (0.0168, 0.0184)∪ (0.9210,∞), and subcritical
for A ∈ (0.0184, 0.9210), as shown in Figure 5.12, where the two points on the blue curves, at
A = 0.0184 and A = 0.9210 are marked by ∗, where ‘supH’ and ‘subH’ represent supercritical
and subcritical Hopf bifurcations, respectively.
It should be pointed out that since E0 is a degenerate saddle point, for any point inside
the region bounded by the blue curve, there must exist stable limit cycles due to Poincare´-
Bendixson theory no matter whether E1 is an unstable focus or node. This seems to imply a
contradiction for the subcritical Hopf bifurcation from the lower branch of the blue curve for
A ∈ (0.0184, 0.9210), giving rise to unstable limit cycles below the curve. But on the other side,
there exist stable limit cycles. This is because the unstable limit cycle is from a local (Hopf)
bifurcation, while the stable limit cycle comes from a global bifurcation. Several representative
parameter sets (A,C) are chosen for this case when B = D = 0.057 as follows:
(A,C) = (0.1, 1.55), (0.3, 3.5), (0.42, 0.50), (0.39, 0.50),
which are marked on Figure 5.12 by black points (the last two are at the same place), and the
corresponding simulations are shown in Figures 5.13 and 5.14. Note that all of them show the
existence of limit cycles. The first two cases confirm that the Hopf bifurcations emerging from
the upper branch of the blue curve are indeed supercritical (with the focus value v1+ < 0), and
so the bifurcating limit cycles are stable (see Figure 5.13). The last two points are very close,
with one below the curve and one above the curve. The third one yields a typical subcritical
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Hopf bifurcation and the bifurcating limit cycle is unstable (see Figure 5.14(a)). The last one
is not generated by Hopf bifurcation though the critical point is near the blue curve. It is a
big limit cycle, generated due to Poincare´-Bendixon theory, and it is stable since it encloses an
unstable focus (see Figure 5.14(b)).
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Figure 5.13: Simulations of system (5.1) when B = D = 0.057, showing stable limit cycles: (a)
(A,C) = (0.1, 1.55) with E1 being an unstable focus; and (b) (A,C) = (0.3, 3.5) with E1 being
an unstable node.
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Figure 5.14: Simulations of system (5.1) when B = D = 0.057, showing (a) an unstable limit
cycle for (A,C) = (0.42, 0.50) with E1 being a stable focus; and (b) a stable limit cycle for
(A,C) = (0.39, 0.50) with E1 being an unstable focus.
Similarly, we can consider the cases B < D and B > D and determine whether the Hopf
bifurcations are supercritical or subcritical. Without giving detailed calculations, we sum-
marize the results as follows. For the case with B = 0.054 < D = 0.057, the blue curve
actually has a turning point at A = 72949000 ≈ 0.014878 while the BT bifurcation point is above
this point at A = 0.014881, as shown in Figure 5.16(a) in the next section. On the lower
branch of the blue curve, the focus value for the Hopf bifurcation (see the blue curve in Fig-
ure 5.1) is shown to have the property that v1 > 0 for A ∈ (0.014981, 0.9455) and v1 < 0
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for A ∈ (0.014878, 0.014981) ∪ (0.9455,∞). On the upper branch of the blue curve, v1 < 0
for A ∈ (0.014878, 0.014881). Hence, when (A,C) = (0.364, 0.823), the Hopf bifurcation is
subcritical, and the bifurcating limit cycle is unstable, as the example shown in Figure 5.4. We
expect that a Hopf bifurcation is supercritical when choosing a point with A > 0.9455. For the
case with B = 0.054 < D = 0.087 (see Figure 5.2), only the upper branch of the blue curve
is the solution, which does not contain the turning point, as shown in Figure 5.16(b) (in the
next section). It is found that the focus value v1 > 0 for A ∈ (0.0393, 1.1708) and v1 < 0 for
A > 1.1708. But for this case, the BT bifurcation point is at A = 0.0529, and the portion for
A < 0.0529 yields H1 < 0. Therefore, for this case, v1 > 0 for A ∈ (0.0529, 1.1708). Several
typical simulations can be seen in Figures 5.3, 5.4, 5.6–5.8.
Finally, we consider the case B = 0.060 > D = 0.057 and confirm the conclusion that we
made at the end of Section 5.2.4. Note that for this case H1 > 0 for all positive parameter
values. Compared to the case B < D, now there are two branches on the blue curve (see
Figure 5.9). For the upper branch, it can be shown that v1+ < 0 for A > 0.0189, and the
Hopf bifurcation emerging from the upper branch of the blue curve is supercritical and so the
bifurcating limit cycles are stable (see the blips example in Figure 5.10). For the lower branch
of the blue curve, it can be shown that the focus value v1− > 0 for A ∈ (0.0214, 0.8964) and
v1− < 0 for A ∈ (0.0189, 0.0214) ∪ (0.8964,∞). Hence, the Hopf bifurcation from the lower
branch of the blue curve is subcritical for A ∈ (0.0214, 0.8964), giving rise to unstable limit
cycles (an example is shown in Figure 5.11). When A ∈ (0.0189, 0.0214) ∪ (0.8964,∞), the
Hopf bifurcation becomes supercritical and so the bifurcating limit cycles are stable. This is
similar to the case B = D (see Figure 5.12 where supercritical and subcritical Hopf bifurcations
are indicated), and thus we omit the details.
By comparing the Figures 5.1, 5.2, 5.9 and 5.12, we have observed an important difference
between the different cases: although all the blue curves are defined by a quadratic polynomial
in A and C, the case B < D shows no turning point on the blue curve, while the cases B ≥ D
do have a turning point on the blue curve. As a matter of fact, if we zoomed in the area
around the BT point in Figures 5.1 and 5.2 (see Figure 5.16 in the next section), we will see
the turning point for the case B = 0.054, D = 0.057 since the blue curve contains the turning
point, while the blue curve for the case B = 0.054, D = 0.087 does not include the turning
point. Summarizing the above results, we have the following theorem.
Theorem 5.3.1 For system (5.1), there always exists Hopf bifurcation which occurs from the
disease equilibrium E1, for suitable positive parameter values. The bifurcations may be su-
percritical or subcritical, and a limit cycle bifurcating from a supercritical (subcritical) Hopf
critical point is stable (unstable), which encloses an unstable (a stable) focus point – the equi-
librium E1.
5.3.2 Generalized Hopf bifurcation
Now we consider possible generalized Hopf bifurcations which may occur from system (5.1),
leading to bifurcation of multiple (two) limit cycles from a Hopf bifurcation point. The con-
dition for generalized Hopf bifurcation is that the first-order focus value vanishes, i.e., v1 = 0.
In other words, on the Hopf bifurcation curve (the blue curves in Figures 5.1, 5.2, 5.9 and
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5.12), such a critical point is identified when the Hopf bifurcation changes from supercritical
to subcritical, or vice versa.
Again, we first consider the case B = D = 571000 , for which there are two generalized Hopf
critical points located on the lower branch of the blue curve (see Figure 5.12): A(1)gH = 0.0184
and A(2)gH = 0.9210, where the subscript ‘gH’ denotes ‘generalized Hopf’. Note that in computa-
tion we take the accuracy up to 30 decimal points A(1)gH = 0.0184128746264075106899349611404,
A(2)gH = 0.921012043225272084984762668632, but only present the results up to 4 decimal
points for brevity. The corresponding critical values of C are given by C−(A) in Eq. (5.22) as
C(1)gH = C−(A(1)gH) = 0.1199 and C(2)gH = C−(A(2)gH) = 1.0456. Then the first equation of the normal
form (5.23) associated with the critical point (A(1)gH,C(1)gH) is given by
dr
dτ = r
[
v0 µ + v1 r
2 + v2 r
4 + o(r6)], (5.25)
where v1 = 0 and v2 = − 0.1076 × 10−3, called the second-order focus value, is obtained by
using the Maple program [26]. Note that we now take the unfolding term from perturbing the
parameter C as C = C−(A) + µ. Thus, we can perturb A from A(1)gH to get v1 > 0 such that
v1 ≪ |v2|, and then find v0µ < 0 satisfying |v0µ| ≪ v1. This gives two limit cycles bifurcating
from the critical point (A(1)gH,C(1)gH). For this case, by perturbing C we have
v0 =
A(1057+1000A)−57C(2+C)
2000A(1+C)2 .
To obtain v1 > 0, we perturb A = A(1)gH to A∗ = A
(1)
gH + 0.00005 = 0.01846287, for which C∗ =
C−(A∗) = 0.11969100 and so v0 = 0.11653286. Now for the Hopf bifurcation associated with
the critical values (A∗,C∗), we obtain v1 ≈ 0.13257095 × 10−4 and v2 ≈ −0.10838198 × 10−3.
Further, we choose µ = −10−6 < 0, i.e. C is decreased to pass through the critical point (A∗,C∗),
yielding v0µ ≈ −0.11653286 × 10−6. Finally, we obtain the normal form for this generalized
Hopf bifurcation, up to 5th-order terms, in the form of
dr
dτ = r
[0.11653286×(−10−6) + 0.13257096 × 10−4r2 − 0.10838198 × 10−3r4],
giving two real positive roots, r1 ≈ 0.09763824 and r2 ≈ 0.33583483, which approximate the
amplitudes of the two limit cycles. Since v2 < 0, the larger limit cycle is stable while the
smaller limit cycle is unstable, and the equilibrium solution at this critical point is a stable
focus.
In order to show the existence of the two limit cycles predicted above, first note that at the
parameter values B = D = 0.057, A = A∗, C = C∗ − 10−6, the Jacobin matrix evaluated at the
fixed point E−= (14.8376281, 0.1542552) has eigenvalues − 0.11918442×10−6±0.08096077 i,
confirming that this fixed point is a stable focus. But the convergence speed of nearby trajec-
tories to this stable focus is very very slow. Next, we only need to show that there exists a
stable limit cycle around this point since v2 < 0, and expect that the convergence speed is also
very slow. Therefore, there exists one unstable limit cycle between the stable focus and the
stable limit cycle, as shown in Figure 5.15. It can be seen from this figure that the analytical
predictions, r1 ≈ 0.10 and r2 ≈ 0.34, give very good approximations for the amplitudes of the
two simulated limit cycles, see Figure 5.15(b).
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Figure 5.15: Simulation of two limit cycles for system (5.1) when B = D = 0.057, A =
0.01846287, C = 0.11969000: (a) three trajectories with moving directions indicated; and (b)
two limit cycles with the inner unstable and outer stable.
Following the above procedure, we can also obtained two limit cycles bifurcating from the
other critical point A(2)gH. We give the normal form for this case below without giving details for
brevity. Taking A = A∗ = A(2)gH − 10−9, C = C∗ = C−(A∗) yields
dr
dτ = r
[0.21278281×(−10−9) + 0.93716102 × 10−7r2 − 0.87730535 × 10−5r4],
which has two real positive roots, r1 ≈ 0.05721775 and r2 ≈ 0.08607204, approximating the
amplitudes of the two limit cycles bifurcating from this critical point (A = A∗,C = C∗). Again,
since v2 < 0, the larger limit cycle is stable and the smaller limit cycle is unstable, and the
equilibrium point is a stable focus. For simulation, we should take A = A∗ = 0.9210120422,
C = C∗ − 10−9 = 1.0456736673, which yields the eigenvalues at the equilibrium point E− =
(2.09166511, 0.88077509) as −0.22645814 × 10−5 ± 0.62756454i, and a similar figure to Fig-
ure 5.15.
Similarly, we can obtain the five normal forms corresponding to the two critical points for
the case of B = 0.054 < D = 0.057, one critical point for the case of B = 0.054 < D = 0.087,
and two critical points for the case of B = 0.060 > B = 0.057. We first define the five cases
followed by the corresponding five normal forms.
(a) B = 0.054 < D = 0.057 with A = A(1)gH = 0.0149805591
(b) B = 0.054 < D = 0.057 with A = A(2)gH = 0.9454739030
(c) B = 0.054 < D = 0.087 with A = AgH = 1.1708464105
(d) B = 0.060 > D = 0.057 with A = A(1)gH = 0.0213860900
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(e) B = 0.060 > D = 0.057 with A = A(2)gH = 0.8963921091
(a) drdτ = r
[0.20278804×(−10−6)+0.89169329×10−4−0.14900851×10−2]
= 0 =⇒ r1 = 0.04866092 (US), r2 = 0.23973712 (S);
(b) drdτ = r
[0.21515679×(−10−10)+0.94588780×10−8−0.22142107×10−6]
= 0 =⇒ r1 = 0.04909881 (US), r2 = 0.20076919 (S);
(c) drdτ = r
[0.21521113×10−9−0.93765555×10−6+0.12177368×10−3]
= 0 =⇒ r1 = 0.01538841 (S), r2 = 0.08638971 (US);
(d) drdτ = r
[ − 0.04825749×10−9+0.15893286×10−6−0.58166912×10−4]
= 0 =⇒ r1 = 0.01865320 (US), r2 = 0.04883049 (S);
(e) drdτ = r
[ − 0.00236277×10−88! +0.92766615×10−7−0.16897622×10−4]
= 0 =⇒ r1 = 0.01636337 (US), r2 = 0.07226452 (S),
where US and S denote unstable limit cycle and stable limit cycle, respectively.
Summarizing the above results we have the following result.
Theorem 5.3.2 For system (5.1), there always exists generalized Hopf bifurcation leading to
two limit cycles bifurcating from the disease equilibrium E1, for suitable positive parameter
values. One of the two limit cycles is stable while the other is unstable.
This theorem indicates that regardless whether B < D or B = D or B > D, the system
can always exhibit complex dynamics including different types of bistability or even tristablity.
More precisely, for Cases (a) and (b) (for which B < D), the disease-free equilibrium E0 is a
stable node, the disease equilibrium E1− is a stable focus (another disease equilibrium E1+ is
a saddle point), and there exist a stable limit cycle, as well as an unstable limit cycle between
the stable limit cycle and the stable focus. This indeed shows tristability involving two stable
equilibrium solutions and one stable periodic solution. Therefore, the first quadrant of the X-Y
plane can be divided into three trapping regions, each corresponding to one of the three stable
solutions. Case (c) (again B < D) shows a bistable situation, since for this case the disease
equilibrium E1− is an unstable focus, and there exist two limit cycles enclosing this unstable
focus, with the inner one stable. The disease-free equilibrium E0 is still a stable node. For
Cases (d) and (e) (for which B > D) and the two cases when B = D, we can see that the
disease-free equilibrium E0 now becomes a saddle point (a degenerate saddle point for B = D)
and there is only one disease equilibrium E1 which is a stable focus. There are two limit cycles
enclosing the stable focus and the outer one is stable. So this again shows a bistability but it
involves one stable equilibrium solution and one stable periodic solution, different from the
Hopf bifurcation case.
The above discussion implies that the real situation could be very complex, showing the
co-existence of a stable disease-free equilibrium, stable disease equilibria, and even stable
oscillating motion, all of which are possible depending upon the initial conditions. Moreover,
note that the above seven cases (five cases plus two cases for B = D) are obtained for fixed
parameter values of B and D. Hence, such phenomena are not uncommon, but quite rich if the
parameters B and D are also allowed to be varied.
5.4. Bogdanov-Takens bifurcation 125
5.4 Bogdanov-Takens bifurcation
Finally, we consider possible Bogdanov-Takens (BT) bifurcations in system (5.1), character-
ized by a critical point with a double-zero eigenvalue. First, we have noticed that it is not
possible to have a double-zero singularity at E0 = ( 1D , 0) since it has eigenvalues ξ1 = −D and
ξ2 =
B
D − 1, implying that it can have at most one zero eigenvalue when B = D. Secondly, for
the case B > D, on the equilibrium solution E1−, det(J) > 0 which cannot have a double-zero
eigenvalue. Thirdly, for the case B = D, again the equilibrium solution E1− cannot have a
double-zero critical point since when Tr(J) = 0, det(J) = A3(1+C)(A+D)2C2 > 0. Thus, the only pos-
sibility comes from the case B < D on the equilibrium E1−, which is observed from Figures 5.1
and 5.2. In fact, it can be seen from (5.12) that det(J) = 0 requires ∆ = 0, together with (5.15)
to solve A and C to obtain the solutions for B = 27500 , D =
57
1000 as
BT1 = (B1, D1, A1,C1) = ( 27500 , 571000 , 3078507206879500 , 61731827518) (5.26)
which is marked as a circle on Figure 5.1, and for B = 27500 , D =
87
1000 as
BT2 = (B2, D2, A2,C2) = ( 27500 , 871000 , 1184282672237439500 , 2195018949758). (5.27)
which is marked by a circle on Figure 5.2. For a clear view, the zoomed areas around the two
BT bifurcation points in Figures 5.1 and 5.2 are shown in Figures 5.16(a) and (b), respectively.
As has been discussed in Section 5.3 that near the BT bifurcation points, the Hopf bifurcation is
supercritical when B = 0.054, D = 0.057; while it is subcritical when B = 0.054, D = 0.087,
which result in stable and unstable limit cycles, respectively. Thus, we will present the results
for both cases.
◦ BT1
◦BT2
(a) (b)
SF
UF
UF
SF
H1 <0 H1 <0
supH
subH
Figure 5.16: The BT bifurcation diagram around the critical points: (a) (B, D, A,C) =( 27
500 ,
57
1000 ,
3078507
206879500 ,
61731
827518
)
, and (b) (B, D, A,C) = ( 27500 , 871000 , 1184282672237439500 , 2195018949758).
5.4.1 Case B = 0.054, D = 0.057
We first consider the case B = 0.054, D = 0.057. We will derive the normal form associated
with the BT1 bifurcation, and then use the normal form to carry out bifurcation analysis. To
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achieve this, we introduce the following transformations:
(
X
Y
)
=
( 943
57
57
1000
)
+
[ − 1000943 0
57
943 1
] (
u1
u2
)
,
(
A
C
)
=
( 3078507
206879500
61731
827518
)
+
(
µ1
µ2
)
, (5.28)
into (5.1) and expanding the resulting system around the point (u1, u2, µ1, µ2) = (0, 0, 0, 0) up
to second order terms yields the system:
du1
dτ = u2 + f (u1, u2, µ1, µ2),
du2
dτ = f (u1, u2, µ1, µ2)
≡ 3901747371013000000µ1 − 4137599500000µ2 − 17119651008158491633000 µ1µ2 + 171196510081517272748500µ22
+
(315698117
513084500µ1 − 22326849399450404618500µ2
)
u1 +
(619297507081
58491633000 µ1 − 827518955259µ2
)
u2
− 1624500900809237u21 + 3990000900809237u1u2 + 541500955259u22.
(5.29)
Next, we apply the near-identity nonlinear transformation (up to second order), given by
u1 = y1 + 268589692119000000 ¯β1 +
(2774136507391115169073729
22529079489117000000000
¯β1 − 5624557927591883413759000000000 ¯β2
)
y1
+ 257312250900809237y
2
1 +
19238822633
2865777000 y1y2 +
6868613670961379723
72599684000000000 y
2
2
u2 = y2 − ¯β1 − 7391462606097622324372514827202000000000 ¯β21 + 6014732664591883413759000000000 ¯β1 ¯β2
+
(17614322633
2865777000
¯β1− 571000 ¯β2
)
y1+
(739146260609762232437
2514827202000000000
¯β1− 6014732664591883413759000000000 ¯β2
)
y2
+ 1624500900809237 y
2
1 +
541500
955259 y1y2 +
17614322633
2865777000 y
2
2,
(5.30)
and the parametrization,
µ1 = − 55157609919171196510081 ¯β1 + 55157609919171196510081 µ2 = − 8836997403671342393020162 ¯β1 + 975576403671342393020162 ¯β2,
to (5.29) to obtain the normal form:
dy1
dτ = y2,dy2
dτ =
¯β1 + α¯ ¯β2 y1 + ¯β2 y2 − a1 y21 + a2 y1y2,
(5.31)
where
α¯ = 571000 , a1 =
1624500
900809237 , a2 =
741000
900809237 .
In order to further simplify system (5.31), we introduce the following scalings:
y1 = m1 x1, y2 = m2 x2, τ1 = m3 τ,
into (5.31) to obtain
dx1
dτ1
= x2,
dx2
dτ1
= β1 + α β2 x1 + β2 x2 − x21 + x1 x2.
(5.32)
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Here,
m1 =
a1
a22
= 900809237338000 , m2 =
a21
a32
= 513461265098788000 , m3 =
a1
a2
= 5726 ,
¯β1 =
a31
a42
β1 =
2926729211013
228488000 β1,
¯β2 =
a1
a2
β2 =
57
26 β2, α =
a2
a1
α¯ = 13500 .
(5.33)
Thus, the relation between the original perturbation parameters (µ1, µ2) and the new perturba-
tion parameters (β1, β2) is given by
µ1 = − 16143138815959769283794739116348195387528000 β1 + 31439837653834451109262106 β2,
µ2 = − 2586349843896995529982872378232696390775056000 β1 + 556078550092478902218524212 β2,
(5.34)
It should be noted that due to the large values of m1 and m2, very small values of (x1, x2) can
result in very large values of (y1, y2) and so (u1, u2), which are perturbations from the BT critical
point (AT ,CT ). Therefore, we should take small values of x1 and x2 when solving system (5.31).
Also note in (5.34) that the coefficients of β1 are large, so we should choose very small values
for the perturbation parameter β1. Moreover, since in general µ2 should take negative values
(see Figure 5.16(a)), we will show in the following that β1 must take positive values.
Now, we use the normal form (5.32) to analyze the BT bifurcation. First, we note that in
almost all existing articles or books, the unfolding terms (i.e. the terms with the coefficient
β1 or β2) are usually taken as in a generic form with no direct relation to the original physical
system parameters, which may cause difficulty in bifurcation analysis when solving practical
problems. Here, we involve perturbation parameters in the nonlinear transformation to obtain
the explicit unfolding terms (in terms of β1 and β2), which have a direct relation to the original
system parameters A and C, and thus facilitate a realistic dynamical study. It should be noted
that our system (5.32) is not in the standard normal form for BT bifurcations, given by (e.g.
see [13])
x˙1 = x2,
x˙2 = β1 + β2x2 + x
2
1 ± x1x2.
(5.35)
However, we will show in the following that our system (5.32) (or the original system (5.1))
does exhibit interesting dynamics that system (5.35) does, for realistic parameter values, in-
cluding Hopf bifurcation and homoclinic loops.
The two equilibrium solutions of (5.32) are given by
E± = (x1±, 0), where x1± = 12
[
αβ2 ±
√
(α2β22 + 4β1)
]
. (5.36)
Since we require α2β22 + 4β1 ≥ 0, we have β1 > 0 or β1 < − 4α2 = − 1000000169 . Thus, for |β1| ≪ 1,
we only consider β1 ≥ 0. In fact, with (5.5) and (5.34), we obtain
H1 ≈ 3063807206879500µ1 − 173223103439750µ2 = 963255946826679308119558174097693764 β1,
and thus the condition H1 ≥ 0 yields β1 ≥ 0. Therefore, in the following analysis we assume
β1 ≥ 0. It is easy to see that when β1 ≥ 0, x1+ > 0 and x1− ≤ 0.
To find the stability of the two equilibrium solutions, we use the Jacobian of (5.32) to obtain
the characteristic polynomial λ2 − Tr λ + det, where
Tr = β2 + x1 and det = −αβ2 + 2 x1.
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Defining ∆ = Tr2 − 4 det, we have
Tr+ = β2 + x1+ =
(
1 + 12α
)
β2 +
1
2
√
α2β22 + 4β1,
det+ = −αβ2 + 2 x1+ =
√
α2β22 + 4β1 > 0,
(5.37)
implying that the equilibrium E+: (x1+, 0) is either a focus or node, which is stable (unstable)
when ∆+= (Tr+)2 − 4 det+ < 0 (> 0). Similarly, for the equilibrium E−: (x1−, 0) we have
Tr− = β2 + x1− =
(
1 + 12α
)
β2 − 12
√
α2β22 + 4β1,
det− = −αβ2 + 2 x1− = −
√
α2β22 + 4β1 < 0,
(5.38)
indicating that E− is always a saddle point. The bifurcation set (only for β1 ≥ 0) and corre-
sponding phase portraits are shown in Figure 5.17. Note that the Hopf bifurcation near the
critical point (denoted by the dashed blue curve in Figure 5.17) is obtained from Tr+ = 0 as
β1 = (1 + α) β22 = 513500 β22. (5.39)
There is another curve in Figure 5.17, shown in red, which denotes the bifurcation of homo-
clinic loop (see [13]).
β1
β2
0
Homo:
supH:
β1=
49
25β
2
2
β1=
513
500β
2
2
Figure 5.17: Bifurcation set and phase portraits of system (5.32).
Before we derive the equation for the bifurcation of the homoclinic loop, we consider the
Hopf bifurcation which occurs from the dashed blue curve. The Hopf critical point on this
curve can be defined as
β2H = − 10
√
5β1
513 ,
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and then introducing the transformation: x1 = x˜1, x2 = ωc x˜2 into (5.32) results in the system:
dx˜1
dτ1
= ωc x˜2 ≡ ˜f (x˜1, x˜2),
dx˜1
dτ1
= −ωc x˜1 − 1ωc x˜21 + x˜1 x˜2 ≡ g˜(x˜1, x˜2),
where
ωc =
√
1013
8550
√
285 β1.
Thus, the first focus value v1 is given by
v1 = − 116ω2c
( − g˜x˜1 x˜1 g˜x˜1 x˜2) = − 116ωc ×
2
ωc
= − 18ω2c
< 0,
indicating that the Hopf bifurcation is supercritical, and bifurcating limit cycles are stable, as
shown in Figure 5.17 (see the ellipse in green). The Hopf bifurcation near the BT critical point
is not surprising since the original system does have Hopf bifurcations which occur from the
blue curve, as shown in Figure 5.16. In fact, as discussed in Section 5.3, we can similarly use
the original system to show that the Hopf bifurcations from the blue curve (see Figure 5.16) are
indeed supercritical, which agrees with the conclusion obtained above, and so the bifurcating
limit cycles are stable.
Next, we consider homoclinic loops which may bifurcate near the BT critical point. Here,
we apply the technique of rescaling, as used in [13] to find the equation for the homoclinic
curve. Set
x1 = ε
2w1, x2 = ε
3w2, β1 = ε
4ν1, β2 = ε
2ν2, α = εα˜, (0 ≤ ε ≪ 1), (5.40)
and rescale time t = ετ1, so that (5.32) can be rewritten (up to ε order) as
dw1
dt = w2,
dw2
dt = ν1 + εα˜ν2w1 + εν2w2 + εw1w2 − w
2
1.
(5.41)
Now, letting ε = 0 in (5.41) yields an integrable Hamiltonian system:
dw1
dt = w2,
dw2
dt = ν1 − w
2
1.
(5.42)
with Hamiltonian
H(w1,w2) = − ν1 w1 + 13 w
3
1 +
1
2
w22. (5.43)
Taking ν1 = 1, which corresponds to β1 ≥ 0, we have two fixed points: (w1,w2) = (±1, 0), with
(1, 0) being a center and (−1, 0) a saddle point, as shown in Figure 5.18.
The solution on the saddle loop Γ based at the point (w1,w2) = (2, 0) is given by
(w1(t),w2(t)) =
(
3 sech2
( t√
2
)
− 1, 3
√
2sech2
( t√
2
(
tanh
( t√
2
))
. (5.44)
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Figure 5.18: The phase portrait of (5.42) with ν1 = 1, showing a homoclinic loop Γ.
Thus, the first-order Melnikov function M(t0) on the vector filed ε (α˜ν2w1 + ν2w2 + w1w2) ∂∂w2
is independent of time, and can be calculated as
M(ν2) =
∫ ∞
−∞
w2(t)[α˜ν2w1(t) + ν2w2(t) + w1(t)w2(t)] dt
=
1√
2
[
ν2
∫ ∞
−∞
18 sech4t′ tanh2t′ dt′
−
∫ ∞
−∞
(3 sech2τ − 1) 18 sech4t′ tanh2t′ dt′
]
,
where t′ = t/
√
2. Note that the first term α˜ν2w1(t)w2(t) yields zero after integration due to
the Hamiltonian being symmetric with respect to the w1 axis, and the negative sign for the
integration of the third term w1(t)w22(t) comes from the definition of the homoclinic loop Γ,
which takes t′ from +∞ to 0 along the positive w1 direction while from 0 to −∞ along the
negative w1 direction. Then, solving M ≡ 0 for the saddle connection yields
ν2 ≈
∫ ∞
−∞(3 sech2t′ − 1) sech4t′ tanh2t′ dt′
α
∫ ∞
−∞ sech
4t′ tanh2t′ dt′
=
∫ ∞
−∞ sech
2t′(2 tanh2t′ − 5 tanh4t′ + 3 tanh6t′) dt′∫ ∞
−∞ sech
2t′(tanh2t′ − tanh4t′) dt′
=
5
7
,
where the formula: ∫ ∞
−∞
sech2t′ tanhkt′ dt′ = tanh
k+1(t′)
k + 1
∣∣∣∣∣∣
∞
−∞
=
3
k + 1
has been used. Finally, noticing ν1 = 1, and β1 = ε4, β2 = ε2 ν2, we obtain the approximate
bifurcation curve for the homoclinic loop as
Homo : β1 =
49
25 β
2
2, β2 ≤ 0. (5.45)
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The true bifurcation curve is tangent to the semi-parabola at β1 = β2 = 0. Combining this
with equation (5.39) for Hopf bifurcation, we indeed see that a second bifurcation curve, de-
noted as ‘Homo’, is located above the Hopf bifurcation curve and tangent to it (and to β1 = 0)
at (β1, β2) = (0, 0), and the phase portrait on this bifurcation set has a saddle loop, as shown
in Figure 5.17. The sign taken by the Melnikov function M for β1 < 4925β
2
2 (or > 4925β22, re-
spectively) gives the relative position of the stable and unstable manifolds (separators of the
saddle). Moreover, note that the trace of the “saddle quantity”, given by (5.38),
Tr−Homo =
(
1 + 12α
)
β2 − 12
√
α2 + 19625 |β2| (β2 < 0),
is negative on the ‘Homo’ curve (5.45). Hence, the homoclinic orbit is stable (an ω-limit set)
attracting the nearby points. Further, it can be shown (see [13]) that in the region between the
Hopf bifurcation curve ‘supH’ and the Homoclinic bifurcation curve ‘Homo’ (see Figure 5.17)
the system has a unique attracting limit cycle for each pair of parameter values (β1, β2).
To demonstrate the bifurcation phenomena discussed above, we show simulations using
the original system (5.1), rather than the normal form equation (5.32), which gives a more
realistic observation. We take seven sets of perturbations on the parameters A and C near the
BT1 critical point (see Figure 5.16(a)) as A = A1 + µ1, C = C1 + µ2, where A1 and C1 are given
in (5.26). These seven sets of perturbations denote seven points in the bifurcation diagram
(see Figure 5.16) on a same vertical line (see the green line in Figure 5.16(a)) with the same
coordinate A = A1 − 0.000001, and different coordinates C = C1 + µ2 with µ2 given from top
to the bottom as follows:
µ2 = −0.0000094, −0.000098, −0.0000106, −0.00003,
−0.0000414239, −0.0000875, −0.0001.
It is noted that the equilibrium E1− is a stable focus at the top and the bottom points, but is
an unstable focus at the other five points. Here, we have found an interesting phenomenon
that since the Hopf bifurcation curve has a turning point and all nearby points can lead to
stable limit cycles in the region where the equilibrium E1− is an unstable focus, there exist two
homoclinic loops when one goes through the five points along the vertical line starting with the
second point from the top. However, the above normal form theory for the BT bifurcation and
the result given in Figure 5.17 only show one homoclinic loop. This is not surprising since the
normal form for the BT1 bifurcation is only applicable for the study of dynamics around the
BT1 point and thus it only predicts the top homoclinic loop. Due to the perturbations being very
small, the convergence of the simulating trajectories is very slow. Moreover, the direction of the
trajectories near the saddle point is hard to distinguish. Therefore, in order to give a clear view,
we, based on the simulating phase portraits which have been rotated by a angle of π55 , present
seven schematic diagrams with exaggerated convergence speed and the part near the saddle
point. Since the simulations for the top and bottom points are similar, we will only present one
figure for these two points (see Figure 5.19(a)). Of course, they are different quantitatively and
the simulation for the bottom point is much clearer than that of the top one. The Figures 5.19(b)
to 5.19(f) correspond to the other five points from top to the bottom. The relation between the
original coordinates (X,Y) and the new coordinates ( ¯X, ¯Y) shown in Figure 5.19 is given by
¯X = cos
( π
55
)
X − sin ( π55)Y, ¯Y = sin ( π55) X + cos ( π55)Y.
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Figure 5.19: Simulations of system (5.1) when B = 0.054, D = 0.057, A = 0.01487968 for (a)
C = 0.07458837 or C = 0.07449777, showing stable focus E1−, (b) C = 0.07458797, showing
unstable focus E1− and a stable limit cycle, (c) C = 0.07458717, showing unstable focus E1−
and a stable homoclinic loop, (d) C = 0.07456777, showing unstable focus E1− and a stable
limit cycle, (e) C = 0.0745563461, showing unstable focus E1− and a stable homoclinic loop,
(f) C = 0.07449777, showing unstable focus E1− and a stable limit cycle.
In the next example for B = 0.054, D = 0.087, we will see true simulating phase portraits,
which clearly show the Hopf bifurcation and homoclinic bifurcation.
5.4.2 Case B = 0.054, D = 0.087
Now we turn to study the case B = 0.054, D = 0.087. As we have discussed, a particular
difference between this case and previous case is that now the Hopf bifurcation near the BT2
critical point is subcritical, and thus the bifurcating limit cycles are unstable. This difference
can cause dramatically different meanings in the biological explanation of this phenomenon.
Since the solution procedure is similar to the previous case, we will skip some detailed
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steps and only present the main results in the following. Using a series of transformations,
similar to (5.28), (5.30) and (5.33), we obtain the following normal form:
dx1
dτ1
= x2,
dx2
dτ1
= β1 + α β2 x1 + β2 x2 − x21 − x1 x2,
(5.46)
where α = 47175500 , and the transformation for the parameters:
µ1 = − 6544335370021308753031010692779307833305870371766996170888000 β1 + 3000793340668563188911529837823194 β2,
µ2 = − 7544255129488549703116068201513158615666611740743533992341776000β1 + 12645552328645797377823059675646388 β2.
(5.47)
The solution formulae are the same as that given in (5.36). Again, we can similarly argue that
β1 ≥ 0, and as a matter of fact, H1 ≥ 0 implies β1 ≥ 0, for which x1+ > 0 and x1− ≤ 0. The
stability of these two equilibrium solutions are determined by
Tr+ = β2 − x1+ =
(
1 − 12α
)
β2 − 12
√
α2β22 + 4β1,
det+ = −αβ2 + 2 x1+ =
√
α2β22 + 4β1 > 0,
(5.48)
and
Tr− = β2 − x1− =
(
1 − 12α
)
β2 +
1
2
√
α2β22 + 4β1,
det− = −αβ2 + 2 x1− = −
√
α2β22 + 4β1 < 0.
(5.49)
These results indicate that (x1−, 0) is a saddle point, while (x1+, 0) is either a focus or node. The
Hopf bifurcation near the BT2 critical point is determined from Tr+ = 0 as
β1 = (1 − α) β22 = 7835500 β22, (5.50)
and the bifurcation is subcritical, since the first focus value can be obtained as v1 = 1ω2c > 0.
Similarly we can obtain the homoclinic bifurcation which occurs from the curve:
Homo : β1 =
49
25 β
2
2, β2 ≥ 0. (5.51)
The bifurcation set and corresponding phase portraits are depicted in Figure 5.20, which is
quite different from the case B = 0.054, D = 0.057 (see Figure 5.17). Simulations based on
the original system (5.1) for this case are shown in Figure 5.21, where the perturbation (µ1, µ2),
on the parameters A and C, take the following values:
(0.004, 0.0085), (0.004, 0.00807), (0.004, 0.0073813), (0.004, 0.007),
which represent four points on the same vertical green line in the bifurcation diagram, shown
in Figure 5.16(b).
It is seen from Figure 5.21(a) that the phase portrait for the first perturbation, corresponding
to a point above the Hopf bifurcation curve (see the blue curve in Figure 5.20), shows a unstable
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Figure 5.20: Bifurcation set and phase portraits of system (5.46).
focus E1− and there exists one trajectory starting from the saddle point E1+ and converging to
this focus as τ → −∞. Figure 5.21(b) shows the phase portrait for the second perturbation,
corresponding to a point between the Hopf bifurcation curve (the blue curve in Figure 5.20)
and the homoclinic bifurcation curve (the red curve in Figure 5.20), shows an unstable limit
cycle (see the green curve in Figure 5.20) and trajectories starting near this limit cycle either
converge to the stable focus E1− or to the stable node E0 (which is not shown in Figures 5.20
and 5.21) as τ → +∞. Figure 5.21(c) shows a homoclinic loop under the third perturbation,
corresponding to a point on the homoclinic bifurcation curve, which encloses the stable focus
E1−, and all trajectories inside this homoclinic loop coverage to the focus as τ → +∞. In fact,
it can be shown that the saddle quantity, given in (5.49),
Tr−Homo =
[
1 − 12α + 12
√
α2 + 19625
]
,
is positive for β2 > 0, implying that the homoclinic loop is unstable. Finally, Figure 5.21(d)
shows a phase portrait for the fourth perturbation, corresponding to a point below the homo-
clinic bifurcation curve, which encloses the stable focus E1−. It is seen from Figure 5.21 that
the saddle connection before and after the homoclinic loop (Figure 5.21(c)) change the way to
connect the focus or the limit cycle. Note that unlike the bifurcation shown in Figure 5.16(a)
where there are two homoclinic loops which occur from the green line, here there is only one
homoclinic loop since no more Hopf bifurcation happens when the parameter C is decreased
to cross the Hopf critical line along the green line (see Figure 5.16(b)).
Summarizing the results obtained in this section we have the following theorem.
Theorem 5.4.1 For system (5.1), when B < D and H1 > 0, there always exists Bogdanov-
Takens bifurcation, which occurs from the precritical disease bifurcation solution, leading to
homoclinic bifurcation near a Hopf bifurcation, with homoclinic loop being either stable or
unstable.
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Figure 5.21: Simulations of system (5.1) when B = 0.054, D = 0.087 for (a) A =
0.0569302656, C = 0.0330259146, showing an unstable focus E1− with one trajectory diver-
gent to the saddle point E1+, (b) A = 0.0569302656, C = 0.0325959146, showing stable focus
E1− enclosed by an unstable limit cycle, (c) A = 0.0569302656, C = 0.0319072146, showing
a homoclinic loop enclosing a stable focus, and (d) A = 0.0569302656, C = 0.0315259146,
showing convergence of the trajectory starting from the saddle point E1+ to the stable focus
E1−.
5.4.3 A new mechanism for generating blips
A detailed study for a 4-dimensional system has been given in [27, 28], shows a mechanism
for generating the blips phenomenon, and four conditions are proposed in a hypothesis, which
guarantee the existence of blips. In [27, 28], blips are also shown to exist in two 3-dimensional
models as well as in the 2-dimensional model (5.1). An important condition for the existence of
blips is Hopf bifurcation, which is the source of oscillation. Very recently, another mechanism
has been identified in [29], which is also related to Hopf bifurcation. These two mechanisms
have a common property that both of them generate oscillations with large changes in both
amplitude and frequency, and they both appear on the post-critical disease bifurcation solution.
It has also been noted that these two mechanisms have a fundamental difference: the former
guarantees blips to occur near a transcritical bifurcation point; while the later yields blips far
away from a transcritical bifurcation point, which are not guaranteed. The second mechanism
needs further investigation.
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In order to discuss a new mechanism of generating blips, in the following we list Hypothesis
1 from [27, 28], and propose a second Hypothesis based on the results obtained in [29].
Hypothesis 1 [27, 28] The following four conditions are needed for an in-host infection model
to generate viral blips:
(i) there exist at least two equilibrium solutions;
(ii) there exists a transcritical bifurcation at an intersection of the two equilibrium solutions;
(iii) there is a Hopf bifurcation which occurs from one of the equilibrium solutions; and
(iv) large oscillations (or, more generally, global, persistent motions) can occur near the tran-
scritical critical point.
Hypothesis 2 [29] The following four conditions are needed for an in-host infection model to
generate viral blips: the conditions (i), (ii) and (iii) are the same as that given in Hypothesis 1;
and
(iv) large oscillations (or, more generally, global, persistent motions) can occur far away from
the transcritical and Hopf critical points.
We use the bifurcation diagrams shown in Figures 5.22(a) and 5.22(b) (which are Fig-
ures 3.3(a) and 3.3(b) in [28]) to illustrate Hypothesis 1, and the bifurcation diagram in Fig-
ure 5.22(c) (which is Figure 3.1(a) in [29]) to explain Hypothesis 2, where R and A are state
variables, B and α are parameters. E0 and E1 denote the disease-free and disease equilibrium
solutions. The green lines indicate where the blip-like oscillations occur. It is clear from Fig-
ures 5.22(a) and 5.22(b) that the blips appear near the transcritical point, and may or may not
appear near the Hopf critical point, where both E0 and E1 are unstable, illustrating condition
(iv) in Hypothesis 1. Figure 5.22(c) (where the second Hopf critical point “Hopf2” is out-
side the figure) shows that the blips occur far away from the transcritical and Hopf bifurcation
points.
Through the study given in this section on the BT bifurcation, we have found a third mech-
anism for generating blips, due to the BT bifurcation, explained as follows. First of all, note
that the trajectory starting from a point on the homoclinic loop will reach the saddle point either
as τ → +∞ or τ → −∞. Therefore, it can be seen from Figure 5.17 that near the homoclinic
bifurcation curve, for certain parameter values, the bifurcating stable limit cycles can be large
close to the saddle separators and thus such a stable limit cycle will move extremely slowly
near the saddle point but will move fast when it is away from the saddle point – giving rise to
the blips phenomenon. A schematic bifurcation diagram for the case, which is depicted in Fig-
ure 5.19 when B = 0.054, D = 0.057, A = 0.01487968, is shown in Figure 5.22(d). Also note
from Figures 5.20 and 5.21 that when the limit cycle inside the saddle separators is unstable,
the trajectories starting near the unstable limit cycle may converge to the stable focus E1−, or to
the stable node E0 but will take very long time since the solution will go through a route close
to the saddle point though not generating blips in this case.
The big difference between the first two mechanisms and the new mechanism is that the
first two mechanisms result in very large oscillations in both amplitude and frequency, while
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Figure 5.22: Bifurcation diagrams illustrating Hypotheses: (a) and (b) for Hypothesis 1, (c) for
Hypothesis 2 and (c) Hypothesis 3.
the new mechanism only causes significant changes in frequency, but very little variation in the
amplitude. The biological implication of the new mechanism is interesting and may explain
some real situations, namely, in some situations a patient may not feel obvious changes nor
will measurable changes in disease progression be apparent, but nonetheless the patient may be
experiencing recurrent disease without any significant observation. In other situations, neither
the infected individual nor the clinician may be able to detect whether the infection has been
cured, since complete recovery may take an extremely long time. In both cases, the patient is
in an uncertain situation. To describe these scenarios, we have the following hypothesis.
Hypothesis 3 The following four conditions are needed for an in-host infection model to gen-
erate viral blips or to take an extremely long time to recover (converge to the disease-free
equilibrium): conditions (i), (ii) and (iii) are the same as that given in Hypothesis 1; and
(iv) there exists Bogdanov-Takens bifurcation, leading to homoclinic loops near a Hopf bi-
furcation, which may yield blips with very small changes in amplitude, or extremely
slow convergence to the disease-free equilibrium.
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5.5 Conclusion and discussion
In this paper, we have given a detailed dynamical study of a 2-dimensional disease model,
which can be used not only for in-host disease modelling, but also for epidemiologic modelling.
We have shown that when the reproduction number, R0 = BD , is varied near R0 = 1, the
system exhibits rich dynamical behaviors, including equilibrium solutions which exchange
their stability at the transcritical point R0 = 1. Both Hopf and generalized Hopf bifurcations
can occur regardless whether R0 < 1 or R0 ≥ 1, which lead to bistability or even tristability.
In particular, our study has indicated that when R0 < 1, the system can have Bogdanov-Takens
bifurcation leading to more complex dynamical behavior such as homoclic orbit bifurcation.
This special bifurcation may provide a new scenario/mechanism for generating recurrence or
the viral blips phenomenon, summarized in Hypothesis 3.
Hypothesis 3 is completely different from Hypotheses 1 and 2, and may provide an ex-
planation for interesting clinical phenomena. In many disease models, the concept of R0 is
straightforward, i.e. if R0 < 1, the disease cannot invade or persist, and the disease only exists
for R0 > 1. In reality, disease dynamics are more complex, and our model indeed reflects
this complexity. Hypothesis 3 allows for the possibility that even if control or therapy reduces
R0 below one, a disease may persist indefinitely with low level oscillations, or may die out,
but with an extremely slow time course of decay. The possibility of disease persistence when
R0 < 1 is a feature of backward bifurcation [9, 30, 5, 4], an issue which we are investigating
for this model and related disease models as well [30].
Mathematically, the most interesting dynamical behavior of our model is the Bogdanov-
Takens bifurcation leading to homoclinic loops, which in turn provides a new mechanism for
explaining a very different blips phenomenon. In particular, this phenomenon does not have
obvious changes in the amplitude of the oscillating motion. This can only happen when B < D
(i.e. R0 < 1). However, this condition, B < D, is not enough, the additional condition H1 ≥ 0,
which guarantees the existence of disease equilibrium, E1, must also be satisfied. Intuitively,
if B < D, then the epidemic cannot get started because near the disease-free equilibrium, E0,
the behavior of the model is similar to that studied in [17], and thus no oscillation can occur
with R0 < 1. However, H1 ≥ 0, as mentioned in Remark 5.2.3, implies that the contact rate
A exceeds its threshold such that the infected cells, denoted by Y , are sufficiently infectious
such that the epidemic can sustain itself once started even if B < D. Therefore, this leads,
after getting over an initial threshold, to potential bistable equilibrium solutions and even more
complex dynamical behavior.
The ideas and methodologies presented in this paper can be used to analyze other types of
in-host disease models as well as epidemiologic models. We hope that they can also be gener-
alized to study functional differential systems (e.g. with time delays), or even other physical or
engineering systems which exhibit similar “blips-like” phenomenon.
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Chapter 6
Conclusion
In this thesis, the problem of recurrent disease in infection and autoimmune models is studied
via the qualitative analysis of dynamical systems using bifurcation theory. Although previous
models with triggers such as stochastic components or forcing terms can simulate the cycle of
long remission and brief relapse, simple deterministic models also exhibit recurrence.
Recurrence in HIV infection is referred to as “viral blips”. A 4-dimensional HIV antioxidant-
therapy model, which exhibits viral blips, is analysed. The first hypothesis consisting of four
conditions for the emergence of viral blips is proposed, which guides the derivation of the
simplest (2- and 3-dimensional) infection model producing viral blips. A complete parame-
ter region for the 3-dimensional infection model exhibiting viral blips is identified. Further
dynamical study is conducted on the simplest 2-dimensional infection model, and gives rise
to two more blips-generating mechanisms: hypothesis 2 and 3. The first hypothesis describes
the scenario in which two equilibrium solutions intersect at a transcritical bifurcation point,
and a Hopf bifurcation occurs at the upper branch of the disease equilibrium. Blips appear
when the bifurcation parameter is close to the transcritical bifurcation point, and located in the
parameter region where both equilibrium solutions are unstable. The second hypothesis adds
another blips-generating mechanism, i.e. that large oscillations (or, more generally, global,
persistent motions) can occur far away from the transcritical and Hopf ciritical points. In the
third hypothesis, the existence of a Bogdanov-Takens bifurcation is proposed, which leads to a
homoclinic loop near a Hopf bifurcation. This scenario may yield blips with very little change
in amplitude, or extremely slow convergence to the disease-free equilibrium. The relapse-
remission cycle is also characteristic of many autoimmune diseases. An autoimmune model
which includes the role of regulatory T cells is modified by adding the terminally differentiated
regulatory T cell subclass. The dynamical behavior is altered. Thus, recurrence is displayed in
the modified autoimmune model and can be explained by the second hypothesis. Recurrence
in infection and autoimmune models can arise naturally from the dynamical behavior of the
system, without stochastic stimulation or exogenous triggers.
From the viewpoint of mathematical modelling, the occurrence of blips in the (2- and 3-
and 4-dimensional) infection model is attributed to the convex incidence rate, which is formed
by an increasing and saturating infectivity function. The convex incidence rate represents a co-
operative effect in infection progression, that is, the existing infection enhances the ability for
new infection to become established. The convex incidence rate also induces backward bifurca-
tion, which facilitates the appearance of Hopf bifurcation, and rich dynamical behaviors, such
141
142 Chapter 6. Conclusion
as bistability, recurrence, and regular oscillation. Cooperative effects in autoimmune disease
occur during the T cell regulation process, since HLA-DR− regulatory T cells differentiate and
proliferate, forming the terminally differentiated HLA-DR+ class, which shows more efficient
regulating capability. The autoimmune model investigated here displays negative backward
bifurcation, in which the turning point is located in the negative state variable space. With the
help of additional state variable, the modified autoimmune model shows Hopf bifurcation and
exhibits recurrence.
We note that the amplitudes and frequencies in the observed oscillating and recurrent mo-
tions are all constant, because all parameter values are fixed for deterministic systems. How-
ever, in reality parameters should be time-varying, rather than constant. Time-varying pa-
rameter values in deterministic systems can generate oscillations with varying amplitudes and
phases, called “amplitude modulation” and “frequency modulation”, which are analogous to
the variation from random perturbations in stochastic models. This is demonstrated in Figure
2.12 of Chapter 2.
Clearly, the models analysed in this thesis are extreme simplifications of the mechanisms
considered, and more precise mechanisms and accurate models could be considered in future.
Nevertheless, the main insight of this thesis is to demonstrate that recurrence in disease can
be generated from the cooperative interplay of dynamic populations. Hypotheses proposed in
this thesis will serve as a starting point for further research on recurrent phenomena in other
physical systems.
Other mechanisms for recurrence also exist, such as the recurrent activation of latently-
infected lymphocytes. The delay which is characteristic of latent infection can be modelled
using delay differential equations (DDEs), which could also generate oscillation and even re-
current patterns. A study of recurrent disease using DDEs would be a clear possibility for
future work.
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